Bartonella Bacilliformis: Understanding The Underlying Causes Of Verruga Peruana Formation During Carrion’s Disease

Drew Eric Kohlhorst

Follow this and additional works at: http://scholarworks.gsu.edu/biology_diss

Recommended Citation
http://scholarworks.gsu.edu/biology_diss/37

This Dissertation is brought to you for free and open access by the Department of Biology at ScholarWorks @ Georgia State University. It has been accepted for inclusion in Biology Dissertations by an authorized administrator of ScholarWorks @ Georgia State University. For more information, please contact scholarworks@gsu.edu.
BARTONELLA BACILLIFORMIS: UNDERSTANDING THE UNDERLYING CAUSES OF VERRUGA PERUANA FORMATION DURING CARRION’S DISEASE

by

DREW KOHLHORST

Under the Direction of Dr. Barbara Baumstark, Ph.D.

ABSTRACT

Bartonella, a group of Gram negative facultative intracellular bacteria, are known to cause diseases, such as Cat Scratch Disease, Trench Fever and Carrion’s Disease, that involve angiogenesis during the infective cycle. *B. bacilliformis*, the etiological agent of Carrion’s Disease, causes a bi-phasic infection resulting in the formation of blood-filled angiogenic proliferative cutaneous nodules called verruga peruana. The work presented here was undertaken to characterize the mechanism by which these nodules are produced.

Previous work in our laboratory suggested that the *Bartonella henselae* genome contains a homologue to the *virB* operon, a set of genes coding for a Type IV Secretion System (TFSS) that has been implicated in the pathogenesis of other α-2-proteobacteria. We identified *virB* operons in two additional *Bartonella* pathogens, *B. quintana* and *B. clarridgeiae*. No corresponding operon sequences were detected in *B. bacilliformis* DNA, however. This finding suggests that *virB* gene products are not required for verruga peruana formation. To continue our search for factors involved in *B. bacilliformis*-induced angiogenesis, we conducted a microarray analysis of differential
gene expression in infected and uninfected endothelial cells. The results suggest similarities between later stage (36 hours) *B. bacilliformis* infection and that of HHV-8, the causative agent of Kaposi’s Sarcoma, particularly in relation to the host immune response. Finally, our research focused on the secreted factors that *B. bacilliformis* produces during its host infective cycle. Our data suggest that the *B. bacilliformis* homologue to the molecular chaperone GroEL not only induces angiogenesis in endothelial cells, but also protects endothelial cell tubule from the degradation seen when these cells are in the presence of live *B. bacilliformis*. In summary, the induction of verruga peruana nodules via *B. bacilliformis* may be the result of multiple factors over the course of persistent infection. Early infection may cause vascular damage, which induces VEGF and hypoxia factors. As infection persists, bacterial secretion of a unique GroEL may result in continued angiogenesis and the ensuing activation of immune cells, producing a localized environment of continual incomplete angiogenesis in areas of cutaneous infection.

INDEX WORDS: *Bartonella*, Angiogenesis, *virB* Operon, Proliferation, GroEL, Kaposi’s Sarcoma, Microarray Analysis
BARTONELLA BACILLIFORMIS: UNDERSTANDING THE UNDERLYING CAUSES OF VERRUCA PERUANA FORMATION DURING CARRION’S DISEASE

by

DREW E. KOHLHORST

A Dissertation Presented in Partial Fulfillment of Requirements for the Degree of Doctor of Philosophy

in the College of Arts and Sciences

Georgia State University

2008
BARTONELLA BACILLIFORMIS: UNDERSTANDING THE UNDERLYING CAUSES
OF VERRUGA PERUANA FORMATION DURING CARRION’S DISEASE

by

DREW E. KOHLHORST

Committee Chair: Barbara Baumstark
Committee: PC Tai
Zehava Eichenbaum

Electronic Version Approved:
Office of Graduate Studies
College of Arts and Sciences
Georgia State University
May 2008
Acknowledgements

There are so many people that have made this degree possible. First, I would like to thank my advisor and committee members. Without Dr. Baumstark’s advice and wisdom this work would never have gotten off the ground, thank you for your patience and encouragement! To my committee members, Dr. Tai and Dr. Eichenbaum, thank you for your time and ideas, you greatly helped this project move forward. To the staff at GSU, thank you for helping me and knowing what I needed to do when I didn’t and how to get me out of the trouble I caused. To my parents, this has been a journey that you have been with me the entire time and for that I am forever grateful. I owe you both more than you can ever know and this is just the beginning of my journey that you have helped me start. To my brother and sister – yes, I’m finally going to be out of school. You have both been there to support me and keep me grounded – thank you! To Scott, from here we can go anywhere and we will get there together, our opportunities are truly endless. Finally, to Tanu you have been there when even I didn’t want to be, you have given me ideas and headaches and I have enjoyed this process because of you – wherever our lives take us we will always be friends and see each other through. To all my other relatives, friends and everyone else thank you for your support and help – you share a part of this with me.
TABLE OF CONTENTS

Acknowledgements ........................................................................................................... iv
List of Tables ....................................................................................................................... vii
List of Figures ..................................................................................................................... viii
List of Abbreviations .......................................................................................................... x
General Introduction .......................................................................................................... 1
  *Bartonella* Species – Microbiological Aspects, Identification & Epidemiology ............ 1
  *Bartonella bacilliformis* – History & Epidemiology ...................................................... 4
  *Bartonella bacilliformis* – Known Virulence Factors .................................................. 5
Adherence-Related Factors ............................................................................................. 9
  The virB Operon .............................................................................................................. 11
Angiogenesis ................................................................................................................... 15
GroEL ............................................................................................................................... 20
Chapter I – Search for virB operon homologues in selected *Bartonella* species .......... 27
  Introduction .................................................................................................................... 27
  Materials and Methods .................................................................................................. 30
  Results .......................................................................................................................... 41
  Discussion ...................................................................................................................... 58
Chapter II – Analysis of HMEC-1 Gene Expression during *B. bacilliformis* Infection .... 67
  Introduction .................................................................................................................... 67
  Materials and Methods .................................................................................................. 71
  Results .......................................................................................................................... 78
  Discussion ...................................................................................................................... 116
Chapter III – Bacterial Components & Secreted Protein(s) .............................................. 129
  Introduction .................................................................................................................... 129
  Materials and Methods .................................................................................................. 133
  Results .......................................................................................................................... 144
  Discussion ...................................................................................................................... 199
Concluding Remarks: A model for the formation of Verruga Peruana ......................... 209
Bibliography ..................................................................................................................... 211
Appendix .......................................................................................................................... 227
AP.1 - *Bartonella quintana* - virB Operon Sequence ......................................................... 228
AP.2 - *Bartonella clarridgeiae* - virB Operon Sequence ....................................................... 233
AP.3 – Alignment of various *Bartonella* GroEL Proteins. ...................................................... 238
List of Tables

Table GI.1 – Homology of selected *Bartonella* virB operon genes compared to the *A. tumefaciens* virB Operon .................................................................................................................................................. 14
Table GI.2 – Factors produced by host cells involved with angiogenesis ............................................................................................................................................................................. 17
Table 1.1 – Consensus and *Bartonella*-specific virB Operon Primers .................................................................................................................................................................................. 32
Table 1.2 – DIG-Labeled Probes for Southern Blot Analysis ................................................................................................................................................................................ 36
Table 1.3 – Gene Specific Primers for GenomeWalk Analysis of *B. bacilliformis* .............................................................................................................................................. 40
Table 1.4 – Comparison of virB Operon Sequences between *A. tumefaciens* and various
*Bartonella*-species .................................................................................................................................................. 47
Table 1.5 – Comparison of VirB Operon Sequences between *Bartonella* species .................................................................................................................................................. 48
Table 1.6 – Comparison of VirB Protein Sequences of *B. quintana* and *B. henselae*, *B. clarridgeiae*, *A. tumefaciens* and *Sinorhizobium meliloti* .................................................................................................................................................. 51
Table 1.7 – Comparison of VirB Proteins of *B. clarridgeiae* and *B. henselae*, *B. quintana*, *A. tumefaciens* and *Sinorhizobium meliloti* .................................................................................................................................................. 51
Table 1.8 – Comparison of VirB Protein Similarities of *A. tumefaciens* and *B. henselae*, *B. clarridgeiae*, *B. quintana* and *Sinorhizobium meliloti* .................................................................................................................................................. 52
Table 1.9 – Putative products identified from probes of the *B. bacilliformis* genome by virB
gene-specific probes .................................................................................................................................................. 53
Table 2.1a – Highly differentially expressed functional HMEC-1 genes 6 hours after *B. bacilliformis* infection .................................................................................................................................................. 84
Table 2.1b – Highly differentially expressed functional HMEC-1 genes 36 hours after *B. bacilliformis* infection .................................................................................................................................................. 87
Table 2.2 – Selected dynamically regulated host genes of infected HMEC-1 cells during *B. bacilliformis* infection .................................................................................................................................................. 92
Table 2.3 – Validation of Microarray Experiment via RT-PCR 6 and 36 hours post-infection .................................................................................................................................................. 102
Table 2.4 – Venn Diagram Analysis comparing genes overlapping between 36hrs *B. bacilliformis*-infected HMEC-1 Cells and 2 day HHV-8 infected Primary Blood Endothelial Cells .................................................................................................................................................. 106
Table 2.5 – Venn Diagram Analysis comparing genes overlapping between 36 hrs *B. bacilliformis*-infected HMEC-1 Cells and 7 day HHV-8 infected Primary Blood Endothelial Cells .................................................................................................................................................. 111
Table 2.6 – Venn Diagram Analysis comparing genes overlapping between 36hrs *B. bacilliformis*-infected HMEC-1 Cells and 2 & 7 day HHV-8 infected Primary Blood Endothelial Cells .................................................................................................................................................. 114
Table 3.1 - *B. bacilliformis* GroEL DNA and Protein Sequence Homology to Bacterial
GroELs/Eukaryotic HSP Homologues .................................................................................................................................................. 195
List of Figures

Figure GI.1 – Assembly of the virB gene products in A. tumefaciens ..................................................13
Figure GII.2 – Proposed Assembly of virB gene products in B. henselae .............................................13
Figure 1.1 – Physical Arrangement of the virB Operon in Bartonella Species ........................................46
Figure 1.2 – Hybridization of virB DNA probes to Bartonella Genomic DNA .................................56
Figure 2.1 – Scatter plot analysis of Affymetrix HG-U133A Microarray chips at various time points .................................................................79
Figure 2.2 – Scatter plot analysis of Affymetrix HG-U133B Microarray chips at various time points .................................................................82
Figure 3.1 – HMEC-1 Proliferation during Infection with B. bacilliformis .............................................145
Figure 3.2 – Pre-formed HMEC-1 Tubule-formation in the presence of B. bacilliformis .............147
Figure 3.3 – Newly-formed HMEC-1 Tubule formation in the presence of B. bacilliformis ..........148
Figure 3.4 – Cross-talk analysis of uninfected HUVEC cells in the presence of infected HUVEC cells ....................................................................................150
Figure 3.5 – Cross-talk analysis of uninfected HUVEC cells in the presence of infected HEp2 cells .........................................................................................151
Figure 3.6 – ELISA analysis of IL-2 production during infection with live B. bacilliformis ..........154
Figure 3.7 – ELISA analysis of IL-6 production during infection with live B. bacilliformis ........155
Figure 3.8 – ELISA analysis of TNFα production during infection with live B. bacilliformis ....156
Figure 3.9 – ELISA analysis of IL-2 production during infection with formalin-killed B. bacilliformis ....................................................................................157
Figure 3.10 – ELISA analysis of IL-6 production during infection with formalin-killed B. bacilliformis ....................................................................................158
Figure 3.11 – ELISA analysis of TNFα production during infection with formalin-killed B. bacilliformis ....................................................................................159
Figure 3.12 – ELISA Analysis of IL-17 Production in the presence of B. bacilliformis .........160
Figure 3.13 – ELISA Analysis of IL-8 Production in the presence of B. bacilliformis .............161
Figure 3.14 – ELISA Analysis of IL-18 Production in the presence of B. bacilliformis .........163
Figure 3.15 – HMEC-1 Proliferation in the presence of B. bacilliformis membranes ..............165
Figure 3.16 – ELISA analysis of IL-2 production in the presence of B. bacilliformis membranes ....................................................................................167
Figure 3.17 – ELISA analysis of IL-6 production in the presence of B. bacilliformis membranes ....................................................................................168
Figure 3.18 – ELISA analysis of TNFα production in the presence of B. bacilliformis membranes ....................................................................................169
Figure 3.19 – SDS & Western blot Analysis of B. bacilliformis Growth on Solid Media ....172
Figure 3.20 – SDS-PAGE and Western Blot Analysis of B. bacilliformis growth in liquid media ....................................................................................173
Figure 3.21 – SDS-PAGE analysis of B. bacilliformis GroEL purification after Ammonium Sulfate Fractionation .................................................................175
Figure 3.22 – SDS-PAGE Analysis of B. bacilliformis GroEL purification after ATP-Agarose elution. ................................................................. 176
Figure 3.23 – SDS-PAGE and Western Blot Analysis of B. bacilliformis GroEL purification after Amicon Filtration. ................................................................. 177
Figure 3.24 – HMEC-1 Tubule-formation in the presence of purified B. bacilliformis GroEL. ........................................................................................................ 180
Figure 3.25 – HMEC-1 Tubule-formation in the presence of Live B. bacilliformis and GroEL........................................................................................................... 181
Figure 3.26 – HMEC-1 Tubule-formation in the presence of E. coli GroEL Antibodies. 182
Figure 3.27 – HMEC-1 Tubule-formation in the presence of Live, B. bacilliformis and E. coli Anti-GroEL Antibodies. ................................................................. 183
Figure 3.28 – HMEC-1 Tubule-formation in the presence of B. bacilliformis GroEL and E. coli GroEL antibodies. ........................................................................ 184
Figure 3.29 – HMEC-1 Tubule-formation in the presence of purified E. coli GroEL and E. coli Anti-GroEL antibodies. ................................................................. 185
Figure 3.30 – ELISA Analysis of IL-2 production in the presence of B. bacilliformis GroEL. ........................................................................................................ 187
Figure 3.31 – ELISA Analysis of IL-6 production in the presence of B. bacilliformis GroEL. ........................................................................................................ 188
Figure 3.32 – ELISA Analysis of IL-8 production in the presence of B. bacilliformis GroEL. ........................................................................................................ 189
Figure 3.33 – ELISA Analysis of IL-17 production in the presence of B. bacilliformis GroEL. ........................................................................................................ 190
Figure 3.34 – ELISA Analysis of IL-18 production in the presence of B. bacilliformis GroEL. ........................................................................................................ 191
Figure 3.35 – Analysis of a possible staphylocoagulase motif site in B. bacilliformis GroEL. ........................................................................................................ 196
**List of Abbreviations**

<table>
<thead>
<tr>
<th>Abbreviation</th>
<th>Description</th>
</tr>
</thead>
<tbody>
<tr>
<td>BHI</td>
<td>Brain Heart Infusion Agar/Broth</td>
</tr>
<tr>
<td>Bp</td>
<td>Base Pair</td>
</tr>
<tr>
<td>FGF</td>
<td>Fibroblast Growth Factor</td>
</tr>
<tr>
<td>GSP</td>
<td>Gene Specific Primer</td>
</tr>
<tr>
<td>HMEC-1</td>
<td>Human Microdermal Endothelial Cell</td>
</tr>
<tr>
<td>HSP</td>
<td>Heat Shock Protein</td>
</tr>
<tr>
<td>HUVEC</td>
<td>Human Umbilical Vein Endothelial Cell</td>
</tr>
<tr>
<td>ialA</td>
<td>Invasion associated locus product A</td>
</tr>
<tr>
<td>ialB</td>
<td>Invasion associated locus product B</td>
</tr>
<tr>
<td>IFN</td>
<td>Interferon</td>
</tr>
<tr>
<td>kDa</td>
<td>Kilodalton</td>
</tr>
<tr>
<td>KS Lesion</td>
<td>Kaposi’s Sarcoma Lesion</td>
</tr>
<tr>
<td>LN₂</td>
<td>Liquid Nitrogen</td>
</tr>
<tr>
<td>Mbp</td>
<td>Mega base pairs</td>
</tr>
<tr>
<td>ORF</td>
<td>Open Reading Frame</td>
</tr>
<tr>
<td>PCR</td>
<td>Polymerase Chain Reaction</td>
</tr>
<tr>
<td>RBC</td>
<td>Red Blood Cell/Erythrocyte</td>
</tr>
<tr>
<td>RT-PCR</td>
<td>Reverse Transcriptase-Polymerase Chain Reaction</td>
</tr>
<tr>
<td>SB</td>
<td>Sheep’s Blood</td>
</tr>
<tr>
<td>TFSS</td>
<td>Type-IV Secretion System</td>
</tr>
<tr>
<td>TSA</td>
<td>Tryptic Soy Agar</td>
</tr>
<tr>
<td>VEGF</td>
<td>Vascular Endothelial Growth Factor</td>
</tr>
</tbody>
</table>
General Introduction

*Bartonella* Species – Microbiological Aspects, Identification & Epidemiology

As emerging pathogens, *Bartonella* species show a wide variety of infective abilities and potential hosts. *Bartonella* are Gram-negative bacilli, many of which possess polar flagella and are highly motile. Clinical growth of *Bartonella* species requires incubation between 25 and 37°C in 5% CO₂ on a blood rich media, such as BHI (Brain Heart Infusion) containing 5-10% sheep’s blood. *Bartonella* are extremely slow growing *in vitro*, typically requiring 14 days for primary isolate culture growth. Although growth in liquid media is possible, *Bartonella* species tend to be grown on solid media due to their fastidious nature and lack of turbidity. *Bartonella* colonies tend to be sticky, irregular, raised, whitish, self-adherent and very small. Biochemically, *Bartonella* species tend to be carbohydrate-metabolism inert, and catalase and oxidase reaction negative (Anderson, 1997; Maurin *et al.*, 1997). *Bartonella* species contain relatively small genomes, with sizes ranging from 1.5 – 2.0 Mbp, and a G+C content of approximately 40% (Schmidt, 1998). Diagnostic identification of intraspecies differentiation has relied heavily on the use of 16S rRNA and the gene for citrate synthesis (*gltA*) (Birtles *et al.*, 1996; Ehrenborg *et al.*, 2000).

Comparative sequence analysis places *Bartonella* in the α-2 subgroup of Proteobacteria, a class that also contains *Afipia*, *Agrobacterium* and *Brucella*.

The first identified *Bartonella* species, *Bartonella bacilliformis*, was originally described in 1909. This strain remained the only member of the *Bartonella* genus for more than 80 years. In the early 1990s, however, detailed 16S rRNA analysis of several species belonging to *Rochalimaea*, a genus previously classified as *Rickettsiaceae*, showed such a close similarity to *Bartonella bacilliformis* that the decision was made to combine these two
genera into a single genus (O'Connor et al., 1991). The taxonomic unification of *Rochalimaea* and *Bartonella* added four more strains, *B. quintana*, *B. henselae*, *B. clarridgeiae* and *B. elizabethae*, to the *Bartonella* genus (Brenner et al., 1993). Since that time, numerous new *Bartonella* species have been identified, bringing the current total to more than 20 (Birtles et al., 1995).

Of the many *Bartonella* species known, only a few have been identified as human pathogens. The best characterized of these are *B. henselae*, and *B. quintana*. *B. henselae*, the causative agent of Cat Scratch Disease (CSD), is the most widely-studied of all *Bartonella* species. Initially identified as a member of the genus *Rochalimaea*, *B. henselae* causes the highest number of infections of any of the human *Bartonella* pathogens. The bacterium is transmitted to humans through the bite or scratch from a cat or other small mammal. Symptoms begin with the formation of localized erythematous papules, followed by a mild fever and lymphadenitis. Normally, the course of the infection is self-limiting in an immunocompetent host (Brenner et al., 1993), with the localized swelling at the site of infection being cleared quickly, and the fever and lymphadenitis disappearing over the course of several weeks. (Dehio et al., 1997; Kordick et al., 1995; Maurin et al., 1997). In patients with damaged or compromised immune function, however, infection by *B. henselae* can result in bacillary angiomatosis (BA) and/or peliosis hepatitis (Koehler et al., 2003; Maurin et al., 1997; Schmidt, 1998), two conditions characterized by the appearance of angiogenic lesions on the skin and internal organs, respectively (Dehio, 2003). Several studies have correlated the production of these lesions directly with *B. henselae* infection, and have highlighted the role played by invading macrophages in the vascular proliferative process (Kirby, 2004; McCord et al., 2005; McCord et al., 2006; Resto-Ruiz et al., 2002).
*B. quintana* is transmitted via the body louse and is found predominantly among homeless and immunocompromised individuals (Foucault *et al.*, 2002; Jackson, 1996; Rolain *et al.*, 2003). Infection by *B. quintana*, which results in a condition known as Urban Trench Fever, is often accompanied by recurring high fevers and severe pain in the back and shins (Ohl *et al.*, 2000). This repeating cycle of clinical symptoms is thought to be caused by the process of *B. quintana* invasion and release from host cells, and can result in bacteremia and BA. Studies have shown that both *B. henselae* and *B. quintana* are able to attach to and invade multiple cell types, including erythrocytes, epithelial and endothelial cells (Batterman *et al.*, 1995). Once they have successfully invaded the cell, these bacteria are able to alter normal cell cycle pathways. Apoptosis is turned off during the initial stages of infection and vascular proliferation is induced, with both processes acting in concert to increase the numbers of infected cells (Liberto *et al.*, 2004; Liberto *et al.*, 2003).

*B. henselae* and *B. quintana* are more closely related to each other than they are to either of two other human pathogens, *B. claridgeiae* and *B. bacilliformis* (Anderson, 1997). Clinical manifestations of *B. claridgeiae* infection are similar to those of CSD. Like *B. henselae* and *B. quintana*, *B. claridgeiae* can induce BA formation in an immunocompromised host (Berger *et al.*, 1993; Maurin *et al.*, 1997). Little research has been done regarding the molecular mechanisms underlying *B. claridgeiae* infection or the role host cells play during the process of infection.
Bartonella bacilliformis – History & Epidemiology

In 1909, Dr. A.L. Barton described an erythrocyte-adherent bacillus-shaped bacterium that he named Bartonella bacilliformis. This bacterium was later determined to be the causative agent of Oroya fever, a disease characterized by severe hemolytic anemia and an untreated mortality rate of 85% (Anderson, 1997; Chomel et al., 2003). The vector responsible for host-to-host transmission of B. bacilliformis is Lutzomyia verrucarum (formerly known as Phlebotomus), a sandfly that inhabits the high-altitude valleys of the Andes mountains (Anderson, 1997; Schultz, 1968b). Transmission of the bacterium takes place when the female sandfly infects its human host during nocturnal blood-feeding; the source of the bacterium in the sandfly is the previous human host on which it fed (Schmidt, 1998). Replication of B. bacilliformis is not known to occur in the sandfly nor does B. bacilliformis infect the sandfly itself. Unlike other Bartonella species, B. bacilliformis has not been conclusively shown to infect any host other than humans, although there have been anecdotal reports of infection of farm animals as well (Anderson, 1997). The requirement for the sandfly as a vector is very specific, and normally limits the infective range of B. bacilliformis to the sandfly’s natural habitat in the inter-Andean mountains of Peru, Columbia and Ecuador.

Bartonella bacilliformis is the causative agent of Carrion’s disease, a biphasic disease consisting of the initial acute phase, Oroya fever, and a second, chronic phase, called verruga peruana. During the Oroya fever phase (so named for a Peruvian valley where it has often been reported), the bacteria invade nearly 100% of the host erythrocytes, causing a life-threatening sepsis and hemolysis. Oroya fever epidemics have been recorded since pre-Incan times. A particularly devastating outbreak occurred between 1869 and 1873, killing nearly
10,000 railroad workers (Hertig, 1942; Schultz, 1968a). Survivors of Oroya fever may subsequently develop verruga peruana, a condition characterized by the eruption of blood-filled nodules on the skin of infected patients. The link between Oroya fever and nodule formation was established by a Peruvian medical student, Daniel Carrion, who injected himself with the bloody material from a patient suffering from verruga peruana, and carefully documented the appearance of Oroya fever symptoms. Carrion died from the resulting illness, and the disease that killed him was subsequently named Carrion’s disease in acknowledgement of his sacrifice.

_Bartonella bacilliformis_ – Known Virulence Factors

_Invasion-related Factors_

_Bartonella bacilliformis_ is known to code for several virulence factors that help the bacterium survive in both its arthropod and human host. Studies have shown that the bacterium is able to invade a wide variety of cells, including red blood cells (RBCs), endothelial and epithelial cells. The majority of research has focused on the invasion of _B. bacilliformis_ into host RBCs during the Oroya fever stage of the infection (Benson _et al._, 1986). Red blood cells, which are nonendocytotic and unnucleated, are the first host cells to be invaded (Dehio, 2001). During RBC infection, _B. bacilliformis_ is known to use at least three bacterial-encoded virulence factors: flagella, deformin and the invasion-associated locus gene products IalA and IalB (Buckles _et al._, 2000; Cartwright _et al._, 1999; Coleman _et al._, 2001; Mernaugh _et al._, 1992; Mitchell _et al._, 1995). The first, and most intensely studied, virulence factor is the flagellum. _B. bacilliformis_ contains several polar flagella and is highly motile. The flagella are composed of multiple 42-kDa flagellin subunits and are highly resistant to both protease K and trypsin treatment (Anderson, 1997; Scherer _et al._, 1993).
Pre-incubation of *B. bacilliformis* with anti-flagella antibodies significantly reduces the efficiency of invasion (Scherer *et al.*, 1993). Moreover, a mutant lacking flagella exhibits a 75% reduction in its ability to bind to erythrocytes (Battisti *et al.*, 1999). At the present time, it is not known whether flagella play a direct role in binding to erythrocytes, or whether the motility they provide simply increases the likelihood that the bacterium will collide with a host cell, although studies with inhibitors of respiration and motive force support the latter interpretation (Benson *et al.*, 1986; Scherer *et al.*, 1993). *B. henselae* and *B. quintana* do not show the presence of flagella, thus leading some investigators to suggest that the motive-force provided by the *B. bacilliformis* flagella is not necessary for invasion (Anderson, 1997).

Deformin, a second well-studied *B. bacilliformis* virulence factor, produces deep invaginations within the RBC cell membrane. The secretion of deformin and the resulting formation of membrane invaginations are believed to enhance the ability of the flagellated *B. bacilliformis* to “push” itself into host RBCs (Mernaugh *et al.*, 1992; Xu *et al.*, 1995). Studies of purified deformin show that it is able to achieve these invaginations even in the absence of bacteria (Iwaki-Egawa *et al.*, 1997). Deformin activity has been reported to reside in a complex of several 36-kDa proteins with a small (1.4 kDa) hydrophobic molecule (Hendrix and Kiss, 2003). The exact composition of the hydrophobic molecule has not yet been determined. The role(s) of IalA and IalB in invasion by *B. bacilliformis* show genetic similarities to invasion-associated genes products found in *Yersinia* species (Anderson, 1997; Mecsas *et al.*, 1995; Wachtel *et al.*, 1995). The *ialA* gene is 510 bp and codes for a putative NTPase core protein, while *ialB* is 558 bp and codes for a homologue of the *Yersinia ail* (adhesion and invasion locus) protein (Cartwright *et al.*, 1999; Coleman *et al.*, 2001). *B. bacilliformis* IalA acts as a (di)nucleoside polyphosphate hydrolase, and has distinct
homology to the nudix class of nucleotide pyrophosphatases produced by *A. tumefaciens* (Xu et al., 2003). The function of IalB has not been determined, but it is known to be an inner membrane protein that is also required for *B. bacilliformis* RBC invasion (Coleman et al., 2003; Mitchell et al., 1995). Studies with *E. coli* harboring recombinant plasmids carrying the *ialAB* locus have shown that both *ialA* and *ialB* are required for invasiveness *in vitro*, as indicated by a 6- to 39-fold increase in invasion in the presence of both genes. Moreover, expression of *ialAB* enhances the efficiency of invasion even in the absence of flagella (Coleman et al., 2003).

*B. bacilliformis* is known to continue replication inside both the endosomal vacuole and the cytoplasm of RBCs without lysing either cell type. While the purpose of RBC colonization is still unknown, it is generally considered to increase the potential for successful invasion, since it provides *B. bacilliformis* with direct access to host iron and any other blood-supplied host growth factor(s) the bacterium might require. Colonization of RBCs would also give *B. bacilliformis* a safe haven in which to replicate where it could effectively evade the host immune response.

Investigations are ongoing to determine the mechanism(s) by which *B. bacilliformis* invades host endothelial and epithelial cells (Dehio, 2001; Garcia et al., 1992), a process that results in the verruga stage of the infection. Cellular invasion is known to require the activity of *B. bacilliformis* flagella, as shown by a 50-90% decrease in invasion when cells are incubated with anti-*B. bacilliformis* flagella antibodies (Scherer et al., 1993). The process is also reported to be Rho-GTPase dependent, as indicated by a decrease in *B. bacilliformis* invasion when endothelial cells are pre-incubated with C3 exoenzyme, a protein known to inactivate Rho-GTPase (Verma et al., 2000; Verma et al., 2002). These data suggest that *B.*
*Bacilliformis* invasion is dependent upon actin rearrangement in host cells. This hypothesis is supported further by the observation that uptake of the bacteria is significantly reduced in the presence of cytochalasin D, which inhibits host actin rearrangement (Hoang *et al.*, 2004). Additional studies indicate that *B. bacilliformis* outer membrane proteins play a direct role in invasion, as the presence of anti-*Bartonella* anti-sera causes a marked decrease in bacteria uptake (Minnick, 1994). Within one hour of invasion, *B. bacilliformis*-induced actin rearrangement leads to the formation of filamentous actin extensions called filopodia. Filopodia formation is accompanied by host cell membrane ruffling, a phenomenon that may implicate the activation of Rac and Cdc42 and other host signaling pathways (Verma *et al.*, 2002). Invasion is most often seen in the endothelial cells which line the capillary beds of the host skin and related subcutaneous tissues. Host endothelial and epithelial cells contain the invaded *B. bacilliformis* within a vacuole called the invasome, a term coined specifically for *B. bacilliformis* (Dehio *et al.*, 1997). The invasome has been shown to migrate from the cell membrane to a position near the host nucleus, although the mechanism and effect of this translocation are unknown. Bacterial invasion into these cells is characterized by two distinct histological manifestations of verruga peruana. The first consists of spindle-form lesions that contain fusiform cells with T cell and monocyte/macrophage infiltration. The second is described as a pyogenic granulomatous hemangioma characterized by a hyperplastic endothelium and extensive vascularization (Anderson, 1997; Maurin *et al.*, 1997). When examined histologically, the spindle-form lesions are strikingly similar to Kaposi’s sarcoma, while the granulomatous forms tend to resemble the bacillary angiomatosis seen during infection by *B. henselae* (Berger *et al.*, 1993; Caceres-Rios *et al.*, 1995; Cockerell, 1992).
The invasion of epithelial cells has been shown to cause the up-regulation of numerous growth factors, cytokines and interleukins, some of which are known to be involved in angiogenesis (Claesson-Welsh, 1999; Fox, 2001). Previous work has indicated that the invasion of *B. bacilliformis* into epithelial cells produces a transient up-regulation of TNF-α, which is in turn known to up-regulate the production of various angiogenic factors. Studies exposing cultured endothelial cells to *B. bacilliformis* extracts have led to the suggestion that the bacterium itself produces a possible mitotic and/or angiogenic factor (Garcia *et al.*, 1990; Garcia *et al.*, 1992). A *B. bacilliformis* heat shock protein, Bb65, strongly activates T cells which in turn produce Eta-1/osteopotin, an inducer of vascular cell proliferation (Knobloch *et al.*, 1990).

**Adherence-Related Factors**

Several laboratories are involved in the characterization of factors responsible for promoting adherence of *B. bacilliformis* to the host cell. Initially, work by Walker and Winkler (1981) suggested that “fiber-like projections” on the polar surface of the bacterium were responsible for contact with the RBC surface (Anderson, 1997; Walker *et al.*, 1981). These “projections” have been studied further and show a resemblance to the Bundle-forming pili (BFP) found in *E. coli* and *S. enteritidis*. The bundles range in size from 50 to 600 nm and have been shown to be resistant to solubilization by SDS and formic acid.

The aforementioned flagella may also play a role in the adhesion of *B. bacilliformis* to host cells (Krueger *et al.*, 1995). Studies have shown that cultures of *B. bacilliformis* that have been highly-passaged or have had their flagella removed bind poorly to host RBCs, although this may be due less to a direct role of flagella in adhesion than to a requirement for flagellar-motive force in promoting collisions between the bacterium and the host cell.
Infection with *B. bacilliformis* begins a rapid and energy-dependent adhesion to and invasion of RBCs. *In vitro* studies show a 15-30 minute lag time between introduction and adhesion, with maximal adhesion at six hours post infection (Verma *et al.*, 2001; Verma *et al.*, 2000; Verma *et al.*, 2002). The treatment of *B. bacilliformis* with agents that inactivate bacterial proton-motive force (N-ethylmaleimide) or respiration (KCN) results in a significant decrease in their binding to RBCs. However, exposure of the RBCs to glycolysis (NaF) or proton-motive force (N-ethylmaleimide) inhibitors has no affect on bacterial adherence, suggesting that the RBC itself is passive in the adhesion process and does not contribute energy (Verma *et al.*, 2002). The host receptor for *B. bacilliformis* has not been identified but the bacterium shows a definite predilection for rabbit or sheep RBCs. Research in the Baumstark lab has shown that *B. bacilliformis* is able to invade both enucleated (sheep) and nucleated (goose) RBCs (McCormick, personal communication).
The virB Operon

Previous studies on the infectious process of the plant pathogen *A. tumefaciens* identified a set of genes, termed the *virB* operon, that are required for the infection of plant cells (Chen et al., 2002; Krall et al., 2002). In *A. tumefaciens*, the *virB* operon was found to contain 11 genes, designated *virB1* through *virB11* depending on their location downstream of the *vir* Box, a regulatory element found directly upstream of *virB1*. It was subsequently proposed that the *virB* operon acts to form a Type IV secretion system (TFSS) that provides a conduit for *A. tumefaciens* to transfer a single stranded copy of T DNA, or T strand, into plant host cells (Boschiroli et al., 2002; Escudero et al., 1995; Ohashi et al., 2002). Originally, Type IV secretion systems were identified in mating-pair formation systems (Mpf systems) required for the conjugal transfer of plasmid DNA. They are thought primarily to form pilus structures for DNA transfer to recipient cells. *A. tumefaciens* and *E. coli* have been the only bacteria positively identified as having these systems (Chen et al., 2002). The functions of all the *virB* proteins composing the *A. tumefaciens* *virB* operon have not yet been elucidated. However, several *virB* proteins have been characterized and a model outlining the structure and assembly of the secretion machinery has been developed (Figure GI.1) (Baron et al., 2001; Sagulenko et al., 2001). The best characterized *virB* gene products in *A. tumefaciens* are VirB2, forming the transfer pilus, VirB4, a putative ATPase, and VirB9, 10 and 11, which interact to form a protein complex that anchors the TFSS to the cell membrane (Figure GI.1) (Boschiroli et al., 2002; Krall et al., 2002; Sagulenko et al., 2001; Stephens, Kathryn et al., 1995).

Previous work in our laboratory revealed the presence of a homologue to the *A. tumefaciens virB* operon in *B. henselae* (Anderson, 1997; Padmalayam et al., 2000b;
Schmiederer et al., 2001). The *B. henselae* vir*B* operon is composed of 10 genes that exhibit homology to the *A. tumefaciens* vir*B* genes, as shown in Table G1.1, and are positioned in a similar order within the operon. While mutagenesis studies and deletions of the vir*B* operon have not been conducted in *B. henselae*, it has been noted that continued passage of the cells leads to a decrease in virulence, which may be related to the loss of VirB2 pilus formation (personal communication, Padmalayam). Interaction studies with vir*B*-encoded proteins suggest that TFSS formation of the *B. henselae* vir*B* operon is similar to that of *A. tumefaciens* (Shamaei-Tousi et al., 2004). These studies indicate that the VirB2 protein acts as the primary subunit of the TFSS pilus, with VirB3, VirB9, the 17kDa antigen (encoded by vir*B*5) and the 15kDa antigen (encoded by vir*B*7) serving as pore-forming anchors in the periplasm. The inner member anchor proteins VirB4, VirB8, VirB10 and VirB11 are proposed to interact to form a pore into the cytoplasm. Recently, identification of vir*B* protein homologues in *S. meliloti, Brucella suis, Brucella abortus, Bordatella pertussis* and additional *Bartonella* species has been reported, with functional studies suggesting that they play a role as TFSS transport machinery (Boschiroli et al., 2002; Gorvel et al., 2002; Ohashi et al., 2002; Weiss et al., 1993).
Figure GI.1 – Assembly of the virB gene products in A. tumefaciens.
The proposed assembly of the virB operon proteins, functioning as a TFSS, is shown above. According to this model, A. tumefaciens VirB2 (in yellow) forms the pilus for cell-to-cell contact, with VirB9 (dark red) as an outer membrane-bound anchor. VirB4, in dark blue, is predicted to act as an ATPase and provide energy into the process for Ti DNA translocation. The associated VirB9/10/11 protein complex (light blue and purple) forms the inner membrane-bound anchor (Christie, 1997).

Figure GI.2 – Proposed Assembly of virB gene products in B. henselae.
The proposed assembly of the virB operon proteins, functioning as a TFSS, is shown above. B. henselae VirB2 (in yellow) forms the pilus, interacting with the 17kDa antigen (VirB5, shown in dark purple). VirB3 (orange), VirB9 (red) and the 15kDa antigen (purple) form a periplasmic pore. The VirB4 (green) and VirB11 (blue) are membrane-bound and predicted to act as ATPases. The associated VirB8/10/11 protein complex (yellow and blue) form the inner membrane-bound anchor (Shamaei-Tousi et al., 2004).
Table GI.1 – Homology of selected Bartonella virB operon genes compared to the A. tumefaciens virB Operon.

The following table indicates the DNA sequence identity within the open reading frames coding for virB proteins of *A. tumefaciens* and the *Bartonella* species.

<table>
<thead>
<tr>
<th>% DNA Sequence Identity</th>
<th>Brucella Suis</th>
<th>Sinorhizobium meliloti</th>
<th>Bartonella henselae</th>
<th>Bartonella tribocorum</th>
</tr>
</thead>
<tbody>
<tr>
<td>virB2-homologue</td>
<td>47</td>
<td>45</td>
<td>34</td>
<td>36</td>
</tr>
<tr>
<td>virB3-homologue</td>
<td>43</td>
<td>39</td>
<td>44</td>
<td>41</td>
</tr>
<tr>
<td>virB4-homologue</td>
<td>47</td>
<td>45</td>
<td>50</td>
<td>49</td>
</tr>
<tr>
<td>17kDa Antigen</td>
<td>N/A</td>
<td>N/A</td>
<td>N/A</td>
<td>N/A</td>
</tr>
<tr>
<td>virB6-homologue</td>
<td>46</td>
<td>46</td>
<td>40</td>
<td>38</td>
</tr>
<tr>
<td>15kDa Antigen</td>
<td>N/A</td>
<td>N/A</td>
<td>N/A</td>
<td>N/A</td>
</tr>
<tr>
<td>virB8-homologue</td>
<td>48</td>
<td>48</td>
<td>38</td>
<td>43</td>
</tr>
<tr>
<td>virB9-homologue</td>
<td>46</td>
<td>46</td>
<td>41</td>
<td>42</td>
</tr>
<tr>
<td>virB10-homologue</td>
<td>48</td>
<td>48</td>
<td>44</td>
<td>43</td>
</tr>
<tr>
<td>virB11-homologue</td>
<td>42</td>
<td>42</td>
<td>48</td>
<td>48</td>
</tr>
</tbody>
</table>
Angiogenesis

The verruga peruana stage of Carrion’s disease is marked by blood-filled skin nodules, resulting from the uncontrolled up-regulation of angiogenesis in localized endothelial cells (Caceres-Rios et al., 1995; Garcia et al., 1992). Up-regulation of angiogenesis is initiated by the invasion of *B. bacilliformis* into host cells. The activation and suppression of angiogenesis is normally tightly controlled by the balanced production of both angiogenic stimulators and angiogenic suppressors in multiple cell types. In general, however, angiogenesis is regulated by Vascular Endothelial Growth Factor (VEGF) and β-Fibroblast Growth Factor (βFGF), and the presence of their respective receptors on endothelial cells. VEGF, and its alternative splicing protein VPF, activate angiogenesis by specifically increasing the microvascular permeability of endothelial cells to other plasma proteins and by phosphorylating VEGFR-1 and 2 (VEGF receptors 1 and 2). This phosphorylation causes the activation of phospholipase C\(_{\gamma}\) and an increase in cytoplasmic Ca\(^{2+}\) levels, resulting in the generation of inositol 1,4,5-triphosphate (IP\(_3\)) and diacylglycerol (DAG). Production of these intracellular messengers along with the activation of VEGFR-1 and -2 results in a strong cell proliferation response and the generation of matrix-degrading proteases (Claesson-Welsh, 1999; Dong et al., 2001). βFGF also functions as a mitogenic protein, specifically stimulating endothelial cells to migrate and form tubules while also increasing the production of proteases (Folkman et al., 1992). However, VEGF and βFGF are not the only angiogenesis effecting factors, as shown in Table GI.2 (Bamias et al., 2003; Conway et al., 2001; Sottile, 2004). The factors listed are all able to upset the natural balance of angiogenesis, driving it in a specific direction, and can be produced by a variety of cell types, including epithelial cells. The process of angiogenesis begins with the
vasodilation and increased permeability of existing blood vessels, along with increased
permeability and degradation of the surrounding extracellular matrix. This allows for the
activated endothelial cells to migrate and form new lumen walls; generating a “pathway” for
returning to a larger blood vessel (Carmeliet, 2000; Neufeld et al., 1999). These endothelial
cells mature by remodeling themselves to supply the surrounding area with their specific
requirements, and are functional once a stable matrix and musculature are established
(Neufeld et al., 1999). In the verruga peruana stage of B. bacilliformis infection, the blood
vessels produced are not seen in a mature form; instead, they are open-ended and allow blood
to leak into the cutaneous and interstitial spaces around them. The invasion of epithelial cells
is known to cause the up-regulation of numerous growth factors, cytokines and interleukins,
some of which (Table GI.2) are known to be involved in angiogenesis (Claesson-Welsh,
1999; Folkman et al., 1992). Previous work has indicated that the invasion of endothelial
cells by B. bacilliformis produces a transient up-regulation of TNF-α, which in turn is known
to up-regulate VEGF production. BB65, a heat shock and highly immunogenic B.
bacilliformis protein, strongly activates T cells which in turn produce host Eta-1/osteopotin, a
protein that is then transiently able to induce vascular cell proliferation. Interestingly, almost
all skin disorders, such as psoriasis, show an increase of VEGF and VEGF-related proteins in
epithelial cells as well as an increase in VEGF receptors in endothelial cells (Carmeliet,
2000; Hudlick et al., 1986; Knobloch et al., 1990; Takahashi et al., 2002).
Table GI.2 – Factors produced by host cells involved with angiogenesis.
The table below shows the wide variety of host cell products which are involved in angiogenesis.

<table>
<thead>
<tr>
<th>Protein</th>
<th>Function</th>
<th>Protein</th>
<th>Function</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Activators</strong></td>
<td></td>
<td><strong>Inhibitors</strong></td>
<td></td>
</tr>
<tr>
<td>Angiopoietin-1</td>
<td>Stabilization of vessels via tightening endothelial-smooth muscle interactions</td>
<td>Angiopoietin-2</td>
<td>Induction of vessel regression without further angiogenesis signals</td>
</tr>
<tr>
<td>Angiotropin</td>
<td>Endothelial growth factor</td>
<td>Angiostatin</td>
<td>Inhibition of growth and migration</td>
</tr>
<tr>
<td>avb3 Integrin</td>
<td>Receptor of matrix macromolecules</td>
<td>Endostatin</td>
<td>Inhibition of growth and survival</td>
</tr>
<tr>
<td>avb5 Integrin</td>
<td>Receptor of matrix macromolecules</td>
<td>IP-10</td>
<td>Inhibition of endothelial growth and survival</td>
</tr>
<tr>
<td>COX2</td>
<td>Essential for tumor angiogenesis</td>
<td>Thrombospondin-1</td>
<td>Inhibition of endothelial migration, growth and differentiation</td>
</tr>
<tr>
<td>Endoglin</td>
<td>Stimulation of extracellular matrix production</td>
<td>Vasostatin</td>
<td>Endothelial cell growth inhibitor</td>
</tr>
<tr>
<td>Ephrins</td>
<td>Regulation of artery/vein phenotype</td>
<td></td>
<td></td>
</tr>
<tr>
<td>FGF</td>
<td>Stimulates angiogenesis &amp; arteriogenesis</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Fibronectin</td>
<td>Promotion of endothelial adhesion, growth and survival</td>
<td></td>
<td></td>
</tr>
<tr>
<td>HIF1a</td>
<td>Hypoxia-induced endothelial growth factor</td>
<td></td>
<td></td>
</tr>
<tr>
<td>IL-6</td>
<td>Endothelial growth factor</td>
<td></td>
<td></td>
</tr>
<tr>
<td>IL-8</td>
<td>Endothelial growth factor</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Laminin 1</td>
<td>Promotion of Endothelial tube formation</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Matrix</td>
<td>Cellular migration and matrix remodeling</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Metalloproteinase</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Protein (con’t)</td>
<td>Function</td>
<td></td>
<td></td>
</tr>
<tr>
<td>---------------------------------</td>
<td>--------------------------------------------------------------------------</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Activators</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>MCP-1</td>
<td>Stimulation of arterogenesis</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>Stimulation of angiogenesis and vasodilation</td>
<td></td>
<td></td>
</tr>
<tr>
<td>NO Synthase</td>
<td>Recruitment of smooth muscle cells</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>Endothelial junction</td>
<td></td>
<td></td>
</tr>
<tr>
<td>PDGF and receptors</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>PECAM</td>
<td>molecule, essential for cell survival</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Perlecan</td>
<td>Enhancement of FGF Signaling</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Ras</td>
<td>Pro-angiogenic oncogene</td>
<td></td>
<td></td>
</tr>
<tr>
<td>TGF-B &amp; B1</td>
<td>Stimulation of extracellular matrix production</td>
<td></td>
<td></td>
</tr>
<tr>
<td>VEGF Receptors</td>
<td>Angiogenic signaling receptor</td>
<td></td>
<td></td>
</tr>
<tr>
<td>VEGF, VEGF-C, PIGF and various</td>
<td>Stimulation of angiogenesis</td>
<td></td>
<td></td>
</tr>
<tr>
<td>homologues</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Vitronectin</td>
<td>Promotion of endothelial survival and migration</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>
The goal of this study is to gain insights into the molecular mechanism by which *B. bacilliformis* induces the formation of verruga peruana during Carrion’s disease. Our research has revealed that *B. bacilliformis* does not contain any homologues to the *virB* operon found in several other *Bartonella* species and has led us to conclude that this operon does not play a role in verruga peruana formation. Interestingly, using microarray-based analysis of infected HMEC-1 cells, we have determined that several hypoxia and angiogenic factors are up-regulated or significantly altered, which may aid in the induction of angiogenesis. We also show that infected HMEC-1 cells produce high levels of immune response genes, corresponding to an interferon-based immune response; this would likely result in the recruitment of immune effector cells which could in turn produce more angiogenic up-regulatory factors. Finally, we have found the secretion, by *B. bacilliformis*, of a unique GroEL protein. Motif analysis indicates that this GroEL contains a staphylocoagulase binding site, which may interact with host integrins up-regulate multiple pathways, including angiogenesis. While this GroEL may be angiogenic, it may also function to protect HMEC-1 cells from the tubule degradation effects seen in the presence of live *B. bacilliformis*. Taken together, these results suggest to us that the infection of host endothelial cells by *B. bacilliformis* induces a strong interferon-based immune response that is coupled with host cell hypoxia in a microenvironment containing high concentrations of an angiogenic GroEL protein, and that this series of events results in the localized formation of verruga peruana.
**GroEL**

The cellular environment is often inhospitable to the folding and unfolding of proteins in their biologically active confirmation. Therefore, both prokaryotes and eukaryotes contain proteins, called molecular chaperones, that allow this confirmation to occur on a physiological timescale (Fenton et al., 2003). Chaperones are classified into two groups according to their sequence homologies: Type I, represented by GroEL; and Type II, represented by eukaryotic CCT (cytosolic chaperonin containing TCP-1) and archaeabacterial chaperones (Carrascosa et al., 2001). GroEL and the CCT chaperones differ in several ways. Firstly, GroEL is considered nonspecific with respect to its substrate binding while CCT is more specialized. Secondly, GroEL is a homeric-protein whereas CCT is a heteromeric complex built of eight different polypeptides (Carrascosa et al., 2001). Finally, GroEL requires a cofactor while CCT does not (Carrascosa et al., 2001). The main Type I cytoplasmic chaperones identified to date include HtpG, the Clp system, trigger factor, the DnaK system, and the GroE system. Little is known about the role of the HtpG system in promoting proper folding, although the chaperone is highly expressed during heat shock. Bacterial strains that do not contain the HtpG system behave like wild-type strains and show no distinctive phenotype associated with the loss of the chaperone (Wong et al., 2004). The Clp family of chaperones consists of a group of ATP-binding proteins that were originally isolated based on their association with the serine protease ClpP. ClpA, ClpX and HslU all exhibit ATP hydrolytic activity, which provides the energy required for ClpP-mediated proteolysis. ClpB also binds to the serine protease, but does not hydrolyze ATP. Clp proteins can be further divided into two classes according to the number of nucleotide binding domains in each protein. ClpA and ClpB contain two nucleotide binding domains
while ClpX and HslU contain only one nucleotide binding domain (Wong et al., 2004). These ATP binding proteins not only target misfolded or foreign proteins for degradation, but can also act as chaperones to promote refolding of improperly folded proteins.

Trigger factor is a chaperone that is common to all eubacteria. In E. coli, it has been shown to interact with nascent chains and to bind closely to the nascent chain exit site of the ribosomal complex (Wong et al., 2004). Trigger factor is involved in the prevention of misfolding and the aggregation of nascent chains as they are translated by the ribosome. DnaK is an ATP-dependent chaperone that functions in concert with the co-chaperone DnaJ. DnaK recognizes hydrophobic sequences in extended polypeptide chains. Like trigger factor, it binds to nascent chains (Wong et al., 2004). In eukaryotes, DnaK is present in the cytosol, endoplasmic reticulum, mitochondria and chloroplasts, and acts in concert with DnaJ and GrpE (Ranson et al., 1998). GroEL often acts in concert with a second protein, GroES. The GroESL system promotes protein refolding in two stages. First, it prevents the aggregation of non-native nascent peptides by forming complexes with them and thus lowering the concentration of aggregation-prone peptides in solution. Second, it releases the bound substrates into the central cavity of the GroEL complex, allowing folding in a protected environment without intramolecular interactions. It has been suggested that GroESL has the ability to unfold kinetically-trapped folding intermediates, thereby giving them a new chance to fold correctly (Wong et al., 2004).

GroEL is an oligomeric complex of 14 identical 57-kilodalton subunits arranged in 7-member rings sticking back to back. The crystal structure of GroEL shows a hollow cylindrical complex 135Å in diameter with a height of 145 Å (Grallert et al., 2001). The openings at each end of the cylinder form the entrance to a cavity with a diameter of 45 Å.
The GroEL monomer consists of 547 amino acids arranged in three distinct domains: equatorial, intermediate and apical. The equatorial domain, which contains a nucleotide binding site, is also used for the inter-and intra-ring interactions of a protein complex. This domain also contains the ATP binding site, which is located on the inner sides of the GroEL cylinder (Gomez-Puertas et al., 2004; Grallert et al., 2001; Wong et al., 2004). The apical domain binds to both the substrate and GroES (Gomez-Puertas et al., 2004; Grallert et al., 2001). The intermediate domain of each subunit transfers the ATP-induced conformational changes from the equatorial domain to the apical domain (Grallert et al., 2001; Wong et al., 2004). GroES, a seven-member ring structure composed of 10-kilodalton subunits, binds ATP on one or both ends of the GroEL cylinder. GroES exhibits a dome-shaped structure with outside dimensions of 80 Å in diameter and 30 Å in height, and inside dimensions of 30 Å in diameter and 20 Å in height (Grallert et al., 2001). Transcription of the E. coli GroESL system is positively controlled by the product of rpoH, the heat shock promoter-specific σ^{32} subunit of RNA polymerase (Arsene et al., 2000). The heat shock response is induced as a consequence of a rapid increase in σ^{32} levels and the stimulation of σ^{32} activity. Down-regulation of the GroESL response occurs as a consequence of declining σ^{32} levels as heat stress signaling decreases (Arsene et al., 2000).

GroEL activity requires communication between the three ring domains, which is accomplished by the interaction of GroES and ATP at specific times during the nascent protein binding cycle (Amir et al., 2004). In the ATP-free conformation, the GroEL chaperone has an open structure and a high affinity for unfolded substrates. In contrast, in the ATP-bound conformation the cavity structure is closed and has a low affinity for substrates (Gomez-Puertas et al., 2004; Ranson et al., 1998). Substrate recognition is
achieved by the presence of hydrophobic residues on the unfolded polypeptide, which are exposed to the surface and are recognized by interaction with hydrophobic residues of the chaperone-binding site (Gomez-Puertas et al., 2004). Functional protein folding in the presence of the whole GroESL chaperone system proceeds by a reaction cycle that begins with the binding of protein substrate to the intermediate domain. This then allows for the binding of GroES. Binding of ATP subsequently produces a conformational change that leads to the closure of the inner GroEL cavity (Amir et al., 2004; Poso et al., 2004; Wong et al., 2004). In the folding cavity, the substrate binds to the apical domain in the top cylinder of GroEL (Gomez-Puertas et al., 2004; Poso et al., 2004; Wong et al., 2004). The folding of the nascent protein is thought to be accomplished, in part, by the binding of both GroES and ATP, which provides a physical stress on the GroEL ring subunits, thereby constraining the hydrophobic interactions and allowing for different conformational structures to be achieved (Keskin et al., 2002; Poso et al., 2004; Sot et al., 2003; van der Vaart et al., 2004; Walter, 2002). Following the conformational changes in the nascent protein, the hydrophobic binding site is altered and the now-folded protein is ejected into the bulk solution (Sot et al., 2003; Walter, 2002). Since each GroEL subunit acts as a protein-binding unit, a full cycle involves binding of both substrate and GroES to one ring of the complex followed by the same steps on the opposite ring (Poso et al., 2004). Inner ring communication is of pivotal importance as it mediates a structural symmetry that imposes alternating functions (Poso et al., 2004). It is been shown that while positive cooperativity governs the binding of ATP, it is negative cooperativity that regulates the communication between rings (Poso et al., 2004). GroEL homologues are found in nearly all prokaryotic and eukaryotic organisms. In many organisms, they were originally isolated as heat shock proteins. This observation, coupled
with their monomeric migration pattern on denaturing gels, led to their early general designation as “hsp60 proteins.” More recently, they have also been called “cpn60” (chaperonin60) proteins.

Recent research has given scientists insight into possible immunological aspects of the presence of GroEL in bacterial-host disease interactions. Chaperones are known to be potent immunogens in both humans and rodents. Given the high degree of sequence similarity between bacterial and the mammalian molecular chaperones, it is surprising that bacterial chaperones elicit such a strong immune response (Ranford et al., 2000). It can often be difficult to extract purified GroEL, as many other bacterial contaminants are often found in GroEL preparations, including LPS (lipopolysaccharide), LAM (lipoarabinomannan), peptidoglycan, or other bacterial exotoxins (Ranford et al., 2000). However, studies that have been done using GroEL homologues from other bacteria have shown that even with the complete removal of these contaminants GroEL is able to induce cytokine activity and is therefore able to elicit an immune response (Ranford et al., 2000). In mice infected with M. tuberculosis, up to 20% of the reactive T cells are responsive toward the chaperonin 60.2 (the GroEL homologue in this organism); moreover, leukocytes, fibroblasts and epithelial cells are also induced to produce pro-inflammatory cytokines in the presence of chaperone 60.2 proteins (Ranford et al., 2000). GroEL homologues from several different Mycobacteria species and from E. coli have been shown to stimulate cytokine-dependent up-regulation of vascular endothelial cell adhesion molecules and are potent inducers of human monocyte IL-1b and IL-6 production (Retzlaff et al., 1994). GroEL from E. coli has also been tested for its ability to induce the expression of various cytokines in HUVEC cells cultures. Incubation of purified GroEL with these endothelial cells resulted in increased GM-CSF, IL-6, E-Selectin,
ICAM-1 and VCAM-1 release in a dose-dependent fashion (Galdiero et al., 1997; Ranford et al., 2000; Retzlaff et al., 1994). The induction of the latter three proteins is controlled by the production of cytokines IL-1 and TNF-alpha (Ranford et al., 2000). Not surprisingly, *Mycobacterium* and *E. coli* are not the only bacteria that produce GroEL proteins with immunological activity. Cpn60 proteins from several bacteria have been reported to localize to the bacterial cell surface, where they can serve as potential antigens. These include proteins from *Helicobacter*, which play a role in preventing bacterial aggregation, from *Legionella*, which increase host intracellular uptake, and *Actinobacillus*, which act as adhesion molecules (Garduno et al., 1998; Ranford et al., 2000). Studies have shown a wide variety of extra-chaperone functions for GroEL as well, including roles in cellular adherence of *Clostridium difficile*, endocarditis in *S. aureus*, and the infection cycle in *Chlamydia trachomatis* and *Rhizobium leguminosarum* (George et al., 2004; Hennequin et al., 2001; Karunakaran et al., 2003; Qoronfleh et al., 1998). Interestingly, a study using *Actinobacillus actinomycetemcomitans* Cpn60 with epithelial cells shows strongly induced phosphorylation and activation of ERK1/2 which inhibits caspase 3 activity in UV-radiation exposed cells, thereby avoiding apoptosis-induced cell death (Zhang et al., 2004).

Several studies have reported the use of GroEL comparisons to establish phylogenetic relationships among the α-2 proteobacteria, and for bacterial identification during infection (Haake et al., 1997; Lee et al., 2003; Paddock et al., 1997). Work with *Rickettsial* GroEL has shown it to be up-regulated early during the infection cycle, where it may act to enhance intracellular survival (Gaywee et al., 2002). Based on their investigation of factors in *B. bacilliformis* lysates that induce proliferation in HUVEC cells cultures, Minnick et al. (2003) proposed that GroEL is a mitogen, and as such may play a direct role in the production of the
vasculoproliferative nodules seen during the verruga peruana stage of *B. bacilliformis* infection (Minnick *et al.*, 2003). Their conclusion was based on: 1) the identification of a mitogen that is heat and trypsin sensitive; 2) a correlation between mitogenicity and the levels of GroEL in *B. bacilliformis* lysates; and 3) the inhibition of mitogen activity in the presence of anti-GroEL antibodies. Subsequent experiments by these authors involving infection of HUVEC cells with GroEL-overproducing strains of *B. bacilliformis* showed a correlation between high levels of GroEL and the acceleration of apoptosis, however. These observations led to the proposal that intracellular *B. bacilliformis* GroEL functions as an ortholog to eukaryotic hsp60 proteins, which are known to accelerate pro-caspase3 activation by enhancing its vulnerability to upstream activator caspase. Since both cell proliferation and the inhibition of apoptosis are believed to be involved in the induction of verruga peruana, the finding that GroEL increases the rate of apoptosis would appear to compromise its role in the angiogenic process. This issue remains unresolved.
Chapter I – Search for virB operon homologues in selected Bartonella species

Introduction

Bartonella species have been assigned to the alpha-2 proteobacterium subgroup, a category that also includes Brucella abortus, Sinorhizobium meliloti and Agrobacterium tumefaciens. Although they are diverse in terms of their host range and growth conditions, alpha-2 proteobacteria all interact directly with the cells of the organisms they infect. The mechanism of interaction has been particularly well-characterized in the plant pathogen A. tumefaciens (Chen et al., 2002; Christie, 1997; de Paz et al., 2005; Krall et al., 2002). Direction interaction by A. tumefaciens with host cells results in the production of tumors called Gall Tumors. The cellular proliferation leading to the formation of Gall Tumors is induced by the expression of genes located on a segment of bacterial DNA, called the Ti DNA, that is transferred to the host cells during the process of infection. Transfer is mediated by the products of the virB operon, a set of 11 genes encoded on the A. tumefaciens chromosome (Christie, 1997; Escudero et al., 1995; Loubens et al., 1997). The virB operon of A. tumefaciens has been shown to code for a Type 4 Secretion System (TFSS), a complex of proteins that uses ATP hydrolysis to promote the movement of the Ti DNA through the VirB pilus and into the host cell (Baron et al., 2001; Baron et al., 1997; Berger et al., 1994; Dang et al., 1997; Das et al., 1997; Finberg et al., 1995; Rashkova et al., 1997; Stephens, Kathryn et al., 1995; Thorstenson et al., 1993).

In 2000, a set of genes was reported in Bartonella henselae that exhibits a high degree of sequence similarity to those encoded by the A. tumefaciens virB operon (Padmalayam et al., 2000a; Schmiederer et al., 2000). The B. henselae operon consists of 10 genes, eight of which have homologues in the A. tumefaciens virB operon. Expression of B. henselae virB
genes is induced following uptake of the bacterium by the host cell (Schmiederer et al., 2001). The virB gene products play essential roles in the processes used by B. henselae to colonize the host cell, including the rearrangement of the host cytoskeleton and the inhibition of apoptosis (Batterman et al., 1995; Dehio et al., 1997; Kordick et al., 1995; Schmid et al., 2004). To date, the virB operon has been identified in three Bartonella species (de Paz et al., 2005; Padmalayam et al., 2000a; Seubert et al., 2003b; Woestyn et al., 2004).

The biphasic infection caused by B. bacilliformis, like the infections produced by other members of the alpha-2 proteobacteria subgroup, involves direct interaction with the cells of the host. During the initial phase, B. bacilliformis invades red blood cells, successfully infecting up to 100% of erythrocytes (Benson et al., 1986; Dehio, 2001; Schulein et al., 2002). The second phase, or verruga phase, is marked by the colonization of epithelial and endothelial cells, which induces the vascular proliferation that is responsible for the cutaneous and subcutaneous vascular lesions that are a hallmark of this phase (Dehio, 2001; Dehio, 1999; Dehio et al., 1997; Kirby, 2004; Verma et al., 2000). While genetically similar to other Bartonella species, B. bacilliformis is unique among Bartonella species for its relatively small genome (1.5 Mbp) and more severe clinical presentation. Its interactions with host cells are also distinct: unlike that of B. henselae and B. quintana, induction of vascular proliferation in B. bacilliformis can occur in an immunocompetent host (Battisti et al., 1999; Krueger et al., 1995).

Given the role the virB operon plays in both A. tumefaciens and B. henselae pathogenesis, we sought to determine whether a homologous operon is present in the genome of B. bacilliformis and other Bartonella species. This study reports the identification of a virB operon in B. quintana, the causative agent of trench fever, and in B. claridgeiae, a
species that, like *B. henselae*, has been associated with Cat Scratch Disease (CSD). In contrast to the results obtained with these *Bartonella* species, our work with *B. bacilliformis* produced no evidence of *virB* homologues. Based on our results, we propose that *B. bacilliformis*, unlike other clinically significant *Bartonella*, does not make use of a *virB*-encoded Type 4 Secretion System to invade cells and induce cellular proliferation.
Materials and Methods

Bacterial Growth and Culture. The following *Bartonella* species were obtained from the American Type Culture Collection (ATCC): *B. henselae* Houston-1, *B. quintana* subspecies Fuller, *B. claridgeiae*, and *B. bacilliformis* KC584. All *Bartonella* species were grown on Brain Heart Infusion (BHI) agar supplemented with 10% sheep’s blood. *Bartonella henselae*, *B. quintana* and *B. claridgeiae* were incubated at 37°C, while *B. bacilliformis* was incubated at 25°C for 5-7 days. Growth was monitored by visual inspection. Once confluent colonies were visible, the *Bartonella* was harvested by the addition of 15 ml of sterile Phosphate Buffered Saline (PBS), pH 7.4, and the plate was gently scraped using a cell scraper (Fisher). The PBS-*Bartonella* mixture was removed by aspiration and placed in a sterile 15 ml tube (Falcon). *Bartonella* to be used for genomic DNA extraction was then centrifuged at 2000xg for 10 minutes at 4°C, and then the PBS was decanted. Unused *Bartonella* was stored at -80°C in 50% PBS/50% glycerol until needed.

Genomic Isolation of *Bartonella* DNA. Harvested *Bartonella* were resuspended in 300 µL of sterile PBS, pH 7.4. To this mixture, 30 µL of 10% Sodium dodecyl sulfate (SDS) and 3 µL of Proteinase K (10mg/ml) was added. The mixture was then incubated at 55°C for 2 hours while shaking at 600 rpm. The *Bartonella* DNA was subsequently extracted three times with a 25:24:1 mixture of phenol:chloroform:isoamyl alcohol (Boehringer Mannheim). After each extraction the phases were separated by centrifugation at 14,000xg at 4°C. The DNA in the aqueous phase was precipitated with 1/10 volume of 3M sodium acetate (pH 4.8) and 3 volumes of ice-cold 100% ethanol. This mixture was then incubated overnight at -80°C. The mixture was centrifuged at 14,000xg for 15 minutes at 4°C then decanted and
allowed to air dry. The precipitated DNA was dissolved in the appropriate volume of Tris-
EDTA pH 8.0 (TE) buffer, containing RNase A (10mg/ml) and stored at 4°C until needed.

**Design of Consensus Primers and virB Gene Sequencing via PCR.** Sequences of *A. tumefaciens*, *B. henselae*, and other members of the alpha-2 proteobacterium family were compiled and placed into a Clustal alignment for each respective *virB* gene. From these analyses, regions of similar sequence were identified and used to make PCR primers (Table 1.1). PCR products were purified on Qiagen columns according to the manufacturer’s instructions and sequenced using capillary sequencing techniques (ABI). These products were then analyzed using Vector NTI Sequence Analysis software (Invitrogen) for restriction sites; open reading frames and the formation of any contiguous regions of DNA. The Vector NTI software was then used to prepare new *Bartonella*-specific PCR primers which were used in a low-stringency cycle of PCR. This process continued until entire open reading frames were identified. All completed sequences were submitted to GenBank.
Table 1.1 – Consensus and Bartonella-specific virB Operon Primers.
A. Consensus PCR primers were prepared by Clustal alignment of DNA sequences from alpha-2-proteobacteria bacteria known to contain homologue virB operon genes. B. Bartonella-specific primers were generated using Vector NTI (Invitrogen) software from DNA sequence data garnered from the use of consensus primers on B. quintana and B. claridgeiae.

### A. Consensus Primers

<table>
<thead>
<tr>
<th>Locus</th>
<th>Primer Name</th>
<th>Primer Sequence (5’ – 3’)</th>
</tr>
</thead>
<tbody>
<tr>
<td>virB2-homologue</td>
<td>CVirB2Fwd</td>
<td>GCTGTTGCCGCGTGATATCGG</td>
</tr>
<tr>
<td></td>
<td>CVirB2Rvc</td>
<td>CGCCAATACGATGGCAACGC</td>
</tr>
<tr>
<td>virB3-homologue</td>
<td>CVirB3Fwd</td>
<td>AGCTTATGGACGACAGATCCC</td>
</tr>
<tr>
<td></td>
<td>CVirB3Rvc</td>
<td>GTGCAGCAAGGGGGATATG</td>
</tr>
<tr>
<td>virB4-homologue</td>
<td>CVirB4Fwd</td>
<td>GCACATCGCAGCATGTCG</td>
</tr>
<tr>
<td></td>
<td>CVirB4Rvc</td>
<td>AAAACGCGCCATCGATAA</td>
</tr>
<tr>
<td>virB6-homologue</td>
<td>CVirB6Fwd</td>
<td>TTAGTTTTCTGTGTGGTTTAACCGC</td>
</tr>
<tr>
<td></td>
<td>CVirB6Rvc</td>
<td>ATGGCCACCAATCGACGAT</td>
</tr>
<tr>
<td>virB8-homologue</td>
<td>CVirB8Fwd</td>
<td>CTTTGCTGTGGCCGTTGGTT</td>
</tr>
<tr>
<td></td>
<td>CVirB8Rvc</td>
<td>CTTTGACATAAACCAACGCC</td>
</tr>
<tr>
<td>virB9-homologue</td>
<td>CVirB9Fwd</td>
<td>GCACCTTCCATTGTTGCA</td>
</tr>
<tr>
<td></td>
<td>CVirB9Rvc</td>
<td>ATACAACAGCACGTGTTGCC</td>
</tr>
<tr>
<td>virB10-homologue</td>
<td>CVirB10Fwd</td>
<td>TCAACGGGATGAAAAACCCGGA</td>
</tr>
<tr>
<td></td>
<td>CVirB10Rvc</td>
<td>AAGCGGTGAGGAGCGCTCCTCC</td>
</tr>
<tr>
<td>virB11-homologue</td>
<td>CVirB11Fwd</td>
<td>GTGAACCTTCCCATCTGGAACC</td>
</tr>
<tr>
<td></td>
<td>CVirB11Rvc</td>
<td>ATCGATCAACCAGATACAGCA</td>
</tr>
</tbody>
</table>

### B. Bartonella-specific virB Primers

<table>
<thead>
<tr>
<th>Locus</th>
<th>Primer Name</th>
<th>Primer Sequence (5’ – 3’)</th>
</tr>
</thead>
<tbody>
<tr>
<td>virB2-homologue</td>
<td>VirB2Fwd</td>
<td>ATGACAGAGACTATAATCCAGAATATT</td>
</tr>
<tr>
<td></td>
<td>VirB2Rvc</td>
<td>TGATGACACCCATATGTACTAACA</td>
</tr>
<tr>
<td>virB3-homologue</td>
<td>VirB3Fwd</td>
<td>ATGAATGGAGGATACCTCTTCCTTTTTCTTGG</td>
</tr>
<tr>
<td></td>
<td>VirB3Rvc</td>
<td>TAATTGACATCTGTTCACTTCTCC</td>
</tr>
<tr>
<td>virB4-homologue</td>
<td>VirB4Fwd</td>
<td>ATGACATTGAGAATACCTCTCTTTCTTCTTGC</td>
</tr>
<tr>
<td></td>
<td>VirB4Rvc</td>
<td>ATGATCATTCCATCCCTTGTGTTGCC</td>
</tr>
<tr>
<td>17kDa Antigen</td>
<td>17kdaFwd</td>
<td>ATGGCCTGCCTATATTTTCACCAAAAGG</td>
</tr>
<tr>
<td></td>
<td>17kdaRvc</td>
<td>AACATTCCGGACACATCAATCTCCCAAAGG</td>
</tr>
<tr>
<td>virB6-homologue</td>
<td>VirB6Fwd</td>
<td>ATGAAATCAACGAGCTGTGAGGAGGTGTTCT</td>
</tr>
<tr>
<td></td>
<td>VirB6Rvc</td>
<td>AATATACGACAGACCTCTCTCCTACTCCAA</td>
</tr>
<tr>
<td>15kDa Antigen</td>
<td>15kdaFwd</td>
<td>ATGAAACGAAAAAATTAACTTTTTTTTA</td>
</tr>
<tr>
<td></td>
<td>15kdaRvc</td>
<td>CTTTTCACGACGAGATTTCCTATTCCATTTGAAT</td>
</tr>
<tr>
<td>virB8-homologue</td>
<td>VirB8Fwd</td>
<td>ATGAAAATTTCTCTGTCAAAATACCGG</td>
</tr>
<tr>
<td></td>
<td>VirB8Rvc</td>
<td>TTTTATCACCTCCTGAGATATCGCAT</td>
</tr>
<tr>
<td>virB9-homologue</td>
<td>VirB9Fwd</td>
<td>ATGATGAGATTTTCAAAAATAATCTCTT</td>
</tr>
<tr>
<td></td>
<td>VirB9Rvc</td>
<td>TCCTTCATGACCATTTCCTATGTCC</td>
</tr>
<tr>
<td>Locus (con’t)</td>
<td>Primer Name</td>
<td>Primer Sequence (5’ – 3’)</td>
</tr>
<tr>
<td>--------------------</td>
<td>-------------------</td>
<td>-------------------------------------------</td>
</tr>
<tr>
<td>virB10-homologue</td>
<td>VirB10Fwd</td>
<td>ATGGTCATGAAGGATGAAATGGATGAA</td>
</tr>
<tr>
<td></td>
<td>VirB10Rvc</td>
<td>TTTCAAAATCACCAGAATTTTTA</td>
</tr>
<tr>
<td>virB11-homologue</td>
<td>VirB11Fwd</td>
<td>ATGAACAAAACCTGCATAAAT</td>
</tr>
<tr>
<td></td>
<td>VirB11Rvc</td>
<td>TAAGCTCCCGACAACTAAAATC</td>
</tr>
</tbody>
</table>

**Design and Synthesis of virB probes for Phage Library Construction and Southern Blot Analysis.** Using *Bartonella*-specific sequence data, probes were prepared as follows for \( \lambda \) phage library construction and Southern blot analysis. A PCR amplification was carried out using the PCR DIG Probe Synthesis kit (Roche) to produce digoxigenin (DIG)-labeled PCR products. These products were analyzed on a 1% agarose gel to verify that they were of the predicted size. Following verification, probes were denatured by heating at 95°C for 10 minutes and were then added to 45 ml of hybridization solution (Roche). The probes were stored at -20°C until needed.

**Southern Blot Analysis of the B. bacilliformis Genome.**

**Digestion of Bartonella Genomic DNA.** Genomic DNA samples from *B. quintana*, *B. clarridgeiae* and *B. bacilliformis* were probed using previously prepared virB gene-specific DIG-labeled probes as follows (Southern, 1975). Briefly, previously purified genomic DNA was incubated with *EcoRI* at 37°C for approximately 16 hours in an Eppendorf variable shaker. To the digested genomic DNA, 10µL of 3M sodium acetate and 1ml of ice-cold 100% ethanol were added, and the samples were incubated for one hour at -80°C. The precipitated DNA was then collected by centrifugation at 14,000xg for 20 minutes at room temperature. The supernatant was decanted and the digested genomic DNA was dried at room temperature. The digestion products were separated by 0.8% agarose gel electrophoresis. The agarose gel was then soaked in 0.25N HCl for 10 minutes and subsequently transferred to 0.5M NaOH and 1.5M NaCl for soaking twice (15 minutes per
soak). An apparatus was then set up to allow the transfer of DNA from the agarose gel to a nitrocellulose membrane that had been rinsed with deionized water. This transfer was completed by placement in a reservoir containing of 20x Standard Saline Citrate (SSC) overnight. The nitrocellulose membrane containing the DNA was rinsed in 5X SSC for five minutes, then UV cross-linked (FisherBiotech) using “Optimal cross-link” settings with the cross-linking step being repeated three times. Cross-linked membranes were stored in airtight bags at -80°C until needed.

**Hybridization and Development of Southern Blot Membranes.** Prepared nitrocellulose membranes were thawed at room temperature as needed, and pre-hybridized with DIG Easy Hyb solution (Roche) at 42°C for two hours with rotation. The appropriate probe (Table 1.2) was removed from storage at -20°C, thawed in a hybridization oven at 80°C for one hour and then denatured at 99°C for 20 minutes before use. After decanting the DIG Easy Hyb solution, the probe was added to the nitrocellulose membrane and the membrane was hybridized at 42°C overnight with rotation. After incubation overnight, the probe solution was removed and stored at -20°C while the membrane was washed twice with 2X SSC containing 0.1% SDS for five minutes per wash at room temperature. The wash solution was decanted and the membrane was washed twice with 2X SSC containing 0.1% SDS at 60°C. This solution was decanted and the membrane was washed by incubating for two minutes with constant shaking at room temperature in the Washing Buffer (Roche) supplemented with 1X malic acid solution (Roche) containing 0.3% Tween-20 (Sigma). The Wash Buffer was decanted and replaced with Blocking Buffer (Roche), consisting of Wash Buffer supplemented with 1:10 Blocking Buffer concentrate for 30 minutes with constant shaking, at room temperature. The Blocking Buffer was decanted, and 100 ml of anti-DIG antibodies
(Roche) diluted 1:5000 in Blocking Buffer was added to membrane. The membrane was incubated with the antibody mixture for one (1) hour, with shaking at room temperature. The Anti-DIG antibody mixture was decanted and saved at -20°C for further use, and the membrane was again washed twice in Washing Buffer for 15 minutes at room temperature. Finally, the membrane was equilibrated in Detection Buffer (Roche), containing 0.1M Tris-HCl, 0.1M NaCl, pH 9.5, for three minutes at room temperature. The Detection Buffer was decanted and the membrane was developed using Nitro-blue tetrazolium chloride/5-bromo-4-chloro-3'-indolyphosphate (NBT/BCIP; Roche) to visualize the banding pattern. After the bands were clear, the membranes were washed with deionized H₂O followed by TE buffer, and allowed to air dry.
Table 1.2 – DIG-Labeled Probes for Southern Blot Analysis.
The following table shows the DNA primer sequences for Southern Blot probes, designed from *B. bacilliformis*, *B. quintana* and *B. clarridgeiae* DNA sequences as noted below.

<table>
<thead>
<tr>
<th><strong>Bartonella Species</strong></th>
<th><strong>Probe Target</strong></th>
<th><strong>Primer Name</strong></th>
<th><strong>Primer Sequence (5’ – 3’)</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td><em>B. bacilliformis</em></td>
<td>18.5kDa Antigen</td>
<td>SB18.5 Fwd</td>
<td>CTATGCCCTTAAGCAGTTAACAC</td>
</tr>
<tr>
<td></td>
<td><em>B. bacilliformis</em>-specific Control</td>
<td>SB18.5 Rvc</td>
<td>AATGCAGAGTATAGTTATGGG</td>
</tr>
<tr>
<td><em>B. clarridgeiae</em></td>
<td>Internal Fragment of <em>virB4</em></td>
<td>SBV4IntFwd</td>
<td>CTCTTCGTTTCACTGCTGTGGAATC</td>
</tr>
<tr>
<td></td>
<td></td>
<td>SBV4IntRvc</td>
<td>CCAGCTTGTTTTTTCAGGAATGACAC</td>
</tr>
<tr>
<td><em>B. quintana</em></td>
<td><em>virA</em> Fragment</td>
<td>SBVirAFwd</td>
<td>CTTCGAGGGGTAGTGTTTACGAGGAG</td>
</tr>
<tr>
<td></td>
<td></td>
<td>SBVirARvc</td>
<td>CGTAATTAATAGAGACCGGACA</td>
</tr>
<tr>
<td><em>B. quintana</em></td>
<td><em>virB3</em>-homologue Fragment</td>
<td>SBVir3Fwd</td>
<td>AATGAAGATACTCTTTTCTTGCC</td>
</tr>
<tr>
<td></td>
<td></td>
<td>SBVir3Rvc</td>
<td>TGACATCTGTTTCACTTTTATAAA</td>
</tr>
<tr>
<td><em>B. quintana</em></td>
<td><em>virB6</em>-homologue Fragment</td>
<td>SBVir6Fwd</td>
<td>TGCAAAATCAGAAACAGCGGAATCTA</td>
</tr>
<tr>
<td></td>
<td></td>
<td>SBVir6Rvc</td>
<td>TATAATCAAAACATTTGCATAGCG</td>
</tr>
<tr>
<td><em>B. quintana</em></td>
<td><em>virB8</em>-homologue Fragment</td>
<td>SBVir8Fwd</td>
<td>ATGAAAAATTCTCTGATAAAAA</td>
</tr>
<tr>
<td></td>
<td></td>
<td>SBVir8Rvc</td>
<td>TTTATCACCTCTGGATAGAT</td>
</tr>
<tr>
<td><em>B. quintana</em></td>
<td><em>virB11</em>-homologue Fragment</td>
<td>SBVir11Fwd</td>
<td>TGTGTTAACAAACACTTTGACCCCATC</td>
</tr>
<tr>
<td></td>
<td></td>
<td>SBVir11Rvc</td>
<td>TTCAATGCTGATAATACGCTTATTA</td>
</tr>
</tbody>
</table>

Plaque hybridization of a *B. bacilliformis* Genomic DNA Library

**Construction of a *B. bacilliformis* λ Phage Library.** A genomic DNA λ phage library was created by digesting *B. bacilliformis* DNA with TSP5091 (New England Biolab). Briefly, purified *B. bacilliformis* genomic DNA was digested for 22 minutes with TSP5091 (1:1 diluted with Reaction buffer (10mM Bis-Tris-Propane HCl, 10mM MgCl2, 1mM Dithiothreitol, pH 7.0)) at 65°C until the reaction was stopped by the addition of 25:24:1 mixture of phenol:chloroform:isoamyl alcohol (Boehringer Mannheim). The digested genomic DNA was then extracted three times with phenol:chloroform:isoamyl alcohol
(Boehringer Mannheim); after each extraction the phases were separated by centrifugation of 14,000xg at 4°C. The DNA in the aqueous phase was precipitated by the addition of 1/10 volume of 3M sodium acetate (pH 4.8) and three volumes of ice-cold 100% ethanol. This mixture was then incubated overnight at -80°C. The mixture was centrifuged at 14,000xg for 15 minutes at 4°C, then decanted and allowed to air dry. The precipitated DNA was dissolved in the appropriate volume of TE buffer containing RNase A (10mg/ml), and stored at 4°C until needed. Digested genomic DNA was ligated into EcoRI-digested Lambda ZapII arms (Stratagene) according to the manufacturer’s instructions and the reaction mixture was incubated overnight at 4°C. The ligated genomic DNA library was then packaged into the λ phage using the Stratagene Gigapack II gold packaging kit per the manufacturer’s instructions. Briefly, the ligated genomic DNA library was incubated with XL-1 Blue MRF’ cells at an MOI of 10:1 in the presence of the ExAssist phage at 37°C for 15 minutes. Luria-Bertani (LB) Broth was added to the reaction mixture and allowed to incubate three hours at 37°C. The cells were then allowed to lyse by heating at 65°C. SOLR cells were added to titer the excised plasmids and were subsequently grown on LB-ampicillin overnight at 37°C. The packaged library products were incubated with XL-1 Blue MRF’ cells infected for 15 minutes and plated onto NZY agar plates, then incubated overnight at 37°C. SM buffer (0.1M NaCl, 0.05M MgSO₄, 0.001% (w/v) gelatin) was used to cover each plate. Following overnight incubation at 4°C, the contents were pooled, chloroform was added to give a 5% solution, and the sample was centrifuged at 5000xg for 10 minutes. After centrifugation, the λ phage library was divided into 1.5 ml aliquots. Samples were stored at -70°C for future use.
**B. bacilliformis-Phage Library Analysis using Bartonella-specific virB probes.** The λ phage library was screened for *B. bacilliformis* genomic DNA and specifically for the presence of various genes of the *virB* operon. DIG-labeled probes were reacted against the library contents as follows. Briefly, XL-1 MRF’ cells were incubated with 5-10µL of λ phage library for 15 minutes. This cell/phage mix was plated onto NZY plates and incubated at 37°C overnight. The plates were transferred to plaque hybridization membranes (Perkin Elmer) and washed with denaturation, neutralization and SSC solutions (Roche). The membranes were UV cross-linked and pre-hybridized in EZ Hyb (Roche) solution at 42°C for two hours. The membranes were probed overnight with previously prepared *virB* gene-specific DIG-labeled probes. The membranes were washed and blocked in a 5% skim milk solution overnight at 4°C. Goat anti-DIG alkaline phosphatase- (AP) labeled antibodies were added and the membranes were incubated at room temperature. Then the membranes were washed again, BCIP-NBT substrate was added, and the membranes were placed in the dark for color development. Plaques that were positive were cored and placed into 1 ml of SM buffer containing chloroform and stored at 4°C, until needed. SOLR cells were used to excise the phagemids, which were then allowed to circularize. Plasmids were subsequently isolated from the SOLR cells according to the manufacture’s instructions for plasmid purification (Omega Bio-Tek). These plasmids were sequenced using T3/T7 primers for the initial screening. The DNA sequences were entered into Vector NTI (Invitrogen) and analyzed for open reading frames and the formation of contigs. BLAST searches were also done to find homologous regions/genes.
**GenomeWalking Sequence Analysis.** GenomeWalking was used with both *B. quintana* and *B. bacilliformis* genomic DNA in order to fill in any sequence gaps. After preparation of *Bartonella* genomic DNA, a GenomeWalking DNA library was prepared per the manufacturers instructions (CloneTech) using the supplied *EcoRV, DraI, PvuII* and *SspI* restriction enzymes. Briefly, *Bartonella* genomic DNA was digested at 37°C for two hours in separate reaction mixtures for each restriction enzyme, then vortexed briefly and incubated at 37°C overnight. The mixture was purified using phenol (Sigma) followed by centrifugation at 14,000xg at room temperature to separate the aqueous layer. The top, aqueous, layer was removed and chloroform (Sigma) was added followed by another 14,000xg centrifugation at room temperature. This aqueous layer was then removed and incubated with 95% ethanol and 3M sodium acetate (pH4.5), followed by centrifugation at 14,000xg for 15 minutes at 4°C. The supernatant was decanted and 80% ethanol was added followed by 14,000xg centrifugation for 10 minutes at room temperature. The supernatant was again decanted and the digested DNA was dried, then dissolved in 20 µl of TE buffer, all per manufacturer’s instructions (CloneTech). The GenomeWalk libraries were kept at 4°C until needed. In order to screen the libraries for specific regions of unknown sequence, previously sequenced *virB* regions were used to design GenomeWalk-specific *virB* primers according to the manufacturer’s instructions. After the completion of the primary PCR GenomeWalk cycle using Gene Specific Primer 1 was complete (Table 1.3), the products were analyzed for expected base pair size using 1% agarose gel electrophoresis, and samples corresponding to the predicted size were subjected to secondary PCR GenomeWalk PCR cycles with the previously designed Gene Specific Primer 2. The secondary GenomeWalking products were again analyzed using a 1% agarose gel and those of the
predicted size were sequenced. The DNA sequences were entered into Vector NTI (Invitrogen) and analyzed for open reading frames and the formation of contigs. BLAST searches were also done to find homologous regions/genes.

**Table 1.3 – Gene Specific Primers for GenomeWalk Analysis of B. bacilliformis.**

GenomeWalker (Clonetech) primers which were used to scan the *B. bacilliformis* genome for specific virB operon homologues.

<table>
<thead>
<tr>
<th>Locus</th>
<th>Primer Name</th>
<th>Primer Sequence 5’ – 3’</th>
</tr>
</thead>
<tbody>
<tr>
<td>virB4-</td>
<td>GWVirB4Fwd</td>
<td>TGTCAATTATGAAACGGGAGTCTTTACCTG</td>
</tr>
<tr>
<td>homologue</td>
<td>GWVirB4Rvc</td>
<td>GGTCATGTCATAACCAATGAATTGTGAGTC</td>
</tr>
<tr>
<td>virB6-</td>
<td>GWVirB6Fwd</td>
<td>ATGAATACGACAGTGAGTGGGTTGTC</td>
</tr>
<tr>
<td>homologue</td>
<td>GWVirB6Rvc</td>
<td>CCACTATCGAGATAACGACACAGGT</td>
</tr>
<tr>
<td>virB8-</td>
<td>GWVirB8Fwd</td>
<td>ATTCTCTGTGATCAAATACGGAAATCGCTCG</td>
</tr>
<tr>
<td>homologue</td>
<td>GWVirB8Rvc</td>
<td>GGATCGAGACCACATGGAAATATTTTCTT</td>
</tr>
<tr>
<td>virB10-</td>
<td>GWVirB10Fwd</td>
<td>ATGATCGCAGTACAATAAAAAGACGTC</td>
</tr>
<tr>
<td>homologue</td>
<td>GWVirB10Rvc</td>
<td>GATACAAGAAGCGCAGATCAATCCCG</td>
</tr>
<tr>
<td>virB11-</td>
<td>GWVirB11Fwd</td>
<td>ACCTGCGATAAAATGAGCAATGAAACTGTC</td>
</tr>
<tr>
<td>homologue</td>
<td>GWVirB11Rvc</td>
<td>TTGGACCAACAGAGCTAAAGCCTTTG</td>
</tr>
</tbody>
</table>
Results

Isolation of the *B. quintana* virB Operon.

Since the original demonstration of a virB operon in *B. henselae*, there have been reports of virB homologues in at least three other *Bartonella* species (Padmalayam *et al.*, 2000a). This raises the possibility that virB-encoded secretion systems are an integral part of the *Bartonella* molecular repertoire.

In order to search for the virB operon in other *Bartonella* species, we designed consensus primers for gene amplification using sequences from other α-2-proteobacteria, such as *A. tumefaciens*, as a template. Initially, the virB4 gene was selected for amplification, as it is the most conserved of the virB genes. Plaque hybridizations on a newly created DraI-generated *B. quintana* phage library, prepared in our laboratory, were conducted using a virB4 probe created from the *B. henselae* virB4 gene. This approach proved unsuccessful, however, and the GenomeWalking protocol was subsequently employed using newly prepared GenomeWalk-specific primers for the virB4 gene. This protocol gave a single 1550 bp product from the *B. quintana* library. Another primer for the *B. quintana* virB4 sequence (GSP2) was prepared using the *B. quintana* sequence obtained from the first GenomeWalk and yielded a 2000 bp product from a second GenomeWalk. BLAST results indicated that the gene product from this round of GenomeWalking corresponded to the middle region of the *B. henselae* virB4 gene, as expected. Unfortunately, due to the A-T rich nature of the *B. quintana* genome no further GenomeWalk primers could be designed which gave definitive products.

Plaque hybridizations were also used to search for homologues to the virB9, virB10 and virB11 genes. Initially, a screening for virB11 using a *B. henselae*-derived probe gave
rise to a plasmid, designated 2A2, that contained *B. quintana* sequences with partial homology to *B. henselae* virB11. Further GenomeWalking using a combination of *B. henselae*-based virB and T3/T7 primers to amplify 2A2 plasmid sequences revealed the presence of virB9, virB10 and the remainder of the virB11. The remaining virB operon genes from *B. quintana* were determined using overlapping PCR reactions based on the sequences obtained from the above plaque hybridizations. The known sequence for the 17kDa antigen gene was used to design *Bartonella*-specific primers for both upstream and downstream PCR products, which allowed for the sequencing of the virB2, virB3, virB4, virB6, 15kDa antigen gene, virB8 and virB9 homologues to be completed. After each sequencing round, the gene products were assembled into contigs and compared with known virB operon sequences from other species to ensure no sequence gaps were remaining. The sequence was verified with the preparation of *B. quintana*-specific virB primers and the sequences were placed in GenBank (Accession Number: AY216720).

Sequencing of the virB operon gene homologues from *B. clarridgeiae* was accomplished in much the same manner, with a higher level of success using *Bartonella*-specific virB operon primers generated from previously sequenced virB genes from *B. henselae* and *B. quintana*. Initially, the virB4 gene was sequenced using *Bartonella*-specific consensus primers. This approach yielded a 1250-bp product, with BLAST analysis suggesting that the gene product corresponded to the distal portion of the *B. clarridgeiae* virB4 gene. *Bartonella*-specific primers based on BLAST homologies for sequencing the virB2, virB3 and missing portions of the virB4 homologies were then used for PCR amplification in order to give rise to the corresponding *B. clarridgeiae* virB genes. Amplification of the virB11 and virB10 genes was accomplished using *Bartonella*-specific
consensus primers designed from information obtained after another round of PCR amplifications. Finally, the remaining virB gene homologues, the 15kDa Antigen, VirB6, VirB8 and VirB9, were sequenced using a series of Bartonella-specific consensus primers initially designed from the published B. clarridgeiae 17kDa antigen sequence (Accession number: AF195506). These primers were designed to target 1000-bp PCR products extending from the 17kDa antigen homologue upstream to the middle of the virB10 gene. These sequences were then verified by the preparation of B. clarridgeiae-specific primers to produce PCR primers of 1000-1250 bp which were then subjected to BLAST and AlignX (Invitrogen) analysis for accuracy.
Physical Arrangement of the virB Operon in *B. quintana* and *B. clarridgeiae*.

Sequence analysis using Vector NTI (Invitrogen) was conducted in order to identify the open reading frames of the newly determined virB homologues from *B. quintana* and *B. clarridgeiae*, and to compare these open reading frames to those of *B. henselae* and *B. tribocorum* (Figure 1.1; a-d). In all cases analyzed the gene organization within the virB operon was identical. The physical arrangement indicates the first gene to be virB2, the smallest gene at 312-366 bp, followed by virB3 and largest gene of the operon virB4, at 2361-3807 bp. The location of the 17kDa antigen and 15kDa antigens remains constant in all *Bartonella* species examined, in every case flanking the ORF of the virB6 homologue. Similarly, each *Bartonella* contains a virB9, virB10 and virB11 homologues downstream of the virB8 homologue. One feature that is unique to the *B. quintana* virB operon is the existence of two potential start codons for the virB8 gene, which would potentially generate both a long-form and a short-form version of the gene product. The extra start codon is not present in any of the other *Bartonella* species that have been characterized.
a. 

B. henselae virB Operon
8828 bp

b. 

B. tribocorum virB Operon
13217 bp
Figure 1.1 – Physical Arrangement of the virB Operon in Bartonella Species. Vector NTI (Invitrogen) was used to analyze the open reading frames of the sequenced virB operon homologues in *B. henselae* (a), *B. tribocorum* (b), *B. quintana* (c) and *B. claridgeiae*. Arrows indicate the direction of the designated open reading frames.
Homology analysis of the *Bartonella* species *virB* operons to the *A. tumefaciens* operon.

DNA-based alignments were created using AlignX (Invitrogen) to determine the degree of sequence identity between various *Bartonella* and *A. tumefaciens* *virB*-homologues (Table 1.4). Identity levels between the *Bartonella* species *virB* genes and those of *A. tumefaciens* range from 34 to 50%. The highest identity values are seen in the *Bartonella* *virB*4 genes, with an average of 49.5% identity to the *A. tumefaciens* homologue, while the lowest identity, averaging 35%, is observed with the *virB*2 gene.

Table 1.4 – Comparison of *virB* Operon Sequences between *A. tumefaciens* and various *Bartonella*-species.

Using the AlignX program (Invitrogen), DNA-based alignments were created to determine the degree of sequence identity between various *Bartonella* and *A. tumefaciens* *virB*-homologues (Seubert *et al.*, 2003a). Alignment was conducted on *virB* gene open reading frames corresponding to each *virB* gene homologue (Padmalayam *et al.*, 2000a; Schulein *et al.*, 2002).

<table>
<thead>
<tr>
<th>% Identity to <em>A. tumefaciens</em> <em>virB</em> genes</th>
<th>B. henselae</th>
<th>B. quintana</th>
<th>B. claridgeiae</th>
<th>B. tribocorum</th>
</tr>
</thead>
<tbody>
<tr>
<td><em>virB</em>2</td>
<td>34</td>
<td>34</td>
<td>35</td>
<td>36</td>
</tr>
<tr>
<td><em>virB</em>3</td>
<td>44</td>
<td>44</td>
<td>43</td>
<td>41</td>
</tr>
<tr>
<td><em>virB</em>4</td>
<td>50</td>
<td>49</td>
<td>49</td>
<td>49</td>
</tr>
<tr>
<td>17kDa</td>
<td>N/A</td>
<td>N/A</td>
<td>N/A</td>
<td>N/A</td>
</tr>
<tr>
<td><em>virB</em>6</td>
<td>40</td>
<td>41</td>
<td>40</td>
<td>38</td>
</tr>
<tr>
<td>15kDa</td>
<td>N/A</td>
<td>N/A</td>
<td>N/A</td>
<td>N/A</td>
</tr>
<tr>
<td><em>virB</em>8</td>
<td>38</td>
<td>42</td>
<td>42</td>
<td>43</td>
</tr>
<tr>
<td><em>virB</em>9</td>
<td>41</td>
<td>41</td>
<td>40</td>
<td>41</td>
</tr>
<tr>
<td><em>virB</em>10</td>
<td>44</td>
<td>43</td>
<td>42</td>
<td>42</td>
</tr>
<tr>
<td><em>virB</em>11</td>
<td>48</td>
<td>43</td>
<td>44</td>
<td>47</td>
</tr>
</tbody>
</table>
VirB operon gene homology among *Bartonella* species.

DNA-based alignments were created using the AlignX program (Invitrogen) to determine the degree of sequence identity between *virB* operons of each of the *Bartonella* species analyzed (Table 1.5). A comparison of *virB* genes from *B. quintana* and *B. tribocorum* with the counterparts in *B. henselae* suggests a high level of homology. Interestingly, *B. clarridgeiae* shows a lower overall level sequence identity for most of the *virB* genes, with the exception of *virB3*, the 17kDa antigen and *virB8*.

**Table 1.5 – Comparison of VirB Operon Sequences between Bartonella species.**

Using the AlignX program (Invitrogen), DNA-based alignments were created to determine the degree of sequence identity between *B. henselae* *virB* operon open reading frames and those of other *Bartonella* species.

<table>
<thead>
<tr>
<th></th>
<th>B. quintana</th>
<th>B. clarridgeiae</th>
<th>B. tribocorum</th>
</tr>
</thead>
<tbody>
<tr>
<td><em>virB2</em></td>
<td>84</td>
<td>42</td>
<td>79</td>
</tr>
<tr>
<td><em>virB3</em></td>
<td>87</td>
<td>82</td>
<td>84</td>
</tr>
<tr>
<td><em>virB4</em></td>
<td>91</td>
<td>54</td>
<td>86</td>
</tr>
<tr>
<td>17kDa</td>
<td>87</td>
<td>75</td>
<td>65*</td>
</tr>
<tr>
<td><em>virB6</em></td>
<td>90</td>
<td>63</td>
<td>79</td>
</tr>
<tr>
<td>15kDa</td>
<td>52</td>
<td>49</td>
<td>48</td>
</tr>
<tr>
<td><em>virB8</em></td>
<td>78</td>
<td>75</td>
<td>78</td>
</tr>
<tr>
<td><em>virB9</em></td>
<td>86</td>
<td>37</td>
<td>85</td>
</tr>
<tr>
<td><em>virB10</em></td>
<td>72</td>
<td>52</td>
<td>81</td>
</tr>
<tr>
<td><em>virB11</em></td>
<td>80</td>
<td>72</td>
<td>83</td>
</tr>
</tbody>
</table>

* the 17kDa antigen was renamed VirB5 (CA51480.1) in *B. tribocorum*
Comparison of VirB protein sequences of *B. quintana* and *B. clarridgeiae* with those of other alpha-2 proteobacteria.

An AlignX-based (Invitrogen) virB protein analysis was completed on *B. quintana* (Table 1.6) and *B. clarridgeiae* (Table 1.7) VirB-homologue proteins in order to determine their relative identity and similarity. As Table 1.6 shows, there is a wide variation in the levels of amino acid sequence identity between the *B. quintana* VirB proteins and those of *B. henselae*, ranging from the low of 13.5% for VirB9 to a high of 88.7% for VirB3. Overall, the level of identity between *B. quintana* and *B. henselae* VirB sequences averages 70%.

When *B. quintana* virB protein sequences were compared to those of *A. tumefaciens*, the level of identity was significantly less, ranging from 6.7% for the 15kDa antigen to 35% for VirB4 and averaging approximately 21%. Analysis between *B. quintana* and *B. clarridgeiae* indicates an average identity of 57%, with the lowest identity between the VirB11 protein at 10.5% and the highest identity with VirB8 at 92%. A similar degree of identity was observed when VirB comparisons were made between *B. quintana* and *S. meliloti*, where the average identity was 43%. In this case, the highest level of amino acid identity between the two species was observed with VirB4 (60%) and the lowest was with VirB10 (33%). Table 1.7 shows a comparison of *B. clarridgeiae* VirB-homologue proteins with those of other alpha-2 proteobacteria. The overall variation between the VirB homologues of *B. clarridgeiae* to *B. henselae* ranges from 11.7% (for VirB11) to 97% (for VirB6), while the overall average of identity between the *B. clarridgeiae* and *B. henselae* virB operons is approximately 59%.

When the sequences of *B. clarridgeiae* and *A. tumefaciens* VirB proteins are compared, there is an overall identity average of 16.6%, with the VirB10 homologues exhibiting the lowest identity level (9.5%), and the VirB2 homologue exhibiting the highest identity level (27%).
Interestingly, *B. clarridgeiae* and *S. meliloti* VirB operons show a lowest identity with virB11 (11%), and the highest identity with the VirB8 (46%). Overall, the average identity of these VirB operons averages approximately 57%. Finally, Table 1.8 shows the similarity between the amino acid sequences of *B. henselae, B. clarridgeiae, B. quintana* and *S. meliloti* with *A. tumefaciens* VirB operon proteins. Our results indicate that while overall *S. meliloti* is most similar to *A. tumefaciens*, with 41% average similarity in analysis of VirB proteins; the *Bartonella* VirB proteins have a 33.9% similarity with *A. tumefaciens* across the proteins examined. Our data shows that *B. henselae* is, of the *Bartonella* species, most similar to *A. tumefaciens* with 37%, *B. quintana* 36.1% and *B. clarridgeiae* the least similar at 28.8% average similarity of VirB proteins. Given the protein identity and DNA sequence homology above it is not surprising that these *Bartonella* species overall very similar to *A. tumefaciens* (34%), while *S. meliloti* is 41.3% similar to *A. tumefaciens*. Among the *Bartonella* VirB proteins examined, VirB4 shows the highest level of similarity between all species at 49%, while the 15kDa antigen homologue shows the lowest similarity, without the inclusion of *S. meliloti*, at 16%.
Table 1.6 - Comparison of VirB Protein Sequences of B. quintana and B. henselae, B. clarridgeiae, A. tumefaciens and Sinorhizobium meliloti.
Amino acid sequences of each of the above VirB homologues were compared to those of B. quintana using the AlignX program (Invitrogen). Open Reading Frame (ORF) analysis utilized Vector NTI (Invitrogen) and was verified by BLAST analysis.

<table>
<thead>
<tr>
<th></th>
<th>B. quintana</th>
<th>B. henselae</th>
<th>B. clarridgeiae</th>
<th>A. tumefaciens</th>
<th>S. meliloti</th>
</tr>
</thead>
<tbody>
<tr>
<td>virB2</td>
<td>80.4</td>
<td>90.7</td>
<td>27.3</td>
<td>38.5</td>
<td></td>
</tr>
<tr>
<td>virB3</td>
<td>88.7</td>
<td>90.5</td>
<td>26.4</td>
<td>36.8</td>
<td></td>
</tr>
<tr>
<td>virB4</td>
<td>88.7</td>
<td>34.6</td>
<td>35.5</td>
<td>59.6</td>
<td></td>
</tr>
<tr>
<td>17kDa</td>
<td>68.3</td>
<td>66.5</td>
<td>N/A</td>
<td>N/A</td>
<td></td>
</tr>
<tr>
<td>virB6</td>
<td>87.9</td>
<td>89.4</td>
<td>16.0</td>
<td>28.3</td>
<td></td>
</tr>
<tr>
<td>15kDa</td>
<td>56.8</td>
<td>14.0</td>
<td>6.7</td>
<td>N/A</td>
<td></td>
</tr>
<tr>
<td>virB8</td>
<td>78.6</td>
<td>92.1</td>
<td>21.5</td>
<td>49.8</td>
<td></td>
</tr>
<tr>
<td>virB9</td>
<td>13.5</td>
<td>49.4</td>
<td>9.7</td>
<td>50.5</td>
<td></td>
</tr>
<tr>
<td>virB10</td>
<td>54.8</td>
<td>33.6</td>
<td>18.9</td>
<td>33.2</td>
<td></td>
</tr>
<tr>
<td>virB11</td>
<td>81.5</td>
<td>10.5</td>
<td>32.9</td>
<td>50.0</td>
<td></td>
</tr>
</tbody>
</table>

Table 1.7 - Comparison of VirB Proteins of B. clarridgeiae and B. henselae, B. quintana, A. tumefaciens and Sinorhizobium meliloti.
Amino acid sequences of each of the above VirB operon homologues were compared to those of B. clarridgeiae using the AlignX program (Invitrogen). Open Reading Frame (ORF) analysis utilized Vector NTI (Invitrogen) and was verified by BLAST analysis.

<table>
<thead>
<tr>
<th></th>
<th>B. clarridgeiae</th>
<th>B. henselae</th>
<th>B. quintana</th>
<th>A. tumefaciens</th>
<th>S. meliloti</th>
</tr>
</thead>
<tbody>
<tr>
<td>virB2</td>
<td>89.7</td>
<td>90.7</td>
<td>27.3</td>
<td>38.9</td>
<td></td>
</tr>
<tr>
<td>virB3</td>
<td>85.4</td>
<td>90.5</td>
<td>26.9</td>
<td>34.9</td>
<td></td>
</tr>
<tr>
<td>virB4</td>
<td>35.6</td>
<td>34.6</td>
<td>16.5</td>
<td>22.8</td>
<td></td>
</tr>
<tr>
<td>17kDa</td>
<td>87.2</td>
<td>66.5</td>
<td>N/A</td>
<td>N/A</td>
<td></td>
</tr>
<tr>
<td>virB6</td>
<td>96.9</td>
<td>89.4</td>
<td>17.3</td>
<td>29.9</td>
<td></td>
</tr>
<tr>
<td>15kDa</td>
<td>8.7</td>
<td>14.0</td>
<td>9.6</td>
<td>N/A</td>
<td></td>
</tr>
<tr>
<td>virB8</td>
<td>72.4</td>
<td>92.1</td>
<td>19.8</td>
<td>45.9</td>
<td></td>
</tr>
<tr>
<td>virB9</td>
<td>61.3</td>
<td>49.4</td>
<td>12.5</td>
<td>33.0</td>
<td></td>
</tr>
<tr>
<td>virB10</td>
<td>39.9</td>
<td>33.6</td>
<td>9.5</td>
<td>18.8</td>
<td></td>
</tr>
<tr>
<td>virB11</td>
<td>11.7</td>
<td>10.5</td>
<td>10.1</td>
<td>11.3</td>
<td></td>
</tr>
</tbody>
</table>
Table 1.8 - Comparison of VirB Protein Similarities of *A. tumefaciens* and *B. henselae*, *B. clarridgeiae*, *B. quintana* and *Sinorhizobium meliloti*.

Amino acid sequences of each of the above VirB operon homologues were compared for similarity to those of *A. tumefaciens* using the AlignX program (Invitrogen). Open Reading Frame (ORF) analysis utilized Vector NTI (Invitrogen) and was verified by BLAST analysis.

<table>
<thead>
<tr>
<th>% Similarity to <em>A. tumefaciens</em></th>
</tr>
</thead>
<tbody>
<tr>
<td><em>A. tumefaciens</em></td>
</tr>
<tr>
<td>virB2</td>
</tr>
<tr>
<td>virB3</td>
</tr>
<tr>
<td>virB4</td>
</tr>
<tr>
<td>17kDa</td>
</tr>
<tr>
<td>virB6</td>
</tr>
<tr>
<td>15kDa</td>
</tr>
<tr>
<td>virB8</td>
</tr>
<tr>
<td>virB9</td>
</tr>
<tr>
<td>virB10</td>
</tr>
<tr>
<td>virB11</td>
</tr>
</tbody>
</table>
Search for a virB Operon in the B. bacilliformis genome.

Both a GenomeWalk and a λ Phage Library were prepared from isolated B. bacilliformis genomic DNA using the procedures that had successfully identified the virB genes in B. quintana and B. claridgeiae. Initially, the GenomeWalk library was screened using PCR primers prepared from consensus sequences derived from B. henselae, B. quintana and B. claridgeiae genes in order to ensure the most Bartonella-specific GenomeWalking primers possible. These GenomeWalk reactions did not yield any virB-specific amplified products. In those cases where PCR products were observed, subsequent sequence analysis revealed partial homology to genes that are unrelated to the virB operon (Table 1.9). Further screening to verify the presence or absence of the virB operon in B. bacilliformis was conducted by carrying out a series of plaque hybridizations with the B. bacilliformis λ Phage Library. While the probes used were successful in screening both the B. quintana and B. claridgeiae λ phage libraries, once again no virB-specific cloned product was identified.

Table 1.9 – Putative products identified from probes of the B. bacilliformis genome by virB gene-specific probes.
The B. bacilliformis genome was probed using Bartonella-based virB-specific PCR primers. The sequence data obtained were then added to a Vector NTI (Invitrogen) database and BLAST analysis was used to identify homologues for each gene sequence. The product of the gene exhibiting the highest homology is given.

<table>
<thead>
<tr>
<th>Probe</th>
<th>Putative Product</th>
</tr>
</thead>
<tbody>
<tr>
<td>virA</td>
<td>Methyltransferase, SocE</td>
</tr>
<tr>
<td>virB2</td>
<td></td>
</tr>
<tr>
<td>virB3</td>
<td>Cytosolic Protein</td>
</tr>
<tr>
<td>virB4</td>
<td>Lysostaphin</td>
</tr>
<tr>
<td>17kDa</td>
<td></td>
</tr>
<tr>
<td>virB6</td>
<td>alanyl TRNA synthetase</td>
</tr>
<tr>
<td>15kDa</td>
<td></td>
</tr>
<tr>
<td>virB8</td>
<td>Possible Flagellar Structural Genes</td>
</tr>
</tbody>
</table>
Southern hybridization of virB-specific probes to B. bacilliformis DNA.

The inability to recover a virB operon homologue from B. bacilliformis DNA could be due to the lack of this operon in this species. Alternatively, all or part of the virB operon sequences could be present, but these sequences might be organized in a way that precludes their identification. To address this possibility, primers used in the PCR reaction were labeled with DIG and used as probes for Southern hybridization against enzymatically digested DNA from B. quintana, B. clarridgeiae, and B. bacilliformis. Probing with the sequences from the 18.5 kDa antigen and virA, two genes known to be in B. bacilliformis, B. quintana, and B. clarridgeiae, clearly shows the presence of a single strong banding pattern, indicating the presence of those genes in the genomic DNA of each selected Bartonella species (Figure 1.2). Screening of B. quintana and B. clarridgeiae DNA with probes derived from virB homologues also reveals hybridizing fragments, including characteristic banding patterns for homologues of virB4 and virB6, based on expected gene product sizes, and multiple banding patterns with the screening of virB3, virB9 and virB11 derived probes. In no case, however, was positive hybridization observed with B. bacilliformis DNA (Table 1.9). From these data we conclude either that the genome of B. bacilliformis lacks an intact virB operon, or that any B. bacilliformis virB homologues present in the genome are so distinct from those of other Bartonella species that they do not cross-hybridize under any of the conditions tested.
Southern Blot Analysis in Search of a *virB* Operon in *B. bacilliformis*.
Figure 1.2 – Hybridization of virB DNA probes to Bartonella Genomic DNA.

Southern blot analysis was carried out on EcoRI-digested Bartonella genomic DNA probed with DIG-labeled DNA probes from various virB genes. Each membrane lane is as follows: 1) DNA Marker, 2) *B. bacilliformis*, 3) *B. quintana* and 4) *B. clarridgeiae* digested DNA. Panel A, the derivation of the DNA probes is indicated at the bottom of each gel.
Table 1.9 – Hybridization of *virB* Operon Fragments to Bartonella Genomic DNA

Southern blot analysis was conducted using probes from the designated *Bartonella* species after digestion of genomic DNA digestion by *EcoRI*, as indicated in Figure 1.2.

<table>
<thead>
<tr>
<th>Probe</th>
<th>Specificity</th>
<th><em>B. quintana</em></th>
<th><em>B. claridgeiae</em></th>
<th><em>B. bacilliformis</em></th>
</tr>
</thead>
<tbody>
<tr>
<td>18.5kDa Antigen (B. <em>bacilliformis</em> Ctrl)</td>
<td><em>B. bacilliformis</em></td>
<td>Negative</td>
<td>Negative</td>
<td>Present</td>
</tr>
<tr>
<td><em>virA</em></td>
<td><em>B. quintana</em></td>
<td>Positive</td>
<td>Positive</td>
<td>Negative</td>
</tr>
<tr>
<td><em>virB3</em></td>
<td><em>B. quintana</em></td>
<td>Multiple Fragments</td>
<td>Positive</td>
<td>Negative</td>
</tr>
<tr>
<td><em>virB4</em> Internal Fragment</td>
<td><em>B. claridgeiae</em></td>
<td>Positive</td>
<td>Positive</td>
<td>Negative</td>
</tr>
<tr>
<td><em>virB6</em></td>
<td><em>B. quintana</em></td>
<td>Positive</td>
<td>Positive</td>
<td>Negative</td>
</tr>
<tr>
<td><em>virB9</em></td>
<td><em>B. quintana</em></td>
<td>Multiple Fragments</td>
<td>Positive</td>
<td>Negative</td>
</tr>
<tr>
<td><em>virB11</em></td>
<td><em>B. quintana</em></td>
<td>Multiple Fragments</td>
<td>Multiple Fragments</td>
<td>Multiple Fragments</td>
</tr>
</tbody>
</table>
Discussion

In this study, we attempted to isolate the virB operon from three different Bartonella species using a variety of methods. We report here the successful isolation and characterization of the operon from B. quintana and B. clarridgeiae, two of the three species we analyzed.

The virB operon was initially identified in A. tumefaciens, where it codes for a TFSS that allows the transfer of the Ti DNA from the bacterium into the host cells, where it causes the formation of gall tumors in infected plants (Chen et al., 2002; Escudero et al., 1995; Loubens et al., 1997). The A. tumefaciens virB operon is composed of 11 genes that are under the control of a virBox regulatory element located upstream of the operon (Berger et al., 1994; Christie, 1997). VirB operon homologues have been identified in two Bartonella species, B. henselae and B. tribocorum (Maurin et al., 1997; Padmalayam et al., 2000a; Schulein et al., 2002). Functions ascribed to the virB operon of B. henselae and B. tribocorum include bacterial uptake, host cytoskeletal rearrangement and inhibition of apoptosis (de Paz et al., 2005; Dehio, 1999; Schmid et al., 2004; Schulein et al., 2005; Seubert et al., 2003a). In addition, the 17kDa antigen, the fourth gene in the Bartonella virB operons, produces a protein that shows high antigenicity and is reactive with CSD-positive host sera (Padmalayam et al., 2000a; Sweger et al., 2000). Despite the information that has been obtained about this operon, there has not yet been convincing evidence presented for a direct role for virB gene products in virulence.

Motif analysis was conducted on each B. quintana and B. clarridgeiae VirB homologue in order to determine the similarity of these genes to those of other bacteria, and to correlate predicted protein structure with possible functions (Soni, personal
communication). Due to their high homology analysis for both of these *Bartonella* species is given below.

**VirB2:** The *virB2* gene was originally identified in *A. tumefaciens*, and has now been found in several *Bartonella* species, including *B. henselae* and *B. tribocorum*. The *virB2* genes from all three of these bacteria show high homology to the *E. coli* *traA* gene, a 12.3-kDa protein. *TraA* contains an N-terminal cleaved signal sequence that is responsible for the export of the gene product to the inner membrane where it aggregates as part of the F-pilin subunit. F-pilin is used by *E. coli* during conjugation and is polymerized at the cell surface to form the F-pilus (Harris *et al.*, 1999; Paiva *et al.*, 1992). Though it also contains a signal sequence, the VirB2 homologue from *B. quintana* exhibits less homology than the other *Bartonella* species to the *E. coli* *traA* gene product, and instead shows 36.8% amino acid identity to the type IV secretion protein of *S. meliloti*. The *B. clarridgeiae* VirB homologue shows a 38.9% degree of identity to the *S. meliloti* secretion protein.

**VirB3:** The role of the VirB3 in bacteria has not yet been fully determined. It is known that the *A. tumefaciens* VirB3 shows homology to the *E. coli* *traL* protein, which is required for assembly of the F-pilus (Hapfelmeier *et al.*, 2000; Paiva *et al.*, 1992). Studies with *B. henselae* suggest that VirB3 interacts with the 15kDa antigen and VirB9 homologues to stabilize the periplasmic proteins which support the TFSS (Shamaei-Tousi *et al.*, 2004). It is likely that the *virB3* of gene products of both *Bartonella* species examined here function similarly due to their high level of sequence identity (85.4% and 90.5% for *B. quintana* and *B. clarridgeiae*, respectively) to the corresponding *B. henselae* protein.

**VirB4:** The largest open reading frame encoded by the *virB* operon, the *virB4* gene codes for a protein of undetermined function. Although the VirB4 protein produced by *B. quintana*, *B.
clarridgeiae and other Bartonella species is predicted to the highly hydrophilic in our laboratory suggests the B. henselae VirB4 protein is not immunoreactive with human sera from Bartonella-infected patients (Soni, personal communication). All of the Bartonella VirB4 proteins contain a NTP binding domain, but binding to NTPs has not yet been demonstrated.

**17kDa Antigen:** The 17kDa Antigen is a highly immunogenic protein originally identified by its reactivity with human anti-sera from B. henselae-infected patients (Sweger et al., 2000). In fact, it was the characterization of the 17kDa antigen gene and the surrounding region that initially led to the discovery of the B. henselae virB operon (Padmalayam et al., 2000a). To date, no A. tumefaciens protein homologous to the 17kDa Antigen has been reported, although this protein is highly conserved among most of the Bartonella species. Instead, A. tumefaciens contains a distinct gene upstream of virB4, termed virB5, that does not have a counterpart in Bartonella species. While the function of this gene has not been determined, the virB5 gene product is known to interact with VirB8 and VirB10 in A. tumefaciens (Yuan et al., 2005). Studies with B. henselae show that the expression of the 17kDa Antigen is triggered by a yet to be determined host cell signal (Schmiederer et al., 2001). Analysis of the open reading frame suggest that the 17kDa Antigen has an N-terminal cleavage signal and a high antigenic index (Jameson et al., 1988), a finding that correlates well with its immunoreactivity to human anti-sera from infected patients.

**VirB6:** The role of VirB6 in A. tumefaciens has yet to be determined, but it is predicted to have six transmembrane domains and may form several complexes with other virB proteins. The hydrophobicity plots of the B. quintana and B. clarridgeiae virB6 gene products show them to be hydrophobic and to have a predicted inner membrane location.
15kDa Antigen: As with the other *Bartonella* species that contain this gene, the *B. quintana* and *B. claridgeiae* 15 kDa antigen genes do not have a counterpart in *A. tumefaciens*. In *A. tumefaciens*, the product of *virB7*, the gene located at this position, functions as a ribonucleotide reductase, converting ribonucleotides into their corresponding deoxyribonucleotides. Instead the *B. quintana* and the *B. claridgeiae* 15kDa antigens show a low protein sequence identity to the 15kDa antigen of *B. henselae* of 8.7% and 14.0%, respectively. The two proteins appear to be truncated versions of the *B. henselae* homologue, however. When compared to the 489-bp *B. henselae* 15kDa antigen, the *B. quintana* open reading frame for this protein contains only 312 bp while the *B. claridgeiae* 15kDa antigen is encoded by 315 bp. This truncation affects the N-terminal portion of both examined *Bartonella* species, with the *B. henselae* 15kDa antigen open reading frame containing 177 bp, corresponding to approximately 59 amino acids, that neither the *B. quintana* nor the *B. claridgeiae* 15kDa antigens possess.

**VirB8, VirB9 and VirB10:** Previous work with *A. tumefaciens* suggests that the *virB8, virB9* and *virB10*-encoded proteins are able to interact with one another to form a transport pore complex (Das *et al.*, 1997; Finberg *et al.*, 1995; Krall *et al.*, 2002). These studies also suggest that this three-protein interaction is required for DNA transfer and is inner membrane bound. Studies with *B. henselae* suggest that the interaction of these *virB* gene homologues are similar to those in *A. tumefaciens*. Analysis of VirB9 interactions suggests that it binds to the 15kDa antigen in the periplasm and may provide a periplasmic anchor of the *virB2*-encoded pilus. Further analysis has shown that VirB8 and VirB10 interact in the inner membrane, aided by the ATPase activity of VirB11, and that this complex acts in an
anchoring capacity for the TFSS formed by the virB gene products (Shamaei-Tousi et al., 2004).

**VirB11:** Studies with *A. tumefaciens* virB11 reveal that it functions as an ATPase (Sagulenko et al., 2001; Stephens, KM et al., 1995; Stephens, Kathryn et al., 1995). This ATPase activity is due to the presence of a NTP binding site and the localization of the virB11 protein in the membrane is directly tied to its ATPase activity. Moreover, work has suggested that the virB11 gene product is required for pilus formation and the export of Ti DNA substrate in *A. tumefaciens* (Sagulenko et al., 2001). In *Bartonella*, the VirB11 homologue is known to interact with VirB8 and VirB10 in the inner membrane and may form a pore for the movement of various factors through the inner membrane and out the virB2-encoded pilus. This pore-forming potential is augmented by the ATPase activity of VirB11 which may provide energy for factor movement through the putative virB-encoded TFSS (Shamaei-Tousi et al., 2004).

The DNA sequence level-homology between *A. tumefaciens* and *Bartonella* suggests that the role of the virB operon in *Bartonella* may be similar to that of *A. tumefaciens*, or at least that the structures are similar. The individual virB genes also show an almost identical pattern of physical arrangement among all of the *Bartonella* species studied. Only *B. quintana* shows a slight differentiation with the inclusion of a long-form virB8 homologue which shows multiple start sites, possibly indicating the production of slightly differing proteins. The long-form virB8 contains 702 bp, coding for approximately 234 amino acids, while the short-form virB8 contains only 610 bp, resulting in a 203 amino acid protein. DNA sequence analysis of these different virB8 forms indicates the long-form contains 96 bp upstream of the short-form start codon, encoding for 32 amino acids. Collectively, the first
seven applicable virB operon genes of Bartonella show an average 41% DNA sequence identity to those of A. tumefaciens. Examination of the extent of homology among all 10 virB homologue genes reveals that a close homology between the B. quintana and B. henselae operons (80.7%) with a slightly lesser degree of homology between those of B. quintana and B. tribocorum (76.7%). Studies were conducted to examine the extent of amino acid identity between virB proteins from A. tumefaciens and their counterparts in B. quintana and B. clarridgeiae. B. quintana had the highest identity (21%) while B. clarridgeiae is slightly lower at 16.6%. Protein similarity between the Bartonella VirB proteins and A. tumefaciens indicates a lower level of similarity between the two organisms. Our data shows an average 34% similarity between A. tumefaciens VirB proteins and Bartonella species examined with B. henselae having the highest similarity (37%) and B. clarridgeiae the lowest (28.8%). While this similarity may be low as compared to S. meliloti (41.3%), it is important to point out that the role of the VirB proteins in Bartonella has not yet been fully elucidated and may be functionally different from A. tumefaciens.

Interestingly, motif and cellular localization analyses of the virB homologues found in B. quintana and B. clarridgeiae reveal similarities to their A. tumefaciens counterparts, providing further evidence for the structural similarities between the Agrobacterium and Bartonella virB gene products while allowing them to provide differing functions.

Following the successful sequencing of the virB operon from both B. quintana and B. clarridgeiae, we attempted to isolate the virB operon from B. bacilliformis. While little research has been completed regarding the virulence factors produced and secreted by B. bacilliformis, this bacterium has been shown to use a variety of gene products to afford itself invasion into host cells. Although the mechanics of invasion by B. bacilliformis into RBCs is
not yet elucidated, it is known that IalA and IalB are involved in the process, as is Deformin, the bacterially encoded protein that is able to produce invaginations into RBC membranes (Coleman et al., 2001; Hendrix et al., 2003; Mitchell et al., 1995; Xu et al., 1995). Even less is known about the process by which *B. bacilliformis* invades host tissues, such as endothelial and epithelial cells, or the gene products that are involved. Attempts to correlate virulence with *virB* operon gene products have been singularly unsuccessful. In fact, *B. bacilliformis*, arguably the most virulent of all known *Bartonella* species, is the only *Bartonella* species tested to date that does not react with antisera directed against the highly immunogenic 17kDa Antigen of *B. henselae* that is encoded within the *virB* operon. DNA sequencing studies completed during screening of various *Bartonella* species had previously suggested that the 17kDa antigen was not found in the *B. bacilliformis* genome, even with the use of multiple PCR primer probes (Sweger et al., 2000).

The attempted sequencing of a *virB* operon from *B. bacilliformis* was initiated using *Bartonella* specific *virB* primers designed from the previously determined *Bartonella* *virB* operon homologue gene sequences. Sequence analysis of the PCR products found using these primers (Table 1.7) revealed similarities to several genes, including those coding for SocE, Lysostaphin, and some putative flagellar proteins, but no VirB homologues were identified. The *virB*-specific primers were subsequently labeled with DIG and used as probes for screening several Southern Blots prepared using enzymatically digested DNA from *B. quintana*, *B. clarridgeiae*, and *B. bacilliformis*. The results (summarized in Table 1.8) reveal a strong banding pattern with probes against two genes, the 18.5kDa antigen gene and *virA*, that are known to be present in all three *Bartonella* species. The use of *virB*-specific probes reveals the presence of all other *virB* homologues in DNA from *B. quintana*...
and *B. clarridgeiae*, including the expected banding pattern, based on gene size, for sequences corresponding to *virB*4 and *virB*6 and multiple banding patterns with screening involving *virB*3, *virB*9 and *virB*11 sequences. The presence of multiple bands in the Southern blot screenings could be due to incomplete hybridization of the probes to the digested DNA targets or the presence of multiple copies of these genes in their respective *Bartonella* genomes, and could be reflective of the overall genetic similarity among these three *Bartonella* species. When the same DIG-based probes were used to screen Southern blots containing *B. bacilliformis* DNA, no significant banding patterns were observed. The only probe to give a positive hybridization result was a *B. quintana*-specific *virB*11 sequence, which showed the presence of multiple bands. This result may be due to the presence of sequences within the *B. bacilliformis* genome that are similar enough to the *virB*11 probe to produce a limited level of hybridization. While these sequences have yet to be determined, it is unlikely that they represent a complete *virB*11 gene.

In January 2007 the genome of *B. bacilliformis* KC583 was released (GenBank Accession CP000524.1). Like the results of the studies presented here with *B. bacilliformis* KC584, sequence analysis of the KC583 strain did not reveal the presence of a *virB* operon. While our studies were with a different strain, it is reasonable to surmise that *B. bacilliformis* KC584 also lacks the *virB* operon. Detailed analysis of accession CP000524.1 shows that not only is *B. bacilliformis* KC583 lacking the *virB* operon but also the *tra* and *bep* operons found in several other *Bartonella* species that are involved in apoptosis and virulence, respectively. While the role of the *tra* operon has not been studied in *Bartonella*, studies with *E. coli* indicate that the *tra* operon codes for a TFSS that is required for some *Escherichia* species DNA conjugation (Wu et al., 1987). Previous work with *B. henselae*
and *B. quintana* has shown that *bepA* plays a role in the vascular cell anti-apoptotic effect seen during infection by these *Bartonella* species, and is able to prevent apoptosis by cytotoxic T cells as well (Schmid *et al.*, 2006).

Collectively, these data suggest that the *virB* operon is not responsible for *B. bacilliformis*-induced formation of verruga peruana in Carrion’s Disease. We have demonstrated that *B. quintana* and *B. clarridgeiae* along with several other *Bartonella* species do contain a *virB* operon homologue. However, our search for a corresponding operon in *B. bacilliformis* was negative. Our results, combined with the recently published sequence for *B. bacilliformis* KC583 and previous studies of the 17kDa antigen, suggest that *B. bacilliformis* does not contain a *virB* operon and, further, that VirB homologues are not involved in the *B. bacilliformis*-induced formation of verruga peruana in Carrion’s Disease (Sweger *et al.*, 2000). There is some anecdotal evidence suggesting that *Bartonella* species that do contain the *virB* operon tend to become less virulent after multiple passages, and investigators have speculated that this decrease in virulence might be connected to the loss of VirB proteins on the bacterial surface (Padmalayam, personal communication). However, this is clearly not the case for *B. bacilliformis*. The virulence and angiogenic properties of *B. bacilliformis* must be the result of other factor(s).
Chapter II – Analysis of HMEC-1 Gene Expression during B. bacilliformis Infection

Introduction

*Bartonella bacilliformis*, the causative agent of Carrion’s Disease, produces proliferative angiogenic lesions in human hosts during the later phase of infection. These lesions, which may be due to the infiltration of *B. bacilliformis* into both cutaneous and subcutaneous epithelial tissues, show histopathology similar to those of Kaposi’s Sarcoma (KS) (Garcia *et al.*, 1990; Nayler *et al.*, 1999; Ramirez *et al.*, 1996; Ramirez Ramirez *et al.*, 1996).

Kaposi’s Sarcoma of the AIDS-associated variety presents itself on the head, neck and trunk of the host after co-infection with HIV and the normally benign KS-associated herpesvirus (KSHV) or Human Herpes Virus 8 (HHV-8). In immunocompromised patients, it has been established that HIV-1 exacerbates HHV-8 pathogenesis via immunosuppression, by the alteration of the localized tissue microenvironment and by direct interaction of viral proteins with host tissues (Barillari *et al.*, 1999; Dourmishev *et al.*, 2003; Sinkovics, 1991). While both viruses (HIV and HHV-8) are sexually transmitted, there is evidence to support an evolutionary link between HHV-8 and humans, as HHV-8 infection is often suppressed by immunocompetent persons.

The similarities in histopathology seen with *B. bacilliformis* infection and HHV-8 infection include the involvement at the site of the lesion of several cell types, including epithelial, endothelial and infiltrating inflammatory cells. Often “spindle” cells are involved. Spindle cells express both endothelial and macrophage markers but their origin remains undefined. During both *B. bacilliformis* and HHV-8 infection, localized aberrant neoangiogenesis is seen, with the extent of neoangiogenesis being greater with Carrion’s
disease than with HHV-8 infection. During HHV-8 infection, elevated levels of many cytokines, including bFGF, Interleukin-1 (IL-1), IL-6, IL-8, platelet-derived growth factor (PDGF), tumor necrosis factor (TNF), gamma interferon (INF-\(\gamma\)), vascular endothelial growth factor (VEGF) and the transcription factor HIF1 (Hypoxia-inducible Factor-1), have been reported (Catrina et al., 2006; Sinkovics, 1991; Sodhi et al., 2000). In HHV-8 lesions, these cytokines are produced by infiltrating spindle cells. This is believed to allow for continued growth and expansion of the lesion, as these cytokines are proangiogenic and necessary for lesion viability (Fiorelli et al., 1995; Poole et al., 2002; Yang et al., 2000).

Interesting, while micro-environmental cytokine levels increase, there does not appear to be a corresponding increase in cytokine levels in the host serum, and a correlation between HHV-8 activity and serum cytokine levels has not been successfully established (Dourmishev et al., 2003).

While the cells infected with HHV-8 have been found to express a wide variety of markers, immunohistochemistry studies have shown that the presence of LANA-1 (latency-associated nuclear antigen) marker cells increases during KS lesion progression; this has been seen in multiple KSHV infected cell types (Dourmishev et al., 2003; Poole et al., 2002). Studies of the histopathology of HIV-1 infected patients implicate the HIV- Tat protein as inducing the KS-like lesions when over expressed in a bFGF rich environment (Mallery et al., 2003). Ex vivo it has been demonstrated that extracellular Tat stimulates monocyte-derived macrophages to secrete IL-8 and Gro\(\alpha\), both of which are known proangiogenic cytokines for endothelial cells (Poole et al., 2002; Samaniego et al., 1998). HIV-1 Tat has also been shown to sustain growth of KS lesions in AIDS-associated KS by direct interaction with host anti-apoptotic genes and activation of Akt kinase activity (Deregibus et al., 2002).
Tat functions are mediated by direct interaction with VEGF receptor 2 (VEGFR2) and insulin growth hormone (IGF) receptor 1 (Catrina et al., 2005). Tat is also able to bind to several host integrins which activate angiogenic and proliferative cascades (Dourmishev et al., 2003; Poole et al., 2002).

To date, research into the interaction of B. bacilliformis with host cells is limited by the growth requirements of the bacterium. Garcia et al. (1990) have shown that B. bacilliformis is able to induce proliferation when live bacteria are co-cultured with endothelial cells. Concurrent with proliferation induction, there is an increase in host tissue plasminogen antigen (t-PA) production. Further studies by this group implicated a 12-14 kDa protein produced by B. bacilliformis in endothelial cell proliferation (Garcia et al., 1990; Garcia et al., 1992). Studies have also shown that the infection of endothelial cells by B. bacilliformis decreases cellular mobility by interfering with the host’s ability to form new actin-based tubules while increasing cytoskeletal rearrangement (Verma et al., 2001). Cerimele et al. (2003) have shown that proteins produced by B. bacilliformis interact with both the VEGF receptor 1 and VEGF receptor 2 and that this results in the production of angiopoietin-2 by epithelial cells. By using co-cultures of epithelial and endothelial cells, the authors demonstrated a cell-signaling link between these cell types as the endothelial cells responded to the angiopoietin-2 produced by the epithelial cells (Cerimele et al., 2003). Finally, in a series of experiments, Minnick et al. (2003) implicated B. bacilliformis GroEL as a mitogen acting directly on host endothelial cells. A mechanism for this interaction has yet to be established.

In this study, we report the global gene expression analysis of B. bacilliformis/HMEC-1 utilizing microarray technology. HMEC-1 cells were infected with B.
bacilliformis and total RNA was extracted after six and thirty-six hours post-infection. The RNA was hybridized to Affymetrix HG-U133 gene chips to evaluate the host transcriptional response to infection. In order to place these responses into context, the information was further analyzed against published HHV-8 infected endothelial cell microarray data (Wang, 2004).
Materials and Methods

**Bacterial Growth and Culture.** *B. bacilliformis* KC584 was obtained from the ATCC and only passages 2-6 were used. *B. bacilliformis* was grown on BHI agar supplemented with 10% sheep’s blood at 25°C for 5-7 days. Growth was monitored by visual inspection; once confluent colonies were observed the bacteria were harvested by the addition of 15 ml of sterile PBS, pH 7.4, and the plate was gently scraped using a cell scraper (Fisher). The PBS-*B. bacilliformis* mixture was removed by aspiration and added to a sterile 15 ml tube (Falcon). Unused *B. bacilliformis* was placed in a 50% PBS/50% glycerol mixture and stored at -80°C until needed.

**Human Cell Growth and Culture.** HMEC-1 cells were obtained as a generous gift from Dr. Thomas Lawley of Emory University and the Centers for Disease Control and Prevention (Ades et al., 1992). HMEC-1 cells from passages 19-27 were grown in a 15 ml mixture of 50% M199 (Cambrex) supplemented with 15% FBS, 2% penicillin-streptomycin and 50% EGM-2 (Cambrex). This medium was changed every 2-3 days until 70-80% confluence was reached. After they became confluent, the cells were released from the flask by decanting the growth media and adding 15mL of CellStripper (Cellgro). The cells were allowed to incubate at room temperature for 10 minutes to facilitate cell release. The cells were then gently scraped with a CellScraper (Sarstedt). The cell mixture was aspirated into a 15 ml tube (Falcon) and centrifuged at 700xg for 10 minutes at room temperature. The liquid was decanted and the pellet was resuspended in 1mL of sterile PBS, pH 7.4. Cells not intended for use immediately were resuspended in DMSO Cryoprotectant (Cellgro), stored at -80°C overnight, and subsequently moved to liquid nitrogen for long term storage.
Infection of HMEC-1 with Live *B. bacilliformis*. HMEC-1 were grown in T150 flasks containing 30 ml of a mixture of 50% M199 supplemented with 15% FBS, 2% penicillin-streptomycin) and 50% EGM-2 media. Cells were incubated at 37°C in 5% CO₂ and saturated humidity. The cells were grown to 90% confluence, as verified by visual inspection. The medium was aspirated and replaced with 30 ml of M199 with 5% FBS, and the HMEC-1 were allowed to incubate for 24 hours at 37°C and 5% CO₂ in saturated humidity. A single flask of HMEC-1 was then counted to give an approximation of the growth in the remaining flasks. Live *B. bacilliformis*, at an MOI of 100:1 in 100 µL, was added to each experimental flask, while 100 µL of sterile PBS, pH 7.4, was added to each control flask. At the appropriate time points (6 and 36 hours post-infection), the media were aspirated and the HMEC-1 cells were detached from the flasks, as described above. The cells were then centrifuged at 700xg for 10 minutes at 4°C. The cells were immediately processed for total RNA.

Preparation of HMEC-1 Total RNA. Extraction of total RNA from HMEC-1 cells was accomplished using the Qiagen RNeasy column (Qiagen). Briefly, the HMEC-1 were harvested as stated previously, but the pellet was resuspended by flicking the tube after adding 600 µL of RTL buffer with β-mercaptoethanol. The lysate was pipetted into a QIAShredder spin column (Qiagen) for homogenization, and centrifuged at 14,000xg for 2 minutes. To the spin column, 700 µL of 70% ethanol was added, and the sample was mixed well with a pipette. Into an RNeasy spin column, 700 µL of the lysate-ethanol mixture was added and the column was centrifuged at 14,000xg for 24 seconds. The procedure was repeated until the entire mixture had been processed through the spin column, while the flow-through was discarded. Into the spin column, 700 µL of RW1 buffer was added, the spin
column was again centrifuged at 14,000xg for 24 seconds, and the flow-through was again discarded. Next, two rounds of 500 µL of RPE buffer was added to the spin column and centrifuged at 14,000xg for 24 seconds for the first round, and 2 minutes for the second round of centrifugation. Finally, 30 µL of RNase-free water was added to the spin column, which was then placed into a fresh 1.5 ml RNase-free microcentrifuge tube (USA Scientific). The spin column was held at room temperature for five minutes, then centrifuged at 14,000xg for one minute. The eluate was placed back into the spin column and allowed to incubate for 30 minutes at room temperature, after which the spin column was centrifuged again at 14,000xg for one minute. The samples were placed in a BioPhotometer (Eppendorf) to determine the RNA concentrations, and the total HMEC-1 RNA was stored at -80°C until needed.

**Microarray Analysis of *B. bacilliformis* Infected HMEC-1.** Purified total HMEC-1 RNA was used for microarray studies with the HG-U133A and HG-U133B Chip Sets (Affymetrix). The manufacturer’s protocol was followed for the entire process, as follows. Briefly, cDNA for each sample was synthesized from 8 µg of total HMEC-1 RNA per reaction using the Affymetrix-supplied SuperScript II first strand synthesis kit. This first-strand cDNA was then used for the synthesis of second-strand cDNA. The second-strand cDNA was then placed in Phase-lock gel tubes (Eppendorf) and extracted with 25:24:1 phenol:chloroform:isoamyl alcohol (Boehringer Mannheim). Next, the second-strand cDNA was used to synthesize Biotin-labeled RNA using the Enzo BioArray High Yield RNA Transcription Labeling Kit, as suggested by Affymetrix. After synthesis, the labeled RNA was cleaned using the Qiagen RNeasy columns, as recommended by Affymetrix. The cRNA was quantified via the included IVT Product calculations, and once it was determined that the
concentration and purity of the cRNA were within the manufacturer’s recommendations the cRNA was fragmented using the supplied fragmentation buffer. The fragmented cRNA was then spiked with the supplied Affymetrix controls, including the B2 Oligonucleotide and Eukaryotic Hybridization Controls. The spiked cRNA from each sample was subsequently hybridized onto the HG-U133A chip for 16 hours at 45°C rotating at 60 rpm. After HG-U133A hybridization, the spiked cRNA was removed and added to the HG-U133B chip, which was hybridized as described above. The hybridized chips were then washed and stained, as per the supplied Affymetrix protocols, using the GeneChip Fluidics Station for automated washing and staining. The chips were subsequently scanned using the GeneArray scanner operating with GeneChip Operating System (GCOS) 5.; normalized values for each gene spot were given via normalization from 0.1 to 1 as compared to spiked-in endogenous chip controls. Raw data from the GCOS analysis were then used for microarray analysis by GeneSpring v7.3 (Agilent).

**GeneSpring Analysis of Human Microarray Data.** GeneSpring v7.3 (Agilent) was used for the analysis of the microarray data. All data were initially preprocessed using the CHP file preprocessor. Following file preprocessing, all data were normalized by setting raw signal values below 0.01 to 0.01. The 50.0th percentile of all measurements in that sample divided each measurement. Each gene was divided by the median of its measurements in all samples. If the median of the raw values was below 10, then each measurement for that gene was divided by 10 if the numerator was above 10; otherwise, the measurement was thrown out. Genes selected for pathway and further analysis were identified by Fold-Change analysis. The significantly differentially expressed genes from the fold-change data were built by comparing "Timed Control" with "Timed Experimental" using all normalized genes.
Statistical analysis was conducted using the parametric test, assuming unequal variances. Genes that were differentially expressed passed this testing method defined by Fold Difference: 2 and a P-value Cutoff: 0.1.

Data from Human Herpes Virus-8 (HHV-8) infected human Blood Endothelial Cells (BEC) were used in various microarray-based comparison studies to *B. bacilliformis* infected HMEC-1. Microarray data generated by Wang, *et al.* (2004) from HHV-8 cells were obtained from the Array Express public microarray database and subjected to the same statistical and sorting methodology as noted above for the HMEC-1 microarray data.

**RT-PCR Verification of Selected HMEC-1 Genes.** Further analysis of fold-change data from the HG-U133A and HG-U133B (Affymetrix) microarray data was done via RT-PCR analysis of selected genes at each time point as follows. Previously collected *B. bacilliformis*-infected HMEC-1 total RNA was used for first strand cDNA synthesis using the SuperScript III Platinum Two-Step qRT-PCR kit (Invitrogen) containing 500 ng of total RNA in RT reaction mix, RT enzyme mix, and DEPC-treated water. These reagents were then gently mixed and incubated at 25°C for 10 minutes, then 42°C for 50 minutes per manufacturer’s instructions. The reaction was terminated by heating the mixture at 85°C for 5 minutes, and the sample was then chilled on ice. After termination, 1 μL of *E. coli* RNase H was added and incubated with the reaction mixture at 37°C for 20 minutes. This reaction mix was stored at -20°C, and used for second-step RT-PCR as needed. The second step RT-PCR reactions were completed using the TaqMan® Universal PCR Master Mix (Applied Biosystems, Inc.). An endogenous control, peptidylpropyl isomerase A (PPIA), was chosen as an mRNA housekeeping gene using the TaqMan Endogenous Control Array kit (Applied Biosystems, Inc.) In brief, each reaction was prepared in triplicate with 100 ng of the above
prepared cDNA, a target-gene specific TaqMan Gene Expression Assay Primer pair (Applied Biosystems Inc.) for HIF1α (Hs00936368_m1), CASP3 (Hs00234387_m1) and CASP8 (Hs00154256_m1) and the TaqMan two-step RT-PCR Master Mix reagent kit (Applied Biosystems, Inc.) The cycling parameters for the Applied Biosystems 7500 sequence detection system were RT at 48°C for 30 minutes, AmpliTaq activation at 95°C for 10 minutes, denaturation at 95°C for 15 seconds, and annealing-extension at 60°C for 1 minute (repeated 40 times). The generated triplicate Ct values were analyzed using Excel (Microsoft) by the comparative Ct (ΔΔCt) method, per Applied Biosystems, Inc. instructions. The amount of target, calculated using the formula RQ = 2^{-\Delta\Delta Ct}, or \Delta\Delta Ct = \log_{2}(RQ), was determined by normalization to the endogenous control (PPIA) and expression relative to a calibrator (uninfected, same time point HMEC-1 sample). Relative quantification between microarray and RT-PCR data was done using previously normalized values for control (uninfected) and experimental (infected) data from microarray data, obtained by dividing the experimental data by the control data. From the normalized ratio (NR), the log 2-based fold-change calculations were performed using Excel. **Fold-Change Calculations.** Fold-change calculations were completed using both the Normalized Ratio (NR), derived from microarray analysis, and RQ values, derived from the comparative Ct (ΔΔCt) method for RT-PCR analysis, with the following formula: IF(NR or RQ<1,-1/NR or RQ) (Ingenuity™). A NR greater than 1.0 represents fold-change directly and no calculation was required. According to this formula if the NR is more than 1, then this value represents a positive fold change or gene up-regulation, however if the NR is less than one, then the values are divided by -1 to give a negative integer representative of gene down-regulation. Finally, if normalized ratio is 1, then this value represents no change in
gene expression. RT-PCR data was processed in a similar manner, once RQ values were obtained, using the RQ value as a substitute for the normalized ratio, thus producing fold-change data for RT-PCR RQ values.
Results

Scatter plot analysis of HG-U133A Microarray chips.

Scatter plot analysis based on control versus experimental gene expression profiles was conducted on the HG-U133A chip following hybridization with HMEC-1 mRNA. As shown in Figure 2.1, HG-U133A microarray data exhibit expected expression variability at both time points with *B. bacilliformis*-infected HMEC-1 cells. As the plot indicates, blue dots represent a down-regulation and orange/red dots represent an up-regulation of the experimental samples relative to the controls. Panel A, the scatter plot generated from host cell gene expression levels 6 hours post infection, reveals 2.3% of the host genes to be up-regulated (as indicated by the orange/red dots), and 6.7% to be down-regulated (as indicated by the blue dots). Panel B, the scatter plot obtained with RNA isolated 36 hours post-infection, shows a similar overall effect on gene expression levels, with 2.6% of the genes being up-regulated and 7.6% being down-regulated.
Figure 2.1 – Scatter plot analysis of Affymetrix HG-U133A Microarray chips at various time points.
HMEC-1 cells were infected with *B. bacilliformis* at a MOI of 100:1 at 37°C. Host mRNA was harvested at six and thirty-six hours post-infection. Cellular total mRNA was isolated post-infection and hybridized to Affymetrix HG-U133A microarray chips containing approximately 54,681 human transcripts. The two panels above indicate the time point data used to generate gene expression profiles from two replicate samples, as follows: Panel A: 6 hours post-infection; and Panel B: 36 hours post-infection. Each data point above represents the relative mean hybridization intensity of one of the mRNA transcripts purified from the infected cells, represented on the y-axis, versus a PBS-mock infected control, represented on the x-axis. Genes whose expression was unchanged in the infected cells compared to controls are shown as yellow dots; genes whose expression was down-regulated as compared to
control are represented as blue dots; and genes whose expression was up-regulated compared to controls are represented as orange/red dots. The green bars indicate the two-fold change range for each chip hybridized.
Scatter plot Analysis of HG-U133B Microarray chips.

Scatter plot analysis of the HG-U133B microarray chips reveals a level of variability of gene expression distribution similar to that shown in the HG-U133A microarray chips. As shown in Figure 2.2, Panel A, which plots data obtained at the 6-hour time point, shows that 2.0% of genes are up-regulated, while 6.8% are down-regulated. Panel B, which incorporates data from the 36-hour time point, shows percentages of up- and down-regulated genes at 2.5% and 8.4%, respectively.
Figure 2.2 – Scatter plot analysis of Affymetrix HG-U133B Microarray chips at various time points.
Analysis was conducted as described in Figure 2.1
Fold Change Analysis of Highly Differentially Expressed Functional HMEC-1 Genes.

Analysis of the most highly differentially expressed functional HMEC-1 genes was conducted utilizing data from the fold change ratios prepared from signal intensity data obtained by hybridization of *B. bacilliformis*-infected and mock-infected HMEC-1 cellular RNA onto HG-U133A and HG-U133B (Affymetrix). The fold change data shown in Tables 2.1a and 2.1b represent approximately 40 of the mostly highly differentially-expressed functional genes at each monitored time point, as organized by highest fold change ratios. These genes were selected due both to their high level of fold change versus the mock-infected control and their role as functional proteins in the host cell. Putative or hypothetical genes were eliminated from this analysis. For example, at 6 hours post-infection, the high-level up-regulation of catalase (a 9-fold increase) may indicate an altered immune response mechanism for *B. bacilliformis* clearance, while the down-regulation of IL-17 and IL-26 precursors may indicate a bacterial mechanism by which infiltration of immune cells is temporally reduced (Table 2.1a). Furthermore, up-regulation of epidermal growth factor receptor(s) and IL-22 binding proteins may indicate an increased responsiveness to micro-environmental growth factors and inflammatory response. The down-regulation of several CDC42-related genes may further indicate the effect *B. bacilliformis* infection has on cellular polarity and alteration of actin fibers (Table 2.1b)
Table 2.1a – Highly differentially expressed functional HMEC-1 genes 6 hours after B. bacilliformis infection.

Fold change analysis for the top selected functional genes, via GeneSpring comparison of mock-infected control HMEC-1 cells versus HMEC-1 cells infected B. bacilliformis. Total RNA extracted from mock and infected cells was hybridized to HG-U133A and HG-U133B (Affymetrix) microarray chips. Hybridization data were then used to determine the fold change of the highly differentially expressed HMEC-1 genes.

<table>
<thead>
<tr>
<th>Gene product</th>
<th>Accession No.</th>
<th>Fold Change</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Up-regulated Gene Products</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>SET and MYND domain containing 3</td>
<td>AW074336</td>
<td>16.04</td>
</tr>
<tr>
<td>Polycystic kidney disease 2-like 2</td>
<td>AF182034</td>
<td>14.69</td>
</tr>
<tr>
<td>UV excision repair protein RAD23 homolog B</td>
<td>T93562</td>
<td>14.26</td>
</tr>
<tr>
<td>F-box only protein 3 isoform 1&amp;2</td>
<td>AL162053</td>
<td>13.68</td>
</tr>
<tr>
<td>Basic helix-loop-helix domain containing, class B, 3</td>
<td>R93946</td>
<td>13.65</td>
</tr>
<tr>
<td>Spermatogenesis associated 1</td>
<td>NM_022354</td>
<td>12.41</td>
</tr>
<tr>
<td>Synaptopodin 2-like</td>
<td>NM_024875</td>
<td>12.04</td>
</tr>
<tr>
<td>Inad-like protein; inad-like protein isoform 4</td>
<td>AB044807</td>
<td>11.47</td>
</tr>
<tr>
<td>Glutamate receptor, ionotopic, AMPA 1</td>
<td>AF007137</td>
<td>11.19</td>
</tr>
<tr>
<td><strong>Down-regulated Gene Products</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Interleukin 17A precursor</td>
<td>Z58820</td>
<td>-19.763</td>
</tr>
<tr>
<td>Potassium inwardly-rectifying channel J15</td>
<td>BG542347</td>
<td>-14.535</td>
</tr>
<tr>
<td>RAP2B, member of RAS oncogene family</td>
<td>NM_002886</td>
<td>-12.887</td>
</tr>
<tr>
<td>Cardiomyopathy associated 4 isoform 1&amp;2</td>
<td>AI800785</td>
<td>-12.837</td>
</tr>
<tr>
<td>Myeloid/lymphoid or mixed-lineage leukemia translocated to, 10 isoform A&amp;B</td>
<td>N64035</td>
<td>-12.837</td>
</tr>
<tr>
<td>N-methyl-D-aspartate receptor subunit 2A precursor</td>
<td>T65537</td>
<td>-11.198</td>
</tr>
<tr>
<td>Mitochondrial ribosomal protein S31</td>
<td>AW007410</td>
<td>-10.627</td>
</tr>
<tr>
<td>Hepatocyte nuclear factor 4, gamma</td>
<td>AI916600</td>
<td>-10.593</td>
</tr>
<tr>
<td>Ras homolog gene family, member A</td>
<td>AW173151</td>
<td>-10.194</td>
</tr>
<tr>
<td>Gene product (con’t)</td>
<td>Accession No.</td>
<td>Fold Change</td>
</tr>
<tr>
<td>----------------------</td>
<td>--------------</td>
<td>-------------</td>
</tr>
<tr>
<td><strong>Up-regulated Gene Products</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>CD24 antigen precursor</td>
<td>BG327863</td>
<td>11.03</td>
</tr>
<tr>
<td>Regulator of G-protein signaling 1</td>
<td>NM_002922</td>
<td>10.88</td>
</tr>
<tr>
<td>Cerebellar degeneration-related protein 1, 34kda</td>
<td>NM_004065</td>
<td>10.67</td>
</tr>
<tr>
<td>Spartan</td>
<td>AI640145</td>
<td>10.11</td>
</tr>
<tr>
<td>Muts homolog 6</td>
<td>D89646</td>
<td>10.05</td>
</tr>
<tr>
<td>Mohawk homeobox</td>
<td>R59304</td>
<td>10.04</td>
</tr>
<tr>
<td>Golgin-67; golgi autoantigen, golgin subfamily a, 8A</td>
<td>AI829170</td>
<td>9.983</td>
</tr>
<tr>
<td>Cholinergic receptor, nicotinic, beta polypeptide 4</td>
<td>NM_000750</td>
<td>9.63</td>
</tr>
<tr>
<td>Actin related protein 2/3 complex subunit 1A</td>
<td>AF070647</td>
<td>9.276</td>
</tr>
<tr>
<td>Neuropeptide Y receptor Y2</td>
<td>U32500</td>
<td>9.217</td>
</tr>
<tr>
<td>Catalase</td>
<td>AU147084</td>
<td>9.162</td>
</tr>
<tr>
<td><strong>Down-regulated Gene Products</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Nude nuclear distribution gene E homolog like 1 (A. Nidulans) isoform A&amp;B</td>
<td>AI963104</td>
<td>-10.173</td>
</tr>
<tr>
<td>Replication protein A3, 14kda</td>
<td>AI022132</td>
<td>-9.901</td>
</tr>
<tr>
<td>Jun D proto-oncogene</td>
<td>AI339541</td>
<td>-9.524</td>
</tr>
<tr>
<td>CDC42 small effector 2 Protocadherin gamma subfamily A, 3 isoform 1&amp;2 precursor</td>
<td>AL122039</td>
<td>-9.346</td>
</tr>
<tr>
<td>Adaptor-related protein complex 1 sigma 2 subunit</td>
<td>N74507</td>
<td>-9.259</td>
</tr>
<tr>
<td>Polymerase (DNA directed), beta</td>
<td>S69873</td>
<td>-9.009</td>
</tr>
<tr>
<td>Epidermal retinal dehydrogenase 2</td>
<td>AI440266</td>
<td>-8.850</td>
</tr>
<tr>
<td>Retinoic acid receptor, beta isoform 1&amp;2</td>
<td>NM_015854</td>
<td>-8.696</td>
</tr>
<tr>
<td>Interleukin 26 precursor</td>
<td>NM_018402</td>
<td>-8.547</td>
</tr>
<tr>
<td>Inhibitor of Bruton's tyrosine kinase</td>
<td>AB037838</td>
<td>-8.403</td>
</tr>
<tr>
<td>Gene product (con’t)</td>
<td>Accession No.</td>
<td>Fold Change</td>
</tr>
<tr>
<td>--------------------------------------------</td>
<td>---------------</td>
<td>-------------</td>
</tr>
<tr>
<td>Up-regulated Gene Products</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Homeodomain interacting protein kinase 3</td>
<td>AI640624</td>
<td>9.004</td>
</tr>
<tr>
<td>Alpha 1 type XI collagen isoform A,B&amp;C preproprotein</td>
<td>BG028597</td>
<td>8.967</td>
</tr>
<tr>
<td>Cytochrome c oxidase subunit 8C</td>
<td>AW269746</td>
<td>8.827</td>
</tr>
<tr>
<td>Low density lipoprotein-related protein 2</td>
<td>R73030</td>
<td>8.817</td>
</tr>
<tr>
<td>RAS-like, estrogen-regulated, growth inhibitor</td>
<td>AW668616</td>
<td>8.679</td>
</tr>
<tr>
<td>Tropomodulin 2 (neuronal)</td>
<td>NM_014548</td>
<td>8.48</td>
</tr>
<tr>
<td>Protocadherin beta 14 precursor</td>
<td>NM_018934</td>
<td>8.332</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Gene product (con’t)</th>
<th>Accession No.</th>
<th>Fold Change</th>
</tr>
</thead>
<tbody>
<tr>
<td>Down-regulated Gene Products</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Solute carrier family 13 (sodium/sulfate symporters), member 1</td>
<td>NM_022444</td>
<td>-8.333</td>
</tr>
<tr>
<td>Homeobox B6</td>
<td>AI125255</td>
<td>-8.065</td>
</tr>
</tbody>
</table>
Table 2.1b – Highly differentially expressed functional HMEC-1 genes 36 hours after *B. bacilliformis* infection.

Fold change analysis for the top selected functional genes, via GeneSpring comparison of mock-infected control HMEC-1 cells versus HMEC-1 cells infected *B. bacilliformis*. Total RNA extracted from mock and infected cells was hybridized to HG-U133A and HG-U133B (Affymetrix) microarray chips. Hybridization data were then used to determine the fold change of the highly differentially expressed HMEC-1 genes.

<table>
<thead>
<tr>
<th>Gene product</th>
<th>Accession No.</th>
<th>Fold Change</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Up-regulated Gene Products</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Progesterone receptor</td>
<td>AI378893</td>
<td>15.02</td>
</tr>
<tr>
<td>G protein-coupled receptor 98 precursor</td>
<td>AL136541</td>
<td>12.89</td>
</tr>
<tr>
<td>Glutamate-rich 1</td>
<td>AA767385</td>
<td>12.27</td>
</tr>
<tr>
<td>Delta-sarcoglycan isoform 1 &amp; 2</td>
<td>U58331</td>
<td>11.27</td>
</tr>
<tr>
<td>Cathepsin S preproprotein</td>
<td>BC002642</td>
<td>10.8</td>
</tr>
<tr>
<td>Tachykinin receptor 1 isoform long</td>
<td>AI492860</td>
<td>10.53</td>
</tr>
<tr>
<td>N-acetylated alpha-linked acidic dipeptidase 2</td>
<td>AJ012370</td>
<td>10.5</td>
</tr>
<tr>
<td>Tripartite motif-containing 58</td>
<td>AL080170</td>
<td>10.49</td>
</tr>
<tr>
<td>Sidekick homolog 1</td>
<td>R38712</td>
<td>10.46</td>
</tr>
<tr>
<td><strong>Down-regulated Gene Products</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Fumarylacetoacetate hydrolase</td>
<td>AA700567</td>
<td>-17.065</td>
</tr>
<tr>
<td>Phosphodiesterase 3B, cgmp-inhibited</td>
<td>AW974995</td>
<td>-13.986</td>
</tr>
<tr>
<td>Sulfortransferase family, cytosolic, 1C, member 1 isoform A&amp;B</td>
<td>AF026303</td>
<td>-13.947</td>
</tr>
<tr>
<td>Diaphanous 2 isoform 156</td>
<td>AA778894</td>
<td>-13.263</td>
</tr>
<tr>
<td>Membrane-spanning 4-domains, subfamily A, member 3 isoform A,B&amp;C</td>
<td>L35848</td>
<td>-12.690</td>
</tr>
<tr>
<td>Dystrobrevin alpha isoform 1-8</td>
<td>R49412</td>
<td>-11.765</td>
</tr>
<tr>
<td>Isoleucine-tRNA synthetase</td>
<td>AW135765</td>
<td>-11.534</td>
</tr>
<tr>
<td>Cell cycle related kinase isoform 1&amp;3</td>
<td>AA758116</td>
<td>-10.449</td>
</tr>
<tr>
<td>Tetra-tripeptide repeat domain 8 isoform A,B&amp;C</td>
<td>AW293826</td>
<td>-10.417</td>
</tr>
<tr>
<td>Gene product (con’t)</td>
<td>Accession No.</td>
<td>Fold Change</td>
</tr>
<tr>
<td>----------------------</td>
<td>---------------</td>
<td>-------------</td>
</tr>
<tr>
<td><strong>Up-regulated Gene Products</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>ZXD family zinc finger C isoform 2</td>
<td>AA702187</td>
<td>10.4</td>
</tr>
<tr>
<td>Family with sequence similarity 9, member C</td>
<td>AI650599</td>
<td>10.23</td>
</tr>
<tr>
<td>Leucine rich repeat containing 7</td>
<td>H07100</td>
<td>10.18</td>
</tr>
<tr>
<td>Ubiquitin-conjugating enzyme E2O</td>
<td>NM_022066</td>
<td>10.06</td>
</tr>
<tr>
<td>Epidermal growth factor receptor pathway substrate 8</td>
<td>AI344149</td>
<td>9.853</td>
</tr>
<tr>
<td>Glutamate receptor, metabotropic 3 precursor</td>
<td>AA608964</td>
<td>9.802</td>
</tr>
<tr>
<td>Calcitonin receptor</td>
<td>AB022177</td>
<td>9.763</td>
</tr>
<tr>
<td>Sodium potassium chloride cotransporter 2</td>
<td>AI632015</td>
<td>9.537</td>
</tr>
<tr>
<td>Phosphoinositide-3-kinase, regulatory subunit 4, p150</td>
<td>AK025026</td>
<td>9.411</td>
</tr>
<tr>
<td>Latrophilin 3 precursor</td>
<td>R20529</td>
<td>9.4</td>
</tr>
<tr>
<td>Fc receptor-like and mucin-like 1</td>
<td>AL560266</td>
<td>9.179</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Gene product (con’t)</th>
<th>Accession No.</th>
<th>Fold Change</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Down-regulated Gene Products</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>IQ motif containing H isoform 1&amp;2</td>
<td>NM_022784</td>
<td>-9.524</td>
</tr>
<tr>
<td>R7 binding protein</td>
<td>H05023</td>
<td>-9.434</td>
</tr>
<tr>
<td>CDC42 small effector 2</td>
<td>AI535736</td>
<td>-9.259</td>
</tr>
<tr>
<td>XK, Kell blood group complex subunit-related, Y-linked 2</td>
<td>NM_004677</td>
<td>-9.091</td>
</tr>
<tr>
<td>Deoxyribonuclease I precursor</td>
<td>AA720770</td>
<td>-8.929</td>
</tr>
<tr>
<td>CDC42 small effector 2</td>
<td>AL117571</td>
<td>-8.850</td>
</tr>
<tr>
<td>Protocadherin 11 Y-linked isoform a, b &amp; c</td>
<td>AI732427</td>
<td>-8.475</td>
</tr>
<tr>
<td>Pleckstrin homology domain containing, family A member 5</td>
<td>AK026344</td>
<td>-8.403</td>
</tr>
<tr>
<td>Calcium-dependent cell-cell adhesion</td>
<td>AI912122</td>
<td>-8.403</td>
</tr>
<tr>
<td>PAR-6 gamma protein</td>
<td>AB044556</td>
<td>-8.403</td>
</tr>
<tr>
<td>Brain-specific protein p25 alpha</td>
<td>AA126642</td>
<td>-8.264</td>
</tr>
</tbody>
</table>
### Up-regulated Gene Products

<table>
<thead>
<tr>
<th>Gene product (con’t)</th>
<th>Accession No.</th>
<th>Fold Change</th>
</tr>
</thead>
<tbody>
<tr>
<td>Similar to FERM domain-containing protein 4B</td>
<td>AK000244</td>
<td>9.164</td>
</tr>
<tr>
<td>(GRP1-binding protein GRSP1) isoform 1</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Interleukin 22-binding protein isoform 1, 2 &amp; 3</td>
<td>BE348657</td>
<td>9.076</td>
</tr>
</tbody>
</table>

### Down-regulated Gene Products

<table>
<thead>
<tr>
<th>Gene product (con’t)</th>
<th>Accession No.</th>
<th>Fold Change</th>
</tr>
</thead>
<tbody>
<tr>
<td>Zinc finger protein 750</td>
<td>NM_024702</td>
<td>-7.874</td>
</tr>
<tr>
<td>Calcium binding protein P22</td>
<td>AF116689</td>
<td>-7.813</td>
</tr>
<tr>
<td>Protein phosphatase 2</td>
<td>AI052441</td>
<td>-7.692</td>
</tr>
</tbody>
</table>
Differential regulation of selected HMEC-1 genes during \textit{B. bacilliformis} infection.

The infection of HMEC-1 by \textit{B. bacilliformis} alters the global gene expression profile in several ways. Table 2.2 shows the alteration of selected genes, which are grouped into specific host cell functions. Infection of \textit{B. bacilliformis} alters the expression patterns of several angiogenesis-related genes throughout its infection cycle from 30 minutes\textsuperscript{1} to 36 hours. Analysis of early infection gene regulation from 30 minutes to 3 hours indicates an overall change in hypoxia factors and plasminogen factors as well as VEGF production. The infection of HMEC-1 cells by \textit{B. bacilliformis} induces a down-regulation, by almost four-fold, in hypoxia inducible factor 1 alpha (HIF1\(\alpha\)) gene expression at 30 minutes of infection. This down-regulation in HIF1\(\alpha\) production diminishes but is still evident by 3 hours, where the levels of gene expression are almost two-fold lower than those of the control. However, the early infection cycle also reveals an increase of hypoxia inducible factor 3 (HIF3\(\alpha\)) expression at both one hour, with an almost seven-fold up-regulation, and at 3 hours, with a three-fold up-regulation. In addition, there is an increased expression of microvascular endothelial differentiation gene(s), plasminogen activators, and VEGF and VEGF-C. By 36 hours, these increases are no longer apparent. There is a slight increase in IL-8 expression of about two-fold over that of the control, and a two-fold decrease in VEGF-A expression at 36 hours.

Differential analysis of anti-apoptotic proteins during \textit{B. bacilliformis} infection of HMEC-1 cells shows an alteration in host gene expression of selected anti-apoptotic genes at the early stages of infection. The data in Table 2.2 reveal a striking increase in anti-apoptotic

\textsuperscript{1} Raw microarray hybridization signal data from 30 minutes, 1 hour and 3 hours post-\textit{B. bacilliformis} infection provided by T. Soni, following the same infection protocol as noted above.
gene expression at 30 minutes post infection. This increase can be seen most dramatically in the almost 8.5-fold increase in expression of the Id2 (Inhibitor of DNA-binding 2) gene as well as the four-fold up-regulation in the BAG-family molecular chaperone regulator. Other genes whose expression is increased include those controlling the B cell lymphoma and myeloid cell leukemia sequences.
Table 2.2 - Selected dynamically regulated host genes of infected HMEC-1 cells during *B. bacilliformis* infection.
The follow table shows an analysis of selected dynamically regulated host genes of infected HMEC-1 cells during *B. bacilliformis* infection. Genes discussed in the text are indicated in red.

<table>
<thead>
<tr>
<th>Gene name and function</th>
<th>Accession no.</th>
<th>30mins</th>
<th>1hr</th>
<th>3hrs</th>
<th>6hrs</th>
<th>36hrs</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Angiogenesis</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Angiopoetin-2</td>
<td>NM_001147</td>
<td>-1.092</td>
<td>3.391</td>
<td>1.313</td>
<td>2.292</td>
<td>1.062</td>
</tr>
<tr>
<td>bFGF2</td>
<td>AW592991</td>
<td>2.076</td>
<td>2.484</td>
<td>2.408</td>
<td>1.107</td>
<td>2.308</td>
</tr>
<tr>
<td>Ephrin B2</td>
<td>AF025304</td>
<td>2.596</td>
<td>1.032</td>
<td>-1.355</td>
<td>1.065</td>
<td>-1.163</td>
</tr>
<tr>
<td>Ephrin B4</td>
<td>NM_004444</td>
<td>1.234</td>
<td>1.185</td>
<td>-1.057</td>
<td>1.081</td>
<td>-1.368</td>
</tr>
<tr>
<td>Fms-related tyrosine kinase</td>
<td>AA058828</td>
<td>-1.431</td>
<td>1.336</td>
<td>1.818</td>
<td>-1.553</td>
<td>1.263</td>
</tr>
<tr>
<td><strong>Hypoxia-inducible factor 1, alpha subunit</strong></td>
<td>AA777349</td>
<td>-3.922</td>
<td>-1.138</td>
<td>-2.301</td>
<td>1.763</td>
<td>1.359</td>
</tr>
<tr>
<td><strong>Hypoxia-inducible factor 2, alpha subunit</strong></td>
<td>AA913703</td>
<td>-1.172</td>
<td>2.036</td>
<td>8.001</td>
<td>3.398</td>
<td>-1.350</td>
</tr>
<tr>
<td>Hypoxia-inducible factor 3, alpha subunit</td>
<td>AK021881</td>
<td>-1.321</td>
<td>7.329</td>
<td>2.776</td>
<td>-1.109</td>
<td>-1.274</td>
</tr>
<tr>
<td>ICAM1</td>
<td>AA284705</td>
<td>1.696</td>
<td>2.612</td>
<td>2.86</td>
<td>-2.070</td>
<td>-2.198</td>
</tr>
<tr>
<td>IL-8 C terminal variant</td>
<td>AF043337</td>
<td>-1.122</td>
<td>-1.59</td>
<td>-1.706</td>
<td>-1.634</td>
<td>2.249</td>
</tr>
<tr>
<td>Inhibitor of DNA binding 3</td>
<td>NM_002167</td>
<td>1.276</td>
<td>1.383</td>
<td>1.32</td>
<td>-1.276</td>
<td>1.208</td>
</tr>
<tr>
<td>Insulin-like Growth Factor</td>
<td>M37484</td>
<td>1.858</td>
<td>4.893</td>
<td>2.548</td>
<td>-1.776</td>
<td>-6.757</td>
</tr>
<tr>
<td>Insulin-like Growth Factor Receptor 1</td>
<td>H05812</td>
<td>3.634</td>
<td>2.221</td>
<td>-3.521</td>
<td>1.198</td>
<td>1.485</td>
</tr>
<tr>
<td>Matrix metalloproteinase 1</td>
<td>NM_002421</td>
<td>1.789</td>
<td>-1.976</td>
<td>-1.3</td>
<td>-1.127</td>
<td>-1.062</td>
</tr>
<tr>
<td>Microvascular endothelial differentiation gene 1</td>
<td>NM_012328</td>
<td>3.446</td>
<td>1.232</td>
<td>-1.081</td>
<td>1.099</td>
<td>1.881</td>
</tr>
<tr>
<td>Plasminogen activator inhibitor 2</td>
<td>NM_002575</td>
<td>1.046</td>
<td>2.356</td>
<td>-1.116</td>
<td>-1.605</td>
<td>1.318</td>
</tr>
<tr>
<td>Plasminogen activator, tissue</td>
<td>NM_000930</td>
<td>1.729</td>
<td>-1.196</td>
<td>1.013</td>
<td>1.01</td>
<td>-1.321</td>
</tr>
<tr>
<td>Gene name and function (cont’t)</td>
<td>Accession no.</td>
<td>30mins</td>
<td>1hr</td>
<td>3hrs</td>
<td>6hrs</td>
<td>36hrs</td>
</tr>
<tr>
<td>--------------------------------</td>
<td>---------------</td>
<td>--------</td>
<td>-----</td>
<td>------</td>
<td>------</td>
<td>-------</td>
</tr>
<tr>
<td>Platelet-derived Growth Factor Receptor 1</td>
<td>M22734</td>
<td>1.514</td>
<td>3.538</td>
<td>4.482</td>
<td>2.285</td>
<td>5.307</td>
</tr>
<tr>
<td>PPAR (gamma) angiopoietin related protein 4</td>
<td>NM_016109</td>
<td>-1.667</td>
<td>-2.257</td>
<td>-1.957</td>
<td>-1.016</td>
<td>-1.802</td>
</tr>
<tr>
<td>Stanniocalcin</td>
<td>A1300520</td>
<td>1.146</td>
<td>-1.58</td>
<td>-1.139</td>
<td>-1.192</td>
<td>1.353</td>
</tr>
<tr>
<td>Thrombomodulin</td>
<td>NM_000361</td>
<td>1.761</td>
<td>-1.068</td>
<td>-1.205</td>
<td>1.083</td>
<td>-1.647</td>
</tr>
<tr>
<td>Tissue inhibitor of metalloproteinase 1</td>
<td>NM_003254</td>
<td>1.259</td>
<td>-1.248</td>
<td>-1.073</td>
<td>-1.181</td>
<td>-1.176</td>
</tr>
<tr>
<td>Urokinase plasminogen activator receptor precursor</td>
<td>AY029180.1</td>
<td>1.857</td>
<td>1.405</td>
<td>1.04</td>
<td>-1.164</td>
<td>1.128</td>
</tr>
<tr>
<td>Urokinase-type plasminogen activator receptor</td>
<td>U08839.1</td>
<td>1.496</td>
<td>1.303</td>
<td>-1.088</td>
<td>-1.236</td>
<td>1.038</td>
</tr>
<tr>
<td>Vascular endothelial growth factor C (VEGFC)</td>
<td>U58111.1</td>
<td>3.451</td>
<td>-1.592</td>
<td>1.031</td>
<td>1.256</td>
<td>1.287</td>
</tr>
<tr>
<td>Vascular permeability factor VEGF (VEGFA)</td>
<td>M27281.1</td>
<td>-1.174</td>
<td>-1.109</td>
<td>1.454</td>
<td>-1.667</td>
<td>-2.066</td>
</tr>
<tr>
<td>VEGF</td>
<td>AF022375.1</td>
<td>4.595</td>
<td>-1.401</td>
<td>-1.104</td>
<td>-1.008</td>
<td>1.276</td>
</tr>
<tr>
<td>Antiapoptotic</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>BAG-family molecular chaperone regulator-2</td>
<td>AF095192.1</td>
<td>4.193</td>
<td>-1.244</td>
<td>-1.393</td>
<td>1.125</td>
<td>1.037</td>
</tr>
<tr>
<td>Basic helix-loop-helix domain containing, class B, 2</td>
<td>BG326045</td>
<td>3.663</td>
<td>-1.114</td>
<td>-4.525</td>
<td>-1.58</td>
<td>-1.156</td>
</tr>
<tr>
<td>B-cell lymphoma 6</td>
<td>NM_001706</td>
<td>2.025</td>
<td>-1.538</td>
<td>1.013</td>
<td>1.043</td>
<td>-1.377</td>
</tr>
<tr>
<td>BCL2-related protein A1</td>
<td>NM_004049</td>
<td>-1.25</td>
<td>-1.003</td>
<td>1.172</td>
<td>-1.379</td>
<td>-1.403</td>
</tr>
<tr>
<td>Cyclin-dependent kinase inhibitor 1A</td>
<td>NM_000389</td>
<td>1.517</td>
<td>-1.88</td>
<td>-1.149</td>
<td>-1.121</td>
<td>-1.129</td>
</tr>
<tr>
<td>Fas-interacting serinethreonine kinase 3</td>
<td>AF305239.1</td>
<td>1.652</td>
<td>1.339</td>
<td>1.144</td>
<td>-1.03</td>
<td>-1.156</td>
</tr>
<tr>
<td>Human IAP homologue C</td>
<td>U37546.1</td>
<td>1.433</td>
<td>-1.071</td>
<td>1.385</td>
<td>3.529</td>
<td>-1.456</td>
</tr>
<tr>
<td>Gene name and function (cont’t)</td>
<td>Accession no.</td>
<td>30mins</td>
<td>1hr</td>
<td>3hrs</td>
<td>6hrs</td>
<td>36hrs</td>
</tr>
<tr>
<td>--------------------------------</td>
<td>---------------</td>
<td>--------</td>
<td>-----</td>
<td>------</td>
<td>------</td>
<td>-------</td>
</tr>
<tr>
<td>Inhibitor of DNA binding 2 (Id2)</td>
<td>NM_002166</td>
<td>8.495</td>
<td>1.044</td>
<td>1.191</td>
<td>-1.08</td>
<td>1.303</td>
</tr>
<tr>
<td>Leukemia inhibitory factor</td>
<td>NM_002309</td>
<td>-1.773</td>
<td>-3.215</td>
<td>1.511</td>
<td>-1.408</td>
<td>-1.761</td>
</tr>
<tr>
<td>Myeloid cell leukemia sequence 1</td>
<td>AI275690</td>
<td>2.085</td>
<td>-1.634</td>
<td>-1.742</td>
<td>-1.269</td>
<td>-1.014</td>
</tr>
<tr>
<td>Phospholipid scramblase 4</td>
<td>NM_020353</td>
<td>1.63</td>
<td>1.171</td>
<td>-1.11</td>
<td>-1.259</td>
<td>-1.199</td>
</tr>
<tr>
<td>TNF alpha-induced protein 3</td>
<td>NM_006290</td>
<td>1.004</td>
<td>-1.536</td>
<td>-1.016</td>
<td>-1.185</td>
<td>1.314</td>
</tr>
<tr>
<td>TNF-induced protein (GG2-1)</td>
<td>BC005352</td>
<td>-1.024</td>
<td>-1.111</td>
<td>-1.211</td>
<td>-1.287</td>
<td>-1.239</td>
</tr>
<tr>
<td><strong>Cancer signatures</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Absent in melanoma 1</td>
<td>U83115.1</td>
<td>1.463</td>
<td>-1.637</td>
<td>-1.186</td>
<td>1.007</td>
<td>1.014</td>
</tr>
<tr>
<td>Insulin-induced gene 1</td>
<td>NM_005542</td>
<td>2.322</td>
<td>-1.067</td>
<td>-1.196</td>
<td>-1.376</td>
<td>1.062</td>
</tr>
<tr>
<td>N-myc downstream regulated</td>
<td>NM_006096</td>
<td>1.618</td>
<td>-1.19</td>
<td>-1.233</td>
<td>-1.053</td>
<td>-1.351</td>
</tr>
<tr>
<td>Nucleoside phosphorylase</td>
<td>NM_000270</td>
<td>1.848</td>
<td>-1.381</td>
<td>-1.181</td>
<td>-1.172</td>
<td>1.152</td>
</tr>
<tr>
<td>Potential tumor suppressor (ST7)</td>
<td>NM_013437</td>
<td>-2.053</td>
<td>-2.89</td>
<td>-1.25</td>
<td>1.068</td>
<td>-2.179</td>
</tr>
<tr>
<td>Snail 1 (Drosophila homologue)</td>
<td>NM_005985</td>
<td>3.413</td>
<td>1.447</td>
<td>1.081</td>
<td>1.39</td>
<td>1.43</td>
</tr>
<tr>
<td>Uridine phosphorylase</td>
<td>NM_003364</td>
<td>1.103</td>
<td>-1.761</td>
<td>1.001</td>
<td>1.415</td>
<td>-1.372</td>
</tr>
<tr>
<td><strong>Cell and structural dynamics</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Cytovillin 2 (ezrin)</td>
<td>J05021.1</td>
<td>2.101</td>
<td>-1.009</td>
<td>-1.279</td>
<td>1.006</td>
<td>-1.25</td>
</tr>
<tr>
<td>Integrin, alpha 2</td>
<td>NM_002203</td>
<td>-1.104</td>
<td>1.065</td>
<td>1.024</td>
<td>1.103</td>
<td>-1.05</td>
</tr>
<tr>
<td>Nephropontin</td>
<td>M83248.1</td>
<td>-6.211</td>
<td>-2.747</td>
<td>1.718</td>
<td>-2</td>
<td>1.259</td>
</tr>
<tr>
<td>Plectin, intermediate filament binding protein</td>
<td>Z54367</td>
<td>1.024</td>
<td>2.35</td>
<td>-1.089</td>
<td>-2.165</td>
<td>-1.658</td>
</tr>
<tr>
<td>Protein kinase-related oncogene (PIM1)</td>
<td>M24779.1</td>
<td>1.454</td>
<td>-1.202</td>
<td>-1.433</td>
<td>-1.292</td>
<td>1.152</td>
</tr>
<tr>
<td>Gene name and function (cont’t)</td>
<td>Accession no.</td>
<td>30mins</td>
<td>1hr</td>
<td>3hrs</td>
<td>6hrs</td>
<td>36hrs</td>
</tr>
<tr>
<td>---------------------------------</td>
<td>---------------</td>
<td>--------</td>
<td>-----</td>
<td>------</td>
<td>------</td>
<td>-------</td>
</tr>
<tr>
<td><strong>Cytokines</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Cytokine, gro-β</td>
<td>M57731</td>
<td>-1.908</td>
<td>-2.959</td>
<td>1.12</td>
<td>1.036</td>
<td>1.111</td>
</tr>
<tr>
<td>Cytokine, Cys-X-Cys, member 10</td>
<td>NM_001565</td>
<td>3.231</td>
<td>1.522</td>
<td>-1.008</td>
<td>-1.664</td>
<td>-1.488</td>
</tr>
<tr>
<td>GRO1 oncogene</td>
<td>NM_001511</td>
<td>-1.14</td>
<td>-1.314</td>
<td>1.01</td>
<td>1.074</td>
<td>1</td>
</tr>
<tr>
<td>GRO3 oncogene (GRO-gamma)</td>
<td>NM_002090</td>
<td>1.056</td>
<td>1.198</td>
<td>-1.431</td>
<td>-1.247</td>
<td>-4.065</td>
</tr>
<tr>
<td>Interleukin 1 β</td>
<td>M15330</td>
<td>-1.224</td>
<td>1.305</td>
<td>-1.458</td>
<td>-1.186</td>
<td>1.673</td>
</tr>
<tr>
<td>Interleukin 4 receptor</td>
<td>NM_000418</td>
<td>3.176</td>
<td>-1.241</td>
<td>1.052</td>
<td>1.188</td>
<td>-1.274</td>
</tr>
<tr>
<td>Interleukin 6 (interferon, β 2)</td>
<td>NM_000600</td>
<td>-1.186</td>
<td>1.182</td>
<td>-1.515</td>
<td>-1.318</td>
<td>-1.247</td>
</tr>
<tr>
<td>Macrophage-specific CSF-1</td>
<td>M37435.1</td>
<td>2.753</td>
<td>-1.196</td>
<td>1.094</td>
<td>1.043</td>
<td>-1.565</td>
</tr>
<tr>
<td>Monocyte chemotactic protein MCP1</td>
<td>S69738.1</td>
<td>2.832</td>
<td>1.373</td>
<td>-1.297</td>
<td>-1.548</td>
<td>2.062</td>
</tr>
<tr>
<td>Pre-B-cell colony-enhancing factor</td>
<td>BF575514</td>
<td>1.151</td>
<td>-1.126</td>
<td>-1.122</td>
<td>1.064</td>
<td>-1.58</td>
</tr>
<tr>
<td>Prostate differentiation factor</td>
<td>AF003934</td>
<td>1.042</td>
<td>-1.795</td>
<td>1.241</td>
<td>-1.012</td>
<td>-1.047</td>
</tr>
<tr>
<td>RAFTK</td>
<td>NM_004103</td>
<td>-2.653</td>
<td>-2.294</td>
<td>-2.667</td>
<td>1.667</td>
<td>1.18</td>
</tr>
<tr>
<td>STAT-induced STAT inhibitor 3</td>
<td>NM_003955</td>
<td>5.037</td>
<td>-2.841</td>
<td>1.605</td>
<td>-1.567</td>
<td>1.405</td>
</tr>
<tr>
<td><strong>IFN responsive</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>2-5 oligoadenylate synthetase 2 (OAS2)</td>
<td>NM_016817</td>
<td>3.835</td>
<td>-1.215</td>
<td>1.385</td>
<td>1.213</td>
<td>1.101</td>
</tr>
<tr>
<td>IFN-inducible, 67kD guanylate binding protein 1</td>
<td>BC002666</td>
<td>1.338</td>
<td>-1.353</td>
<td>1.237</td>
<td>-1.142</td>
<td>-1.311</td>
</tr>
<tr>
<td>IFN-stimulated T-cell alpha chemoattractant</td>
<td>AF030514</td>
<td>-12.21</td>
<td>-1.626</td>
<td>3.137</td>
<td>3.639</td>
<td>5.249</td>
</tr>
<tr>
<td>Interferon regulatory factor 1</td>
<td>NM_002198</td>
<td>-1.018</td>
<td>1</td>
<td>1.564</td>
<td>1.135</td>
<td>1.188</td>
</tr>
<tr>
<td>Interferon regulatory factor 2</td>
<td>AW968775</td>
<td>-1.019</td>
<td>5.385</td>
<td>2.848</td>
<td>-1.316</td>
<td>-2.632</td>
</tr>
<tr>
<td>Interferon regulatory factor 2 Binding Protein</td>
<td>BF968057</td>
<td>5.727</td>
<td>-1.025</td>
<td>-1.832</td>
<td>1.408</td>
<td>-1.422</td>
</tr>
<tr>
<td>Interferon regulatory factor 4</td>
<td>D78261</td>
<td>-6.250</td>
<td>4.23</td>
<td>2.701</td>
<td>2.541</td>
<td>-4.082</td>
</tr>
<tr>
<td>Gene name and function (cont’t)</td>
<td>Accession no.</td>
<td>30mins</td>
<td>1hr</td>
<td>3hrs</td>
<td>6hrs</td>
<td>36hrs</td>
</tr>
<tr>
<td>---------------------------------</td>
<td>---------------</td>
<td>--------</td>
<td>-----</td>
<td>------</td>
<td>------</td>
<td>------</td>
</tr>
<tr>
<td>Interferon regulatory factor 5</td>
<td>BF223643</td>
<td>4.777</td>
<td>-2.336</td>
<td>-3.984</td>
<td>-1.323</td>
<td>1.263</td>
</tr>
<tr>
<td>Interferon regulatory factor 7, transcript variant c</td>
<td>NM_004030</td>
<td>1.691</td>
<td>-1.224</td>
<td>-1.054</td>
<td>1.409</td>
<td>-1.52</td>
</tr>
<tr>
<td>Interferon-stimulated protein, 15 kDa</td>
<td>NM_005101</td>
<td>1.099</td>
<td>-1.199</td>
<td>-1.122</td>
<td>-1.155</td>
<td>1.132</td>
</tr>
<tr>
<td>ISGF-3</td>
<td>BC002704</td>
<td>3.352</td>
<td>-1.054</td>
<td>1.21</td>
<td>-1.188</td>
<td>-1.471</td>
</tr>
<tr>
<td>Mx resistance 1, IFN-inducible protein p78</td>
<td>NM_002462</td>
<td>1.763</td>
<td>-1.481</td>
<td>1.19</td>
<td>1.053</td>
<td>-1.527</td>
</tr>
<tr>
<td><strong>Metabolism</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Carnitine octanoyltransferase</td>
<td>NM_021151</td>
<td>2.823</td>
<td>1.023</td>
<td>-1.389</td>
<td>-1.333</td>
<td>-1.508</td>
</tr>
<tr>
<td>Glutamine-fructose-6-phosphate transaminase 2</td>
<td>NM_005110</td>
<td>1.131</td>
<td>-1.437</td>
<td>1.078</td>
<td>1.056</td>
<td>-1.524</td>
</tr>
<tr>
<td>GTP cyclohydrolase 1</td>
<td>NM_000161</td>
<td>1.085</td>
<td>-1.664</td>
<td>-1.034</td>
<td>1.007</td>
<td>-1.377</td>
</tr>
<tr>
<td>Prostaglandin-endoperoxide synthase 2 (Cox2)</td>
<td>NM_000963</td>
<td>-1.379</td>
<td>1.018</td>
<td>-3.096</td>
<td>2.743</td>
<td>-3.115</td>
</tr>
<tr>
<td>Tryptophanyl-tRNA synthetase</td>
<td>NM_004184</td>
<td>1.416</td>
<td>-1.013</td>
<td>-1.508</td>
<td>-1.006</td>
<td>1.076</td>
</tr>
<tr>
<td>Hexokinase 1</td>
<td>NM_000188</td>
<td>1.412</td>
<td>-1.183</td>
<td>-1.024</td>
<td>1.13</td>
<td>-1.205</td>
</tr>
<tr>
<td>Phosphofructokinase, liver</td>
<td>NM_002626</td>
<td>2.201</td>
<td>1.418</td>
<td>-1.035</td>
<td>-1.232</td>
<td>-1.342</td>
</tr>
<tr>
<td>Phosphofructokinase, platelet</td>
<td>NM_002627</td>
<td>1.69</td>
<td>1.287</td>
<td>-1.25</td>
<td>1.014</td>
<td>1.099</td>
</tr>
<tr>
<td><strong>Molecular chaperons</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>DnaJ-like heat shock protein 40</td>
<td>NM_007034</td>
<td>1.204</td>
<td>1.496</td>
<td>-1.435</td>
<td>-1.335</td>
<td>1.613</td>
</tr>
<tr>
<td>Superoxide dismutase 2</td>
<td>X15132.1</td>
<td>1.754</td>
<td>-1.119</td>
<td>1.042</td>
<td>-1.852</td>
<td>-1.186</td>
</tr>
<tr>
<td>Zinc finger protein 133</td>
<td>U09366</td>
<td>-1.263</td>
<td>1.223</td>
<td>1.003</td>
<td>1.233</td>
<td>-1.279</td>
</tr>
<tr>
<td>Zinc finger protein 238</td>
<td>AJ223321</td>
<td>1.541</td>
<td>-1.043</td>
<td>-1.453</td>
<td>-1.171</td>
<td>-1.151</td>
</tr>
<tr>
<td>Gene name and function (cont’d)</td>
<td>Accession no.</td>
<td>30mins</td>
<td>1hr</td>
<td>3hrs</td>
<td>6hrs</td>
<td>36hrs</td>
</tr>
<tr>
<td>---------------------------------------------------</td>
<td>---------------</td>
<td>--------</td>
<td>------</td>
<td>------</td>
<td>------</td>
<td>-------</td>
</tr>
<tr>
<td><strong>Proteolysis/protein processing</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Secretory granule, neuroendocrine protein 1</td>
<td>NM_003020</td>
<td>-1.148</td>
<td>1.006</td>
<td>1.553</td>
<td>1.141</td>
<td>1.478</td>
</tr>
<tr>
<td>Ubiquitin-conjugating enzyme E2D 1</td>
<td>AL545760</td>
<td>1.657</td>
<td>1.62</td>
<td>1.18</td>
<td>1.13</td>
<td>1.436</td>
</tr>
<tr>
<td><strong>Signal transduction</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>A kinase (cAMP) anchor protein 13</td>
<td>AK022014</td>
<td>-4.386</td>
<td>5.275</td>
<td>-4.348</td>
<td>1.185</td>
<td>1.44</td>
</tr>
<tr>
<td>ADP-ribosylation factor-like 7</td>
<td>BG435404</td>
<td>1.36</td>
<td>-1.012</td>
<td>-1.056</td>
<td>1.055</td>
<td>1.077</td>
</tr>
<tr>
<td>Diphtheria toxin receptor</td>
<td>NM_001945</td>
<td>1.854</td>
<td>-1.161</td>
<td>-1.318</td>
<td>-1.012</td>
<td>1.139</td>
</tr>
<tr>
<td>Dual specificity phosphatase 1</td>
<td>NM_004417</td>
<td>1.406</td>
<td>-2.114</td>
<td>-1.795</td>
<td>-1.157</td>
<td>1.065</td>
</tr>
<tr>
<td>Dual specificity phosphatase 5</td>
<td>U16996</td>
<td>2.579</td>
<td>-1.224</td>
<td>-1.013</td>
<td>1.111</td>
<td>-1.145</td>
</tr>
<tr>
<td>Dual specificity phosphatase 6</td>
<td>BC005047</td>
<td>-3.367</td>
<td>-2.02</td>
<td>-1.224</td>
<td>2.079</td>
<td>-1.675</td>
</tr>
<tr>
<td>Heparin-binding</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>EGF-like growth factor</td>
<td>M60278</td>
<td>1.948</td>
<td>-1.203</td>
<td>-1.949</td>
<td>-1.047</td>
<td>-1.235</td>
</tr>
<tr>
<td>Immediate early response 3</td>
<td>NM_003897</td>
<td>1.815</td>
<td>-1.323</td>
<td>-1.577</td>
<td>1.044</td>
<td>1.062</td>
</tr>
<tr>
<td>Inositol 1,4,5-triphosphate receptor, type 1</td>
<td>NM_002222</td>
<td>-1.049</td>
<td>-2.208</td>
<td>1.738</td>
<td>1.33</td>
<td>-1.381</td>
</tr>
<tr>
<td>Mitogen-activated protein kinase 3</td>
<td>AA780381</td>
<td>1.549</td>
<td>-1.066</td>
<td>-1.117</td>
<td>1.344</td>
<td>-1.066</td>
</tr>
<tr>
<td>Phospholipase A2, group IVA</td>
<td>M68874</td>
<td>1.857</td>
<td>1.029</td>
<td>1.458</td>
<td>1.486</td>
<td>1.092</td>
</tr>
<tr>
<td>Phospholipid scramblase 1</td>
<td>NM_021105</td>
<td>3.443</td>
<td>-1.034</td>
<td>1.039</td>
<td>-1.193</td>
<td>-1.101</td>
</tr>
<tr>
<td>Phosphoprotein regulated by MAPK pathways</td>
<td>NM_025195</td>
<td>-1.182</td>
<td>-2.632</td>
<td>-1.149</td>
<td>1.244</td>
<td>1.11</td>
</tr>
<tr>
<td>Preprourokinase</td>
<td>K03226.1</td>
<td>1.331</td>
<td>1.013</td>
<td>-1.193</td>
<td>-1.196</td>
<td>-1.03</td>
</tr>
<tr>
<td>Protein kinase C, delta</td>
<td>NM_006254</td>
<td>2.377</td>
<td>2.129</td>
<td>1.013</td>
<td>-1.403</td>
<td>-2.387</td>
</tr>
<tr>
<td>Gene name and function (cont’t)</td>
<td>Accession no.</td>
<td>30mins</td>
<td>1hr</td>
<td>3hrs</td>
<td>6hrs</td>
<td>36hrs</td>
</tr>
<tr>
<td>---------------------------------</td>
<td>--------------</td>
<td>--------</td>
<td>-----</td>
<td>------</td>
<td>------</td>
<td>-------</td>
</tr>
<tr>
<td>Regulator of G-protein signaling 16</td>
<td>U94829.1</td>
<td>-2.262</td>
<td>-2.667</td>
<td>-1.134</td>
<td>1.098</td>
<td>-1.1</td>
</tr>
<tr>
<td>Serum-inducible kinase</td>
<td>NM_006622</td>
<td>1.432</td>
<td>1.056</td>
<td>-1.28</td>
<td>1.048</td>
<td>1.151</td>
</tr>
<tr>
<td>SMAD7</td>
<td>NM_005904</td>
<td>1.354</td>
<td>-1.374</td>
<td>1.7</td>
<td>1.418</td>
<td>-1.143</td>
</tr>
<tr>
<td>Sprouty (Drosophila) homologue 2</td>
<td>NM_005842</td>
<td>1.609</td>
<td>-1.61</td>
<td>-1.147</td>
<td>-1.151</td>
<td>-1.174</td>
</tr>
<tr>
<td>Sprouty (Drosophila) homologue 4</td>
<td>W48843</td>
<td>-1.13</td>
<td>-1.189</td>
<td>2.184</td>
<td>1.328</td>
<td>-1.517</td>
</tr>
</tbody>
</table>

**Small molecular/vesicle transport**

<table>
<thead>
<tr>
<th>Small molecular/vesicle transport</th>
<th>Accession no.</th>
<th>30mins</th>
<th>1hr</th>
<th>3hrs</th>
<th>6hrs</th>
<th>36hrs</th>
</tr>
</thead>
<tbody>
<tr>
<td>Aquaporin</td>
<td>N74607</td>
<td>-1.099</td>
<td>-1.701</td>
<td>1.287</td>
<td>1.274</td>
<td>-1.022</td>
</tr>
<tr>
<td>Importin alpha 3</td>
<td>U93240.1</td>
<td>-1.014</td>
<td>-1.104</td>
<td>-1.106</td>
<td>-1.134</td>
<td>-1.233</td>
</tr>
<tr>
<td>Niemann-Pick disease, type C1</td>
<td>NM_000271</td>
<td>1.263</td>
<td>1.16</td>
<td>1.174</td>
<td>1.306</td>
<td>1.078</td>
</tr>
<tr>
<td>RAB31, member RAS oncogene family</td>
<td>BE789881</td>
<td>2.315</td>
<td>-1.001</td>
<td>-1.101</td>
<td>1.311</td>
<td>-1.025</td>
</tr>
<tr>
<td>Ral guanine nucleotide dissociation stimulator</td>
<td>AI421559</td>
<td>1.06</td>
<td>1.085</td>
<td>1.02</td>
<td>1.519</td>
<td>-1.036</td>
</tr>
<tr>
<td>RAN binding protein 2-like 1</td>
<td>AL043571</td>
<td>1.909</td>
<td>1.099</td>
<td>1.076</td>
<td>1.135</td>
<td>1.029</td>
</tr>
<tr>
<td>Solute carrier family 2</td>
<td>NM_006931</td>
<td>1.461</td>
<td>1.312</td>
<td>-1.183</td>
<td>-1.037</td>
<td>-1.481</td>
</tr>
<tr>
<td>Solute carrier family 20, member 1</td>
<td>NM_005415</td>
<td>1.418</td>
<td>-1.174</td>
<td>-1.271</td>
<td>1.237</td>
<td>-1.258</td>
</tr>
<tr>
<td>Solute carrier family 4, NaHC03 cotransporter 3</td>
<td>AF047033.1</td>
<td>-3.745</td>
<td>-1.142</td>
<td>1.022</td>
<td>-1.07</td>
<td>1.309</td>
</tr>
</tbody>
</table>

**Transcription factors/proto-oncogenes**

<table>
<thead>
<tr>
<th>Transcription factors/proto-oncogenes</th>
<th>Accession no.</th>
<th>30mins</th>
<th>1hr</th>
<th>3hrs</th>
<th>6hrs</th>
<th>36hrs</th>
</tr>
</thead>
<tbody>
<tr>
<td>B-cell CLL lymphoma 3</td>
<td>AI829875</td>
<td>1.115</td>
<td>2.087</td>
<td>1.065</td>
<td>1.037</td>
<td>1.135</td>
</tr>
<tr>
<td>Cas-Br-M, retroviral transforming sequence-b</td>
<td>U26710.1</td>
<td>-1.292</td>
<td>2.021</td>
<td>-1.067</td>
<td>1.128</td>
<td>-1.294</td>
</tr>
<tr>
<td>CCAAT enhancer binding protein (CEBP), delta</td>
<td>NM_005195</td>
<td>-1.185</td>
<td>1.205</td>
<td>-1.044</td>
<td>-1.156</td>
<td>-1.031</td>
</tr>
<tr>
<td>CCAAT enhancer binding protein, B</td>
<td>AL564683</td>
<td>1.749</td>
<td>-1.548</td>
<td>-1.195</td>
<td>1.036</td>
<td>1.041</td>
</tr>
<tr>
<td>Gene name and function (cont’t)</td>
<td>Accession no.</td>
<td>30mins</td>
<td>1hr</td>
<td>3hrs</td>
<td>6hrs</td>
<td>36hrs</td>
</tr>
<tr>
<td>-------------------------------</td>
<td>--------------</td>
<td>--------</td>
<td>-----</td>
<td>------</td>
<td>------</td>
<td>-------</td>
</tr>
<tr>
<td>DNA-binding zinc finger</td>
<td>AB017493</td>
<td>1.155</td>
<td>1.228</td>
<td>1.067</td>
<td>-1.33</td>
<td>1.077</td>
</tr>
<tr>
<td>Early growth response 1</td>
<td>NM_001964</td>
<td>-1.443</td>
<td>-1.623</td>
<td>-1.05</td>
<td>-1.292</td>
<td>2.033</td>
</tr>
<tr>
<td>Early growth response 3</td>
<td>NM_004430</td>
<td>-2.083</td>
<td>1.232</td>
<td>3.765</td>
<td>1.02</td>
<td>1.092</td>
</tr>
<tr>
<td>ELL-related RNA pol II elongation factor</td>
<td>NM_012081</td>
<td>1.515</td>
<td>1.071</td>
<td>-1.064</td>
<td>-1.33</td>
<td>1.077</td>
</tr>
<tr>
<td>Estrogen-responsive B box protein</td>
<td>NM_006470</td>
<td>1.455</td>
<td>1.206</td>
<td>-1.393</td>
<td>-1.065</td>
<td>-1.149</td>
</tr>
<tr>
<td>Forkhead box O1A</td>
<td>NM_002015</td>
<td>1.056</td>
<td>-1.136</td>
<td>-1.661</td>
<td>-1.007</td>
<td>-1.074</td>
</tr>
<tr>
<td>FOS-like antigen 2</td>
<td>NM_024530</td>
<td>3.272</td>
<td>1.434</td>
<td>-1.024</td>
<td>-2.096</td>
<td>-1.016</td>
</tr>
<tr>
<td>FOS-like antigen-1</td>
<td>BG251266</td>
<td>2.183</td>
<td>-1.106</td>
<td>1.001</td>
<td>1.215</td>
<td>1.439</td>
</tr>
<tr>
<td>Glucocorticoid receptor alpha-2</td>
<td>U01351.1</td>
<td>1.157</td>
<td>1.154</td>
<td>-1.351</td>
<td>-1.233</td>
<td>-1.174</td>
</tr>
<tr>
<td>HIV-1 enhancer-binding protein 2</td>
<td>AL023584</td>
<td>-1.142</td>
<td>4.605</td>
<td>-1.565</td>
<td>-1.264</td>
<td>-2.865</td>
</tr>
<tr>
<td>jun B</td>
<td>NM_002229</td>
<td>4.503</td>
<td>-1.783</td>
<td>-2.674</td>
<td>1.143</td>
<td>-1.309</td>
</tr>
<tr>
<td>NF- kappa B enhancer in B cells 1</td>
<td>M55643.1</td>
<td>1.056</td>
<td>-1.458</td>
<td>1.018</td>
<td>1.184</td>
<td>-1.174</td>
</tr>
<tr>
<td>(p105)</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>NF-kappa B enhancer in B-cells 2</td>
<td>NM_002502</td>
<td>1.13</td>
<td>1.508</td>
<td>1.911</td>
<td>-1.379</td>
<td>-1.161</td>
</tr>
<tr>
<td>(p49p100)</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Nf-kappa B enhancer in B-cells inhibitor, alpha</td>
<td>AI078167</td>
<td>2.305</td>
<td>-1.072</td>
<td>-1.126</td>
<td>1.817</td>
<td>1.255</td>
</tr>
<tr>
<td>Nuclear factor, interleukin 3 regulated</td>
<td>NM_005384</td>
<td>2.103</td>
<td>-1.282</td>
<td>-1.218</td>
<td>1.011</td>
<td>-1.079</td>
</tr>
<tr>
<td>Nuclear receptor subfamily 2, group F, member 2</td>
<td>AL554245</td>
<td>3.262</td>
<td>1.051</td>
<td>-1.053</td>
<td>1.037</td>
<td>-1.095</td>
</tr>
<tr>
<td>p54 (EGR binding protein 1)</td>
<td>AF045451.1</td>
<td>1.698</td>
<td>1.075</td>
<td>-1.054</td>
<td>-1.294</td>
<td>1.05</td>
</tr>
<tr>
<td>Pleckstrin homology-like domain, family A,1</td>
<td>NM_007350</td>
<td>1.36</td>
<td>-1.832</td>
<td>1.3</td>
<td>-1.34</td>
<td>1.159</td>
</tr>
<tr>
<td>ß-Glucocorticoid receptor</td>
<td>X03348.1</td>
<td>2.126</td>
<td>-1.277</td>
<td>-1.359</td>
<td>-1.282</td>
<td>-1.142</td>
</tr>
<tr>
<td>TGFB-inducible early growth response</td>
<td>NM_005655</td>
<td>2.098</td>
<td>-1.33</td>
<td>1.026</td>
<td>1.009</td>
<td>-1.111</td>
</tr>
<tr>
<td>Gene name and function (cont’t)</td>
<td>Accession no.</td>
<td>30mins</td>
<td>1hr</td>
<td>3hrs</td>
<td>6hrs</td>
<td>36hrs</td>
</tr>
<tr>
<td>--------------------------------</td>
<td>--------------</td>
<td>--------</td>
<td>-------</td>
<td>-------</td>
<td>-------</td>
<td>-------</td>
</tr>
<tr>
<td>Transcription factor 8 (represses IL2 expression)</td>
<td>NM_030751</td>
<td>-1.359</td>
<td>-1.404</td>
<td>-3.077</td>
<td>-1.908</td>
<td>-1.529</td>
</tr>
<tr>
<td>Transcriptional coactivator with PDZ-binding motif</td>
<td>AA081084</td>
<td>1.162</td>
<td>-1.29</td>
<td>-1.314</td>
<td>-1.063</td>
<td>-1.004</td>
</tr>
<tr>
<td>v-ets homologue 2</td>
<td>NM_005239</td>
<td>1.44</td>
<td>1.167</td>
<td>1.007</td>
<td>1.007</td>
<td>-1.49</td>
</tr>
<tr>
<td>v-maf, oncogene family, protein F</td>
<td>AL021977</td>
<td>2.237</td>
<td>-1.582</td>
<td>-1.471</td>
<td>-1.284</td>
<td>-1.035</td>
</tr>
<tr>
<td>Zinc finger protein homologous to Zfp-36</td>
<td>NM_003407</td>
<td>-1.076</td>
<td>-1.048</td>
<td>1.279</td>
<td>-1.312</td>
<td>-1.212</td>
</tr>
<tr>
<td><strong>Others</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>IFN-induced transmembrane protein 1</td>
<td>AA749101</td>
<td>1.299</td>
<td>-1.106</td>
<td>1.279</td>
<td>-1.427</td>
<td>-1.116</td>
</tr>
<tr>
<td>Progesterone membrane binding protein</td>
<td>NM_006320</td>
<td>1.246</td>
<td>-1.018</td>
<td>-1.004</td>
<td>1.088</td>
<td>1.011</td>
</tr>
</tbody>
</table>
Real Time RT-PCR Validation of Microarray Data.

In order to validate the microarray data obtained from the hybridization of total mRNA onto the HG-U133A and HG-U133B (Affymetrix) microarray chips, a series of real time RT-PCR reactions were completed for genes coding for the transcription factor HIF1α (AA913703), and the apoptotic enzymes caspase-3 (CASP3; NM_004346) and caspase-8 (CASP8; NM_001228). For each reaction (Figure 2.3), pre-validated RT-PCR primers (ABI) corresponding to each gene selected were used and the results were compared to an internal control, PPIA (cyclophilin A, CAG32988), which has been shown to have little significant regulation changes throughout the experimental time points (Soni, personal communication). Every RT-PCR primer set gave products of the expected size. As shown in Table 2.3, all three genes examined agreed 100% between the RT-PCR and microarray fold change values, as defined by falling within 2.5 fold of one another with overall regulation agreement (Gao et al., 2004; Stintzi, 2003). While the data presented here fall within our correlation scheme, as with any microarray study we can expect some discordance between RT-PCR and microarray fold change analysis. We have noted this discordance with other genes at earlier infection time points including: 30 minutes, 1 hour and 3 hours post-infection (Soni, personal communication). When correlation analysis includes these time points, with the same genes, the RT-PCR and microarray fold change correlation decreases to 73%, which remains acceptable for microarray validation (Draghici, 2002; Nadon et al., 2002).
Table 2.3 – Validation of Microarray Experiment via RT-PCR 6 and 36 hours post-infection. Validation of the HG-U133A&B (Affymetrix) microarray chips was completed via RT-PCR of selected HMEC-1 host genes. Raw RT-PCR data analysis was completed with respect to a PPIA internal control and uninfected HMEC-1 cells to give the relative gene expression value (RQ) versus GeneSpring fold change value at each time point. Correlation is noted by values within ±2.5-fold change of GeneSpring analysis value.

<table>
<thead>
<tr>
<th>Selected Gene</th>
<th>Entrez ID</th>
<th>Time Point</th>
<th>RT-PCR Fold Change</th>
<th>GeneSpring Fold Change Analysis</th>
</tr>
</thead>
<tbody>
<tr>
<td>HIF1α</td>
<td>AA913703</td>
<td>6hrs</td>
<td>1.35</td>
<td>1.76 Correlate</td>
</tr>
<tr>
<td></td>
<td></td>
<td>36hrs</td>
<td>1.91</td>
<td>1.36 Correlate</td>
</tr>
<tr>
<td>CASP3</td>
<td>NM_004346</td>
<td>6hrs</td>
<td>0.00</td>
<td>0.87 Correlate</td>
</tr>
<tr>
<td></td>
<td></td>
<td>36hrs</td>
<td>2.91</td>
<td>0.79 Correlate</td>
</tr>
<tr>
<td>CASP8</td>
<td>NM_001228</td>
<td>6hrs</td>
<td>1.06</td>
<td>0.34 Correlate</td>
</tr>
<tr>
<td></td>
<td></td>
<td>36hrs</td>
<td>1.61</td>
<td>1.25 Correlate</td>
</tr>
</tbody>
</table>
Comparative gene expression analysis of 36 hour post-infection HMEC-1 infected with *B. bacilliformis* and two-day post-infection BEC infected with HHV-8.

Venn diagram analysis was carried out on data from *B. bacilliformis*-infected HMEC-1 cells 36 hours post-infection versus two-day post-infection HHV-8 infected primary blood endothelial cells (BEC) (Table 2.4). Analysis of *B. bacilliformis*-infected HMEC-1 cells versus HHV-8 infected BEC cells was conducted because of the functional similarities between the two endothelial cell lines. Genes showing a two-fold change or greater were selected for comparison and then these genes were grouped by pathway/function commonalities. Groupings included angiogenic, apoptotic, cell adhesion, cell signaling, and immune response factors. Analysis shows a dramatic increase in the expression of angiogenic genes in HHV-8 infected cells relative to *B. bacilliformis*-infected cells. For example, infection with HHV-8 results in a 15-fold up-regulation in IL-8 production with an increase in IL-8 in *B. bacilliformis*-infected cells of two fold. Platelet derived growth factor (PDGF) is up-regulated during *B. bacilliformis* infection by almost two fold, while in HHV-8 infected cells PDGF gene production is down-regulated almost 2.5-fold. Examination of apoptosis/cell death functional genes indicates that HHV-8 infection of BEC cells results in an increase of chemokine ligand 2 (CCL2) expression that is almost four-fold higher than HMEC-1 cells infected by *B. bacilliformis* (6.4-fold vs. 2.1-fold increase, respectively). Also, TNF superfamily receptor 21 is down-regulated almost six-fold in *B. bacilliformis* infected HMEC-1 cells while its gene expression is up-regulated almost five-fold in HHV-8 infected BEC cells. Cell adhesion and mobility regulated genes show almost universal down-regulation during infection with *B. bacilliformis*, as opposed to those infected by HHV-8. This includes the down-regulation of Claudin 1 (CLDN1), epithelial V-like antigen
(EVA1), Alpha 5-integrin (PLTP) and laminin gamma 2 (LAMC2), all of which are down-regulated during the infection of *B. bacilliformis* but are up-regulated during the infection by HHV-8. It should be noted that thrombospondin 3 (THBS3) is down-regulated almost three fold in *B. bacilliformis* infected cells, while it is up-regulated two fold in HHV-8 infected cells. Cell signaling genes show similar gene expression patterns between HHV-8 infected cells and *B. bacilliformis* infected cells; however, HHV-8 infected cells exhibit an increased cytokine receptor 7 (CMKOR1) expression of eight fold, whereas *B. bacilliformis* infected HMEC-1 cells CMKOR1 expression increases by 2.5-fold. Ficolin (FCN3) gene expression is up-regulated almost three-fold in *B. bacilliformis* infected HMEC-1 cells, but is down-regulated 2.5-fold in HHV-8 infected cells. The immune response is also differentially regulated in *Bartonella* infected cells and HHV-8 infected cells. For example, CD69 is up-regulated almost 5.5-fold by HHV-8 infected cells, but is down-regulated over three-fold in *B. bacilliformis* infected cells, while *B. bacilliformis* infection increases chemokine ligand 11 (CXCL11) production over five-fold versus a 3.5-fold increase by HHV-8 infected cells.

HHV-8 infection induces production of IL-2 receptor and IL-32 greater than *B. bacilliformis*, showing almost a seven-fold increase in the production of IL-32 versus *B. bacilliformis* infected cells. *B. bacilliformis*, however, induces an up-regulation of IL-6 signal transducer production with a 2.6-fold increase versus a two-fold decrease in HHV-8 infected cells. *B. bacilliformis* also induces the increased expression of G-protein signaling regulator genes (RGS1) by a four-fold greater rate than that of HHV-8 infected cells, while HHV-8 infected cells appear to induce the production of Selectin E (SELE) over five-fold greater than that of *B. bacilliformis*. Host cell metabolism gene expression patterns are very similar between *B. bacilliformis* infected cells and HHV-8 infected cells. The only exception is the expression
of the carboxypeptidase E gene (CPE), which shows a two-fold decrease during *B. bacilliformis* infection and a two-fold increase during HHV-8 infection. Lastly, analysis of proliferation-related genes in *B. bacilliformis* infected HMEC-1 indicates a down-regulation of almost three-fold for Cyclin D2 (CCND2), while HHV-8 infected cells up-regulate CCND2 expression two-fold. Breast cancer marker 2 (BRCA2) gene expression shows a modest difference between HHV-8 and *B. bacilliformis* infected cells, increasing about four-fold during *B. bacilliformis* infection and two fold following infection with HHV-8.
Table 2.4 – Venn Diagram Analysis comparing genes overlapping between 36hrs B. bacilliformis-infected HMEC-1 Cells and 2 day HHV-8 infected Primary Blood Endothelial Cells.

Venn diagram analysis was conducted comparing HMEC-1 36 hour post-infection with B. bacilliformis versus HHV-8 two-day infected BEC; genes were selected by two-fold or more change over control and those which overlapped between both infective conditions. Genes discussed in the text are highlighted in red.

<table>
<thead>
<tr>
<th>Gene name and function</th>
<th>Accession no.</th>
<th>B. bacilliformis Infected Fold Change</th>
<th>2 day HHV-8 Infected Fold Change</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Angiogenesis</strong></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>EPH receptor B2</td>
<td>D31661</td>
<td>-2.392</td>
<td>2.481</td>
</tr>
<tr>
<td>Interleukin 8</td>
<td>AF043337</td>
<td>2.249</td>
<td>15.500</td>
</tr>
<tr>
<td>Interleukin 8 receptor beta</td>
<td>NM_001557</td>
<td>3.828</td>
<td>2.198</td>
</tr>
<tr>
<td>Platelet-derived growth factor alpha polypeptide</td>
<td>X03795</td>
<td>2.173</td>
<td>-2.519</td>
</tr>
<tr>
<td><strong>Apoptosis/Cell Death</strong></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Chemokine (C-C motif) ligand 2</td>
<td>S69738</td>
<td>2.062</td>
<td>6.417</td>
</tr>
<tr>
<td>GULP, engulfment adaptor</td>
<td>AK023668</td>
<td>-4.000</td>
<td>-2.252</td>
</tr>
<tr>
<td>PTB domain containing 1</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Interferon induced with helicase C domain 1</td>
<td>NM_022168</td>
<td>2.133</td>
<td>2.188</td>
</tr>
<tr>
<td>Tumor necrosis factor receptor superfamily, member 21</td>
<td>NM_016629</td>
<td>-5.780</td>
<td>4.258</td>
</tr>
<tr>
<td>Tumor necrosis factor receptor superfamily, member 9</td>
<td>BC006196</td>
<td>2.992</td>
<td>2.020</td>
</tr>
<tr>
<td><strong>Cell Adhesion &amp; Mobility</strong></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>BH-protocadherin (brain-heart)</td>
<td>NM_002589</td>
<td>2.105</td>
<td>2.054</td>
</tr>
<tr>
<td>Cadherin-like 22</td>
<td>AF035300</td>
<td>-4.926</td>
<td>-2.037</td>
</tr>
<tr>
<td>Claudin 1</td>
<td>NM_021101</td>
<td>-5.525</td>
<td>2.035</td>
</tr>
<tr>
<td>Epithelial V-like antigen 1</td>
<td>NM_005797</td>
<td>-4.808</td>
<td>2.649</td>
</tr>
<tr>
<td>Extracellular link domain containing 1</td>
<td>NM_016164</td>
<td>-2.283</td>
<td>-3.077</td>
</tr>
<tr>
<td>Gelsolin (amyloidosis, Finnish type)</td>
<td>BE675337</td>
<td>-2.381</td>
<td>-2.262</td>
</tr>
<tr>
<td>Heparan sulfate proteoglycan 2 (perlecan)</td>
<td>AI991033</td>
<td>5.000</td>
<td>2.863</td>
</tr>
<tr>
<td>Integrin, alpha V</td>
<td>NM_006227</td>
<td>-3.106</td>
<td>2.275</td>
</tr>
<tr>
<td>Laminin, gamma 2</td>
<td>NM_005562</td>
<td>-2.646</td>
<td>3.967</td>
</tr>
<tr>
<td>Gene name and function</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>------------------------</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>Accession no.</strong></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>B. bacilliformis-Infected Fold Change</strong></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>2 day HHV-8 Infected Fold Change</strong></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

**Gene name and function (con’t)**

| PDZ domain containing 2 | AF338650 | 2.961 | 2.123 |
| Thrombospondin 3 | L38969 | -3.049 | 2.059 |

**Cell Signaling**

Chemokine (C-X-C motif)

| receptor 7 | AI817041 | 2.477 | 8.148 |
| Ficolin | NM_003665 | 2.892 | -4.566 |
| G protein-coupled receptor 37 (endothelin receptor type B-like) | T16257 | 2.836 | 2.321 |
| G protein-coupled receptor 4 | NM_005282 | -2.037 | -2.262 |
| PDZ domain containing 1 | NM_002614 | -2.336 | 2.059 |

**Immune Response**

| CD69 molecule | L07555 | -3.115 | 5.426 |
| Chemokine (C-X-C motif) ligand 11 | AF030514 | 5.249 | 3.855 |
| Interleukin 1 receptor antagonist | BE563442 | 3.346 | 2.190 |
| Interleukin 2 receptor, gamma | NM_000206 | -2.096 | 2.253 |
| Interleukin 32 | NM_004221 | 2.101 | 7.348 |
| Interleukin 6 signal transducer RAB7, member RAS oncogene family | BE856546 | 2.681 | -2.033 |
| Regulator of G-protein signaling 1 | NM_002922 | 8.016 | 2.028 |
| Selectin E (endothelial adhesion molecule 1) | NM_000450 | 3.813 | 18.500 |
| Serine proteinase inhibitor | AB046400 | -3.597 | -9.009 |
| Tachykinin | NM_003182 | 3.469 | 2.001 |

**Metabolism**

| Carboxypeptidase E | NM_001873 | -2.179 | 2.182 |
| Glutamate-ammonia ligase (glutamine synthase) domain containing 1 | NM_016571 | 2.965 | 2.483 |
| Klotho | NM_004795 | 2.600 | 2.091 |
| Phosphatidylinositol glycan, class C | AL035301 | 2.141 | 2.201 |

**Proliferation**

<p>| Cyclin D2 | AI635187 | -3.367 | 2.043 |</p>
<table>
<thead>
<tr>
<th>Gene name and function</th>
<th>Accession no.</th>
<th>B. bacilliformis-infected Fold Change</th>
<th>2 day HHV-8 infected Fold Change</th>
</tr>
</thead>
<tbody>
<tr>
<td>Breast cancer 2, early onset</td>
<td>NM_000059</td>
<td>3.834</td>
<td>2.038</td>
</tr>
</tbody>
</table>
Comparative gene expression analysis of 36 hour post-infection HMEC-1 infected with *B. bacilliformis* and seven-day post-infection BEC infected with HHV-8.

Venn diagram analysis was conducted comparing gene expression in *B. bacilliformis* infected HMEC-1 36 hours post-infection with that observed in HHV-8 infected BEC seven days post-infection. Groups of genes were selected as noted above (Table 2.5). This analysis was completed in order to determine the expression of genes during both infected conditions to establish commonalities of expression during both infective conditions. Analysis of cell adhesion and mobility differentially regulated genes indicates *B. bacilliformis* infection at 36 hours is down regulated (-5.2 fold) versus up regulation (2.1 fold) in HHV-8 infected cells after seven-days. Cell signaling Venn analysis of overlapping regulated genes indicates *B. bacilliformis* infection down-regulates the production of Aquaporin 8 (AQP8) (2.3 fold), as opposed to a two-fold increase of AQP8 (2.1 fold) during HHV-8 infection. A three-fold decrease in somatostatin receptor (SSTR2) expression levels is seen in *B. bacilliformis* infected cells (-3.0 fold) versus a two-fold increase (2.0 fold) in HHV-8 infected cells. Immune response gene regulation between *B. bacilliformis* infected cells and HHV-8 infected BEC cells indicate similar expression patterns. However, *B. bacilliformis* up-regulates the expression of cytotoxic and regulatory T cell molecules (CRTAM) to a four-fold greater extent than HHV-8 (8.1 fold vs. 2.0 fold). Also, CD 28 gene (CD28) expression is up-regulated two-fold during *B. bacilliformis* infection (4.0 fold) when compared to HHV-8 infection (2.1 fold). Interestingly, both IgE fragments (FCER1A) and serpin peptidase inhibitor (SERPINF2) show a down-regulation during *B. bacilliformis* infection (-3.3 fold and -2.6 fold versus 2.2 fold and 2.3 fold, respectively) while infection with HHV-8 shows an increase in the expression of both of these genes. Finally, analysis of genes which are
differentially regulated regarding metabolism reveals a three-fold down-regulation in fucosyltransferase 9 (FUT9) and almost a four-fold down regulation of SMA4 (SMA4) expression in *B. bacilliformis* infected HMEC-1 cells, while both of these genes are up-regulated in HHV-8 infected cells (2.0 fold and 2.2 fold).
Table 2.5 – Venn Diagram Analysis comparing genes overlapping between 36 hrs *B. bacilliformis*-infected HMEC-1 Cells and 7 day HHV-8 infected Primary Blood Endothelial Cells.

Venn diagram analysis was conducted comparing *B. bacilliformis*-infected HMEC-1 36 hour post-infection with HHV-8 infected BEC 7 days post-infection. Genes with 2-fold change over control were selected and those which overlapped between both infective conditions. Genes referred to in the text are highlighted in red.

<table>
<thead>
<tr>
<th>Gene name and function</th>
<th>Accession no.</th>
<th>B. bacilliformis-Infected Fold Change</th>
<th>7 day HHV-8 Infected Fold Change</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Cell Adhesion &amp; Mobility</strong></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Dynein, axonemal, HC3</td>
<td>AK026793</td>
<td>2.901</td>
<td>2.288</td>
</tr>
<tr>
<td>Formyl peptide receptor-like 1</td>
<td>U81501</td>
<td>-5.208</td>
<td>2.129</td>
</tr>
<tr>
<td>K-cadherin</td>
<td>NM_004932</td>
<td>-3.472</td>
<td>2.107</td>
</tr>
<tr>
<td>Leucine rich repeat neuronal 5</td>
<td>AK024867</td>
<td>2.430</td>
<td>2.064</td>
</tr>
<tr>
<td><strong>Cell Signaling</strong></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Aquaporin 8</td>
<td>NM_001169</td>
<td>-2.398</td>
<td>2.134</td>
</tr>
<tr>
<td>Interleukin 5 receptor, alpha</td>
<td>M96651</td>
<td>3.743</td>
<td>2.023</td>
</tr>
<tr>
<td>Phosphodiesterase 6C, cGMP-specific, cone, alpha prime</td>
<td>U31973</td>
<td>3.057</td>
<td>2.047</td>
</tr>
<tr>
<td>Somatostatin receptor 2</td>
<td>BC000256</td>
<td>-3.086</td>
<td>2.062</td>
</tr>
<tr>
<td>Tetraspanin 7</td>
<td>NM_004615</td>
<td>-2.294</td>
<td>-2.045</td>
</tr>
<tr>
<td><strong>Immune Response</strong></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Apolipoprotein H</td>
<td>NM_000042</td>
<td>3.811</td>
<td>2.120</td>
</tr>
<tr>
<td>CD28 molecule</td>
<td>AF222343</td>
<td>4.015</td>
<td>2.177</td>
</tr>
<tr>
<td>Chemokine (C-X-C motif) ligand 14</td>
<td>NM_004887</td>
<td>2.462</td>
<td>2.193</td>
</tr>
<tr>
<td><strong>Cytotoxic and regulatory T cell molecule</strong></td>
<td>NM_019604</td>
<td>8.193</td>
<td>2.086</td>
</tr>
<tr>
<td>Deducator of cytokinesis 2</td>
<td>D86964</td>
<td>3.174</td>
<td>2.130</td>
</tr>
<tr>
<td>Fc fragment of IgE</td>
<td>BC005912</td>
<td>-3.367</td>
<td>2.244</td>
</tr>
<tr>
<td>Myelin basic protein</td>
<td>M13577</td>
<td>2.426</td>
<td>2.116</td>
</tr>
<tr>
<td>Serpin peptidase inhibitor</td>
<td>NM_000934</td>
<td>-2.667</td>
<td>2.308</td>
</tr>
<tr>
<td>Urotensin 2</td>
<td>NM_021995</td>
<td>2.794</td>
<td>2.041</td>
</tr>
<tr>
<td><strong>Metabolism</strong></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Fucosyltransferase 9</td>
<td>BC001879</td>
<td>-3.096</td>
<td>2.048</td>
</tr>
<tr>
<td>Proline dehydrogenase (oxidase) 2</td>
<td>U95090</td>
<td>2.284</td>
<td>2.363</td>
</tr>
<tr>
<td>SMA4</td>
<td>X83300</td>
<td>-4.274</td>
<td>2.208</td>
</tr>
<tr>
<td>Gene name and function (con’t)</td>
<td>Accession no.</td>
<td>B. bacilliformis-Infected Fold Change</td>
<td>2 day HHV-8 Infected Fold Change</td>
</tr>
<tr>
<td>--------------------------------</td>
<td>---------------</td>
<td>--------------------------------------</td>
<td>---------------------------------</td>
</tr>
<tr>
<td>UDP-Gal:betaGlcNAc beta 1,3-galactosyltransferase 2</td>
<td>Y15014</td>
<td>2.094</td>
<td>2.120</td>
</tr>
</tbody>
</table>
Comparative gene expression analysis of 36 hour post-infection HMEC-1 infected with 
*B. bacilliformis* versus two-day and seven-day post-infection BEC infected with HHV-8.

A final Venn diagram analysis was completed comparing *B. bacilliformis* infected HMEC-1 36 hour post-infection with HHV-8 infected BEC two- and seven-day post-infection. Genes were selected as noted above (Table 2.6). One major outcome of this analysis as it relates to angiogenesis genes concerns the differential response of the cells with respect to the expression of IL-8. In HHV-8 infected cells, there is an up-regulation in IL-8 expression at both time points, while the gene is two-fold down-regulated in cells infected with *B. bacilliformis* Overall, the immune response genes show similar expression patterns following infection with either *B. bacilliformis* or HHV-8, with the exception of the Fc fragment of IgA and the von Hippel-Lindau tumor suppressor, both of which are down-regulated in *B. bacilliformis* infected cells and up-regulated in HHV-8 infected cells. Cell Adhesion-related genes exhibit a dissimilar gene regulatory pattern between *B. bacilliformis* and HHV-8 infected cells, with the most dramatic differences seen with the Epithelial V-like antigen 1 gene, which is 2-fold down-regulated in *B. bacilliformis* infected cells but 7-fold up-regulated at the two-day post HHV-8 infection BECs. The up-regulation of Pappalysin in *B. bacilliformis*-infection HMEC-1 cells does not correlate with the down-regulation of this gene by HHV-8 infection. Finally, analysis of the expression changes in Transport-related genes reveals differences in the expression of the glutamate receptor, which is down-regulated 7.5 fold in *B. bacilliformis*-infected cells, but up-regulated in HHV-8 infected cells at both time points.
**Table 2.6 – Venn Diagram Analysis comparing genes overlapping between 36hrs *B. bacilliformis*-infected HMEC-1 Cells and 2 & 7 day HHV-8 infected Primary Blood Endothelial Cells.**

Venn diagram analysis was completed comparing HMEC-1 36 hour post-infection with *B. bacilliformis* versus HHV-8 day-two and seven-day infected BEC; genes were selected due to their two-fold change over control and those which overlapped between all three infective conditions. Genes discussed in the text are highlighted in red.

<table>
<thead>
<tr>
<th>Gene name and function</th>
<th>Accession no.</th>
<th><em>B. bacilliformis</em>-Infected Fold Change</th>
<th>2 day HHV-8 Infected Fold Change</th>
<th>7 day HHV-8 Infected Fold Change</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Angiogenesis</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Interleukin 8</td>
<td>X77737</td>
<td>2.249</td>
<td>15.500</td>
<td>2.579</td>
</tr>
<tr>
<td>Aminopeptidase A</td>
<td>NM_001977</td>
<td>2.342</td>
<td>2.235</td>
<td>2.191</td>
</tr>
<tr>
<td>Kruppel-like factor 5</td>
<td>AF132818</td>
<td>4.193</td>
<td>2.214</td>
<td>2.112</td>
</tr>
<tr>
<td>Endothelin receptor type A</td>
<td>AU118882</td>
<td>7.052</td>
<td>2.221</td>
<td>2.311</td>
</tr>
<tr>
<td><strong>Immune Response</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Immunoglobulin lambda locus</td>
<td>D01059</td>
<td>2.137</td>
<td>2.129</td>
<td>2.131</td>
</tr>
<tr>
<td>Immunoglobulin heavy constant g1</td>
<td>AJ275383</td>
<td>2.375</td>
<td>-3.175</td>
<td>-2.404</td>
</tr>
<tr>
<td>Major Histocompatibility Complex, class II, DR beta 1</td>
<td>AJ297586</td>
<td>-2.212</td>
<td>-2.994</td>
<td>-2.283</td>
</tr>
<tr>
<td>T cell receptor alpha locus</td>
<td>AE000659</td>
<td>2.452</td>
<td>2.414</td>
<td>2.311</td>
</tr>
<tr>
<td>Fc fragment of IgA</td>
<td>U56237</td>
<td>-3.096</td>
<td>2.250</td>
<td>2.350</td>
</tr>
<tr>
<td>Interleukin 26</td>
<td>NM_018402</td>
<td>2.211</td>
<td>2.090</td>
<td>2.082</td>
</tr>
<tr>
<td>von Hippel-Lindau tumor suppressor</td>
<td>NM_00551</td>
<td>-2.041</td>
<td>2.297</td>
<td>2.064</td>
</tr>
<tr>
<td><strong>Cell Adhesion</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>CD1c molecule</td>
<td>NM_001765</td>
<td>2.371</td>
<td>-2.762</td>
<td>-2.174</td>
</tr>
<tr>
<td>Epithelial V-like antigen 1</td>
<td>AF275945</td>
<td>-2.320</td>
<td>7.489</td>
<td>2.121</td>
</tr>
<tr>
<td>Embryonal Fyn-associated substrate</td>
<td>NM_005864</td>
<td>-2.294</td>
<td>2.328</td>
<td>2.056</td>
</tr>
<tr>
<td>Neurofibromin 2</td>
<td>BC003112</td>
<td>3.939</td>
<td>2.106</td>
<td>2.246</td>
</tr>
<tr>
<td>Gene name and function</td>
<td>Accession no.</td>
<td>B. bacilliformis-Infected Fold Change</td>
<td>2 day HHV-8 Infected Fold Change</td>
<td>7 day HHV-8 Infected Fold Change</td>
</tr>
<tr>
<td>--------------------------------------------</td>
<td>---------------</td>
<td>---------------------------------------</td>
<td>----------------------------------</td>
<td>---------------------------------</td>
</tr>
<tr>
<td><strong>Cell Cycle Regulation</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Pappalysin 2</td>
<td>BF435151</td>
<td>7.014</td>
<td>-4.049</td>
<td>-3.205</td>
</tr>
<tr>
<td>fyn-related kinase</td>
<td>NM_002031</td>
<td>5.549</td>
<td>2.130</td>
<td>2.054</td>
</tr>
<tr>
<td><strong>Transport</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Glutamate receptor</td>
<td>AU156204</td>
<td>-7.519</td>
<td>2.161</td>
<td>2.113</td>
</tr>
<tr>
<td>Transferrin</td>
<td>NM_014111</td>
<td>2.112</td>
<td>2.424</td>
<td>2.375</td>
</tr>
<tr>
<td>Cystic Fibrosis transmembrane conductance regulator</td>
<td>W60595</td>
<td>7.713</td>
<td>2.172</td>
<td>2.128</td>
</tr>
<tr>
<td>Solute carrier family</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>13 m1</td>
<td>AF260824</td>
<td>-2.825</td>
<td>2.029</td>
<td>2.051</td>
</tr>
<tr>
<td>CD36 molecule</td>
<td>M98399</td>
<td>2.879</td>
<td>3.774</td>
<td>3.103</td>
</tr>
</tbody>
</table>
Discussion

The infection of host endothelial cells by *B. bacilliformis* results in the alteration of numerous gene regulation profiles. To date, little research has been done to analyze these regulatory changes. The experiments described herein were undertaken to provide information about the global regulation of host genes in response to infection with *B. bacilliformis* KC584. Genes analyzed were divided into several key categories, depending on their roles in angiogenesis, apoptosis, the immune response and signal transduction. A comparison of gene regulatory patterns induced by *B. bacilliformis* infection with those observed following infection by HHV-8, the etiological agent of Kaposi’s Sarcoma (Naranatt *et al.*, 2004; Wang, 2004) was also carried out due to the striking histopathological similarities between the clinical presentation of Kaposi’s Sarcoma and that of verruga peruana.

**Microarray analysis of cellular gene expression in response to infection by *B. bacilliformis***

Work in our laboratory has focused on the response of HMEC-1 cells during early (within 3 hours) and late (36 hours) *B. bacilliformis* infection, as determined by microarray analysis. Early host response has shown the expression of several key host genes relating to angiogenesis, apoptosis and immune response (Soni, personal communication). Early infection, within 30 minutes, of *B. bacilliformis* shows the highest degree of change in overall gene expression change (21.9%), with 7.9% of the genes being up-regulated and 14.0% being down-regulated. Those genes relating to angiogenesis that are up-regulated through the first three hours of infection include bFGF, ICAM-1, Insulin-like growth factor (IGF), and Platelet-derived Growth Factor Receptor 1 (PDGFR-1). While bFGF and IGF
have been clearly associated with angiogenesis and blood vessel formation, PDGFR1 up-regulation may indicate that infected endothelial cells are priming not only for angiogenesis, but also involvement of the immune system in clearance of the *B. bacilliformis* infection. Up-regulation of ICAM-1, a cellular adherence factor, may indicate the restructuring and increased attachment of endothelial cells as they begin priming for the angiogenic cascade. Several angiogenesis-related genes, including HIF2α and HIF3α, Insulin-like Growth Factor receptor I (IGFR-1), Microvascular endothelial differentiation gene I and VEGF, are only transiently up-regulated early in infection. While HIF2α gene expression is a known response to hypoxia and able to induce angiogenesis via the VEGF pathway, recent research suggests that HIF3α may actually be involved in a destruction of tubules by a yet unknown method (Hirota *et al.*, 2006). HHV-8 has been found to contain genetic elements which are activated in hypoxic environments (HRE); these genetic elements have not been found in *B. bacilliformis* (Haque *et al.*, 2003). HIF1α expression has also been implicated in the infective cycle of HHV-8; its accumulation is believed to be due to the presence of up-regulated IGF-I and the subsequent induction of VEGF (Catrina *et al.*, 2006). Research into the role of HIF1α has shown that *B. henselae* infection actively increases HIF1α expression and decreases ATP stores. Interestingly, this study suggests that *B. henselae* strains which are pilus negative do not induce HIF1α or VEGF expression, thus indicating the role of the pilus in HIF1α activation. However, to date the role and presence of a *B. bacilliformis* pilus homologue has not been established in HIF1α induction (Kempf *et al.*, 2005). Our data, however, show a constant down-regulation of the transcription factor HIF1α throughout early *B. bacilliformis* infection. The down-regulation of HIF1α upon *B. bacilliformis* infection is unexpected, since HIF1α plays a significant role in mediating VEGF expression
during HHV-8 infection. Under these conditions, HIF1α activation is achieved through phosphorylation by p38 and proteins in the MAPK signal pathways (Sodhi et al., 2000). HHV-8 induced tumors express the gene coding for the IGF-I receptor, suggesting an autocrine role during angiogenesis. The 3.6-fold increase in IGF-1 gene expression seen early in B. bacilliformis infection may indicate that this protein is also involved in the formation of verruga peruana (Catrina et al., 2005).

Expression of anti-apoptotic genes during early B. bacilliformis infection reveals the transient up-regulation of several genes. Of these, the Id2 (Inhibitor of DNA binding-2) gene, whose expression is increased 8-fold 30 minutes post-infection, is the most highly up-regulated. ID2 is able to inhibit cellular differentiation and may actually act as a tumor suppressor (Lavarone et al., 1994). In a manner similar to that of HHV-8 infection, the host response in the early stages of B. bacilliformis infection exhibits an interferon-based immune response (Dourmishev et al., 2003; Naranatt et al., 2004). Transiently up-regulated genes include CXC10, MCP-1, MS-CSF and STAT-induced stat inhibitor 3 (SSI-3) which are involved in the recruitment and chemotaxis of immune cells to sites of inflammation and infection (Poole et al., 2002). Consistently down-regulated during early B. bacilliformis infection, RAFTK, a focal adhesion kinase, is expressed in cells infected by HHV-8 and acts as a coordinator of cytokine, integrin receptor, cytoskeletal and actin processes by direct activation of JNK (Liu et al., 1997). While RAFTK activation can be induced by bFGF, IL-6 or VEGF in B. bacilliformis infection, RAFTK down-regulation may indicate that B. bacilliformis is bypassing this kinase while still able to alter the angiogenic cascade. Several transcription factors are also activated during early infection by B. bacilliformis, including the activation of multiple NF-kB factors. The role of NF-kB as a downstream gene
transcription factor and its involvement in pathogenesis has been established by the work by Fuhrmann et al. (2001). These authors report that *B. henselae* is able to activate NF-κB, thereby increasing PMN rolling and adhesion to infected endothelial cells during infection.

During the later phase of infection (6 and 36 hours post infection) far fewer genes show altered expression as compared with their earlier time point levels. Those that are up-regulated include the Interferon-inducible T Cell Alpha Chemoattractant (I-TAC) gene and the gene coding for Chemoattractant Protein-1 (MCP-1). Both I-TAC and MCP-1, an activator protein of monocytes, are able to induce monocyte influx into the site of infection. At six hours post-infection an up-regulation of the gene coding for IAP homologue C, a known inhibitor of apoptosis via the TRAF pathway, is also seen. This gene product may play a role in the established anti-apoptosis strategy of many *Bartonella* species (Dehio, 2003; Kirby et al., 2002; Liberto et al., 2004). This continued depression of the apoptosis pathway suggests a mode and methodology of continued survival not only for infected endothelial cells, but also a way by which *B. bacilliformis* can avoid the immune response.

A wider examination of the regulation patterns indicates several up and down-regulatory trends over the 36 hour infection period studied. For example, the bFGF gene shows an overall up-regulation, and therefore could act as a stimulant for angiogenesis throughout the 36 hours of *B. bacilliformis* infection. However, this is in contrast to the overall down regulation of the IL-8, one of the primary inducers of angiogenesis, which may indicate that the angiogenesis seen during *B. bacilliformis* infection does not involve the IL-8 signaling pathway. Also down-regulated throughout the time period under investigation are the tissue inhibitors of MMP-1, a protein involved in the degradation of extracellular matrix. This is an essential prelude to the migration of endothelial cells and tubule formation. An
overall decrease in this inhibitor would therefore result in a higher potential activity for MMP-1 activity in the localized area surrounding infected tissues. Several anti-apoptosis genes were also down-regulated throughout the monitored 36 hour infective cycle studied; including BCL-2, and the leukocyte inhibitory factor. Down-regulation of these genes is probably due to the influx of immune response cells and follows the up-regulation trend of these genes at earlier time periods, which was discussed previously. These observations suggest that there is a robust interferon-dominated immune response and an alteration of host cell apoptosis during *B. bacilliformis* infection. It should also be noted that there is an overall down-regulation of the TNF induced genes, an indication that TNF is not involved in infection during *B. bacilliformis*. Since TNF expression is closely linked to LPS infectivity, *B. bacilliformis* LPS may not play a role in the infection or in the immune response of the cell to *B. bacilliformis* infection. The analysis of known cancer signatures reveals an overall down-regulation of tumor suppressor genes during the infection of HMEC-1 cells by *B. bacilliformis* and may indicate similarities between tumorgenesis and *B. bacilliformis* infection. Interestingly, there is an overall down-regulation of IL-6 gene expression during *B. bacilliformis* infection, which may be counteracted by the influx of highly activated immune cells. These cells are able to produce IL-6, which could potentially act in an autocrine manner, affecting the immune cells themselves in addition to infected and uninfected endothelial cells. As expected, metabolism genes such as phosphofructokinase are up-regulated throughout the entire 36-hour infective cycle. It has previously been established that HIF1α expression increases several glycolytic enzymes (Greijer *et al.*, 2005). While our 36 hour microarray-based infection study of HMEC-1 cells infected by *B. bacilliformis* does not seem to provide a clear-cut model by which *B. bacilliformis* is
inducing angiogenesis, there are several key points that can be taken away from this study. We suggest that a high number of genes are up-regulated within 30 minutes of \textit{B. bacilliformis} infection of HMEC-1 cells. This high level of gene up-regulation may result in the expression of genes that are directly involved in angiogenesis or are involved in the pathways which lead to the angiogenesis cascade. Next, our data have shown that hypoxia factors HIF1\textalpha{}, HIF2\textalpha{} and HIF3\textalpha{} are clearly involved at several different stages of \textit{B. bacilliformis} infection. While HIF1\textalpha{} and HIF2\textalpha{} are known to be involved in VEGF expression, HIF3\textalpha{} may actually be involved in the degradation of newly formed and pre-existing endothelial tubules which are created during periods of high oxygen consumption. This may in fact be a key element in the poor tubule formation during \textit{B. bacilliformis} infection (discussed in Chapter 3). The resulting expression of HIF1\textalpha{} and HIF2\textalpha{} may result in the induction of the angiogenic cascade through both VEGF and other factors, including the constitutively up-regulated bFGF. However, due to the presence of up-regulated HIF3\textalpha{}, the tubules formed are weak and/or highly permeable. This could result in the pooling of blood in the subcutaneous location of \textit{B. bacilliformis} infection, producing the clinical presentation of verruga peruana formation (Hirota \textit{et al.}, 2006). Also, the transient rather than continual increase in ICAM-1 expression may indicate that while endothelial cells are able to migrate and form tubules, cell-to-cell contact is not properly reinforced. Therefore, the tubules that are formed are highly permeable, establishing another route of blood leakage into the localized subcutaneous environment. Our microarray studies also suggest a role for the interferon dominated immune response during the infection of \textit{B. bacilliformis}. During the 36 hour time window, several chemoattractant genes regulated by interferon-\textgamma{} are up-regulated, and may be involved in the chemoattraction of monocytes, macrophages and
activated T cells into the localized infective environment. These cells in turn could produce several factors involved in endothelial cell migration and tubule formation.

The study presented here of the gene regulation pattern of *B. bacilliformis* infected HMEC-1 cells is similar to the results seen by Dehio *et al.* (2005) during their study of *B. henselae* infection of HUVEC cells, with a few key differences. As with our studies, Dehio and his coauthors used the Affymetrix HG-U133 human microarray set to study the global gene regulation pattern of infected endothelial cells. They chose to harvest RNA for analysis at 6 and 30 hours post infection, and to use HUVEC cells rather than HMEC-1 hosts. Their findings indicate a significant increase in interferon-dependent gene transcription factors, which is also seen during the *B. bacilliformis* infection. Similarly, Dehio *et al.* (2005) suggest that interferon (IFN) is involved in the immune response during *B. henselae* infection, even though its expression was not found via ELISA detection from infected HUVEC cells. Although our study did not seek to determine if IFN was produced by HMEC-1 cells during *B. bacilliformis* infection, we would expect the results to be similar to those reported by Dehio *et al.* (2005). The authors are also able to show the involvement of the NF-κB transcriptional factor in *B. henselae* infection, as we have in our studies, which relates to the up-regulation of IL-6, IL-8, ICAM-1 and CXC cytokine family members. Our study shows the involvement of these and several other NF-κB-induced gene products.

While Dehio *et al.* (2005) suggest a role for the virB/Bep operon in the induction of NF-κB, research in our lab, as well as the published *B. bacilliformis* KC583 genome, indicates that the virB operon is not present in *B. bacilliformis* (see Chapter 1). Therefore, the induction of NF-κB during *B. bacilliformis* infection must be mediated by some other factor(s). Lastly, Dehio *et al.* (2005) examined the genes related to angioproliferation, and were able to show
that 22% of the 100 most highly differentially regulated genes were related to angiogenesis. These results correlate well with our own studies of \textit{B. bacilliformis} infection. While infection by the two \textit{Bartonella} species resulted in the up-regulation of several similar angioproliferative genes, infection by \textit{B. henselae} did not show an increase in Hypoxia-inducible factors (HIF) of any kind, while our results reveal differential regulation patterns consistent with a key role for these factors in the on-going angiogenesis seen in verruga peruana formation during Carrion’s disease.

Real-time RT-PCR analysis was also conducted on three genes as a way to verify the microarray data (Table 2.3). The RT-PCR data and the microarray fold-change analysis show a 73% correlation when both early and late time points are included in the validation analysis. Most successful microarray studies prefer a fold-change range of no more than a 2.5 fold difference between microarray and RT-PCR data (Draghici, 2002; Firestein \textit{et al.}, 2002; Gao \textit{et al.}, 2004; Nadon \textit{et al.}, 2002; Stintzi, 2003). Differences between RT-PCR and microarray data are commonly ascribed to several factors, including the different microarray hybridization probes used for each technique. Even a slight difference in binding locations can result in differential fold-change data. Also, the required use of microarray imaging software, such as GCOS, can result in analysis of microarray data with different hybridization intensity levels. While intensity levels were adjusted to be as close to one another as possible, slight gene spot intensity differences will lead software-based analysis to different fold change results. While we did not obtain the expected correlation between microarray and RT-PCR data at all time points, we are confident that these studies will provide the necessary tools for further research into the interaction of \textit{Bartonella} species with their hosts.
Venn diagram-based analysis of *B. bacilliformis* infected HMEC-1 cells versus Kaposi's sarcoma BEC infected cells.

Due to the histopathological similarities between *B. bacilliformis* infected endothelial cells and HHV-8 infected blood endothelial cells, a Venn diagram-based comparison was conducted utilizing microarray data from *B. bacilliformis*-infected HMEC-1 cells 36 hours post-infection versus HHV-8 infected blood endothelial cells (BEC) after two and seven days post-infection. Microarray data from HHV-8 infected cells was generated by Wang, *et al.* (2004) and published to the ArrayExpress database ([www.ebi.ac.uk](http://www.ebi.ac.uk)) accession number E-MEXP-66. These data were treated in the same manner as *B. bacilliformis* data with regard to software-based analysis. Gene regulation analysis of genes with at least a two-fold change from mock infected cells was completed on several basic categories of host gene pathways including angiogenesis, apoptosis, cell adhesion, and immune response. Table 2.3 shows the comparison between *B. bacilliformis*-infected cells and two-day HHV-8 infected BECs. The first striking difference between *Bartonella* infected cells and HHV-8 infected cells is the expression of IL-8, a hallmark of angiogenesis. Expression of the IL-8 cytokine is up-regulated by 15-fold in HHV-8 infected but only by two-fold in *B. bacilliformis* infected cells. These data suggest that HHV-8 infected cells are more responsive to and produce higher levels of IL-8, thus indicating its role in infection by the virus, while suggesting that IL-8 may play only a small role in angiogenesis seen in *B. bacilliformis*-infected cells. This difference in IL-8 expression raises the possibility that the role of IL-8 may be offset in *B. bacilliformis*-infected cells by the up-regulation of Platelet-derived Growth Factor (PDGF), as compared to the down-regulation of the same gene in HHV-8 infected cells. PDGF is a
known vascular growth factor able to induce proliferation while acting as a chemoattractant for a wide variety of immune cells. Upon examination of apoptosis-related genes, it is interesting to note the down-regulation of GULP in both infective conditions, as this gene is responsible for an increase in the engulfment of cells which have undergone apoptosis via phagocytes. This observation may indicate a survival strategy for both infective conditions, since it will decrease uptake by host cells that are actively undergoing apoptosis or have recently undergone apoptosis, thereby allowing *B. bacilliformis* a protected location for continued growth. Interestingly, a five-fold down-regulation of tumor necrosis factor receptor 21 (TNFR21) is seen in *B. bacilliformis* infected cells while up-regulation of four-fold of this gene is observed in HHV-8 infected cells. This may indicate that TNF plays a less important role in *B. bacilliformis* infection as compared with HHV-8 infection. Analysis of genes involved in cell adhesion and mobility again indicates differences between *Bartonella* infection and HHV-8 infection. The up-regulation of Perlecan in both infective conditions indicates yet another possible mode of survival. Induction of this gene results in the inhibition of apoptosis in fibroblasts following the initiation of apoptosis in nearby endothelial cells. Perlecan binds to the fibroblast α2β1 integrin, and may inhibit apoptosis via integrin activation. Interestingly, this analysis shows the down-regulation of several genes that are directly involved in endothelial cell maintenance, including Claudin 1, Laminin and Thrombospondin 3. All three are involved in binding of the extracellular matrix and have been implicated in endothelial cell permeability *in vivo*. The down-regulation of each of these genes may provide deeper clues into the overall effect that *B. bacilliformis* infection has on endothelial cells and their ability to form tight junctions and maintain tubule integrity during infection. The analysis of cell signaling molecules, a category which shows
the highest difference in gene regulation between *B. bacilliformis*-infected and HHV-8 infected cells, reveals the different possible roles the immune system plays in clearance of both infective conditions. HHV-8 infected cells show a higher level of up-regulation of chemokine receptor 7, a B cell binding site and attractant, and a greater down-regulation of Ficolin, a protein functioning in the clearance of non-self foreign material from the host. The weaker levels of chemokine receptor 7 up-regulation in *B. bacilliformis*-infected cells may indicate that the B cell response does not play as important a role in *B. bacilliformis* infection as it does in HHV-8 infection. The up-regulation of Ficolin expression may indicate that phagocytosis or other direct uptake methods for infective clearance are more important during *B. bacilliformis* infection than during HHV-8 infection. The immune response gene regulation patterns indicate a high similarity of regulatory patterns between *B. bacilliformis*-infected cells and HHV-8 infected cells. The down regulation of CD69 expression following *B. bacilliformis* infection may further indicate the lack of a TNF-α response, as CD69 expression is induced by TNF-α expression in endothelial cells. The eight-fold up regulation of G-protein signaling involved in Rho/rac proteins suggests that these proteins play a role during infection (Verma *et al.*, 2000; Verma *et al.*, 2002).

Venn diagram analysis was also used to compare the overall gene expression profiles between *B. bacilliformis*-infected HMEC-1 and seven-day HHV-8 infected BEC, using the same methodology as described above (Table 2.4). Most interesting is the overall similarity of immune response gene regulatory patterns between the two infective conditions. An example of this similarity is the up-regulation of the cytotoxic and regulatory T cell molecule which, while up-regulated more during *B. bacilliformis* infection than HHV-8 infection, still reveals the immune response similarities between the two infective conditions. This again
suggests a role for INF-γ in both infective conditions, with a possible higher immune response in *B. bacilliformis* infection of HMEC-1.

A final analysis was completed using 36 hour *B. bacilliformis*-infected HMEC-1 cells and two- and seven-day HHV-8 infected BECs via a Venn diagram analysis (Table 2.5). These data overall show the striking similarity by which *B. bacilliformis* infection and HHV infection alter endothelial cell gene profiles, as indicated by the 50% overall similarity in gene expressions. Interestingly, several genes involved in *B. bacilliformis* infection are indicative of the slightly difference host responses to *B. bacilliformis* infection versus HHV-8 infection. An example of this is the up-regulation of angiogenesis-related endothelium receptor type A (ET1RA) expression, ET1RA is a mitogen involved in the escape from apoptosis and the induction of angiogenesis via a pathway mediated by ILK, an integrin linked kinase involving α2β1 and α3β1 integrins. The up-regulation of this factor indicates a continued strategy of *B. bacilliformis* to alter host apoptosis while implicating various integrins in the induction of angiogenesis. This analysis shows an almost four-fold increase of Neurofibromin 2, a protein that is able recruit rac proteins, which in turn promote mitogenesis of host cells. This protein up-regulation provides further evidence for the proposed survival strategy used by *B. bacilliformis*: by inducing cell proliferation, *B. bacilliformis* gains increasing numbers of host cells that can support bacterial proliferation and provide a place to avoid host immune responses. Finally, we note the up-regulation of two genes involved in cell cycle regulation, Pappalysin 2 and fyn-related kinase. Pappalysin 2 interacts with the localized matrix metalloproteins, while fyn-related kinase is an inducer of cell proliferation via insulin receptors.

This comparative analysis between *B. bacilliformis*-infected HMEC-1 cells and
HHV-8 infected BEC reveals the striking commonality of endothelial cell host response to both of these infective conditions. While individual commonalities may be difficult to determine, it is clear that with over 50% similarity in the up- or down-regulation of the various genes examined, the infective condition of both *B. bacilliformis* and HHV-8 do induce similar gene regulation profiles in the host cells. These similar host gene regulation profiles may provide vital insights into the formation of both verruga peruana and Kaposi's Sarcoma lesions while providing key information about the commonalities in the histopathology between both infective states. It should be noted that the cell lines used for these studies do differ in function and localization. HMEC-1 cells consist of an established immortalized microdermal endothelial cell line which would be commonly found lining vessels, while BEC are a progenitor cell line which can differentiate into lymphatic or other endothelial cells as necessary. This contrast may account for the slight difference in degrees of fold-change seen during different infective conditions.
Chapter III – Bacterial Components & Secreted Protein(s)

Introduction

*Bartonella bacilliformis* is the causative agent of Carrion’s disease, a serious infection that exhibits a biphasic disease progression. The first phase, Oroya fever, is characterized by colonization of red blood cells followed by a severe hemolytic anemia (>80% untreated fatality rate). The disease can then progress into the second phase, termed verruga peruana, which is marked by cutaneous and subcutaneous eruptions of angiogenic lesions (Anderson, 1997). Verruga peruana resembles a similar condition called Bacillary Angiomatosis (BA), that is observed in immunocompromised individuals infected with *B. henselae* or *B. quintana* (Berger et al., 1993; Cockerell, 1992). In both cases, the lesions are the result of uncontrolled angiogenesis involving host endothelial and epithelial cells with a histopathology similar to the lesions resulting from HHV-8 (Human Herpesvirus 8) infection that are seen in patients with Kaposi’s Sarcoma (Dourmishev et al., 2003; Nayler et al., 1999). Several attempts have been made to identify the factor(s) from *B. henselae* that are responsible for BA; however, to date no definitive factor has been found (Dehio, 1999; Kirby, 2004; McCord et al., 2005; Resto-Ruiz et al., 2002; Schmidt, 1998; Schulte et al., 2006). Similarly, research into the angiogenic factor(s) encoded by *B. bacilliformis* has provided relatively few insights.

When applied to vascular endothelial cells, a soluble fraction of a *B. bacilliformis* cell homogenate has been reported to produce a mitogenic effect approximately threefold greater than that of control cells (Garcia et al., 1990). The mitogenic factor(s) has been shown to be angiogenic in a rat model. The authors were able to eliminate lipopolysaccharide (LPS) as the mitogen in these studies, and also tentatively identified the factor as a protein based on its
heat lability (Garcia et al., 1990). Additional studies have demonstrated that live *B. bacilliformis* is able to produce these proliferate lesions when co-cultured with human umbilical vascular endothelial cells (HUVEC cells) (Garcia et al., 1992). Knobloch, *et al.* have shown that serum from Carrion’s disease positive patients exhibits reactivity to a 65kDa *B. bacilliformis* produced protein, which could implicate this antigenic protein in lesion formation (Knobloch *et al.*, 1990). Recently, the suggestion was made that this 65kDa protein is a homologue of GroEL, a stress-induced molecular chaperone that is highly conserved among prokaryotes (Chatellier et al., 1998; Keskin et al., 2002; Zeaiter et al., 2002). The assignment of a role in angiogenesis for *B. bacilliformis* GroEL is based on several findings. First, a study in which HUVEC cells were infected with a strain of *B. bacilliformis* that overproduces GroEL revealed that the secretion of GroEL was accompanied by a 6- to 20- fold increase in endothelial cell growth (Minnick *et al.*, 2003). A positive correlation between GroEL levels and the degree of mitogenesis supported a role for GroEL in this increase. In addition, mitogenesis was found to be significantly inhibited in the presence of anti-GroEL antiserum.

GroEL is a highly conserved Type I chaperone, with non-specific substrate-binding requirements. In the cell, the GroE system consists of two proteins which function together to aid in conformational changes of both nascent and mature proteins, by hydrolyzing ATP and possibly providing a protected environment for protein rearrangement (Amir *et al.*, 2004; Poso *et al.*, 2004). Structurally, the GroE system consists of two proteins: GroES, a seven-member ring composed of 10kDa GroES subunits; and GroEL, a cylinder of 14 identical 57kDa GroEL subunits arranged back-to-back in a seven-member ring (Gomez-Puertas *et al.*, 2004; Grallert *et al.*, 2001; Wong *et al.*, 2004). When functional, the stacked GroEL rings
are capped by GroES, which provides an ATP-binding site. The GroEL rings are open in the absence of ATP, and have a high affinity for unfolded or misfolded substrates. With the binding of ATP, the cavity of the ring structure closes and protein re-folding can take place with the hydrolysis of ATP. Once the ATP has been hydrolyzed, the GroEL ring cavity re-opens and the folded substrate is released (Amir et al., 2004; Poso et al., 2004; Wong et al., 2004).

While the role of the GroE system in protein folding has been known for some time, it is only recently that researchers have considered GroEL to be a protein with pathological implications. Upon infection, bacterial GroEL can be exposed to host immune machinery by lysis or by active bacterial secretion. During *M. tuberculosis* infections, for example, populations of T cells show reactivity to chaperone 60.2 (the GroEL homologue) and the active secretion of two populations of *M. tuberculosis* GroEL homologues are seen inside macrophages (Ranford et al., 2000). GroEL production from *E. coli* has been seen to correlate with the increase of numerous signaling molecules with as little as 1ug/ml of GroEL in co-culture with HUVEC cells (Galdiero et al., 1997; Ranford et al., 2000; Retzlaff et al., 1994). Several other bacteria, including *Helicobacter, Legionella, and Actinobacillus*, have all been shown to use GroEL as a factor in their pathology (Garduno et al., 1998; Ranford et al., 2000; Zhang et al., 2004). These data, combined with previous research into the role of *B. bacilliformis* GroEL as a mitogen, raises the possibility that GroEL might play an important part in the eruption of verruga peruana lesions during the *B. bacilliformis* infective cycle. In order to determine the role of GroEL in angiogenesis, we have isolated GroEL from low-passage number *B. bacilliformis* cultures and examined its angiogenic potential using purified GroEL co-cultured with Human Microdermal Endothelial Cells (HMEC-1).
We report here an increase in HMEC-tubule formation in the presence of purified \textit{B. bacilliformis} GroEL.
Materials and Methods

**Bacterial Growth and Culture.** *B. bacilliformis* KC584 was grown as previously described in Chapter I (page 30). Unused *B. bacilliformis* was placed in a 50% PBS/50% glycerol mixture and stored at -80°C until needed.

**Human Cell Growth and Culture.** HMEC-1 cells were obtained as a generous gift from Dr. Thomas Lawley, of Emory University and the Centers for Disease Control and Prevention (Ades *et al.*, 1992). HMEC-1 cells were grown and cultured as previously described in Chapter II (page 70). Cells not intended for use immediately were resuspended in DMSO Cryoprotectant (Cellgro) and stored at -80°C overnight, then moved to liquid nitrogen for long term storage.

The HUVEC cells (Cambrex) were prepared via growth of the first passage HUVEC cells in EGM-2 media (Cambrex) until 70-80% confluent in a T-75 flask (Starsdt). Upon reaching confluency, the EGM-2 media was aspirated and 15 ml of trypsin-EDTA (CellGro) solution was added and incubated until the cells began to round up and detach from the flask. The trypsin solution was neutralized with the addition of 15 ml of EGM-2 media (Cambrex) and the cell slurry was aspirated and transferred to a 50 ml conical tube (Falcon). The T-75 flask was then washed with 5 ml of HBSS (CellGro) and this was added to the conical tube cell slurry. The HUVEC cells were then centrifuged for 8 minutes at 200xg, the supernatant was decanted and the cells were resuspended in 5 ml of EGM-2 media. Aliquots of these primary cells were made and those not intended for immediate use were resuspended in DMSO Cryoprotectant (CellGro) and stored at -80°C overnight, then moved to liquid nitrogen for long-term storage. Due to the unique nature of the primary HUVEC cell line, only cells passaged 2-6 were used for experimental purposes.
The epithelial cell line HEp-2 (ATCC) was maintained in T-75 flasks containing M199 media (CellGro) replaced every 2-3 days depending on confluence. Upon reaching 75-80% confluency, the cells were released using 15 ml of Trypsin-EDTA (CellGro), after aspiration of the M199 media. After allowing the cells time to round up, M199 with 5% FBS was added to neutralize the trypsin and the detached cells were decanted into a 50 ml conical tube (Fisher). The T-75 flask was rinsed with 5 ml of HBSS, which was also transferred into the 50 ml tube. The cells were then pelleted by centrifugation at 200xg for 8 minutes. The supernatant was then decanted and the HEp-2 cells were resuspended in 5 ml of M199 media. Aliquots of these cells were made and those not intended for immediate use were resuspended in DMSO Cryoprotectant (CellGro) and stored at -80°C overnight, then moved to liquid nitrogen for long-term storage.

**Host Cross-talk Analysis via Corning TransWell System.** Analysis of cross-talk between *B. bacilliformis* infected endothelial (HUVEC) and epithelial (HEp-2) cells, and uninfected endothelial (HUVEC) cells, was done using the Corning TransWell Insert system. Briefly, 24-wells cell culture plates (Corning) were coated with Matrigel™ (BD BioSciences) and after drying 750μl of M199 media was added. The wells were inoculated with 2x10⁶ cell/ml of PBS-washed HUVEC cells (Cambrex) (lower chamber). The HUVEC cells were then allowed to grow at 37°C, 5% CO₂ in a humidified incubator for 24 hours. After 24 hours of incubation unused wells were filled with 1 ml of M199 media, to which a single TransWell Insert was added. Into the TransWell insert chamber 300 μL of M199 media and HUVEC cells (2 x 10⁶ cells/ml) added into the TransWell Insert (upper chamber). The cell culture plates were allowed to incubate for 24 hours at 37°C, 5% CO₂ in a humidified incubator.
B. bacilliformis KC584 were grown and harvested as previously described in Chapter I (page 30). Bacteria were diluted in PBS to a MOI of 100:1 for the infection of upper chamber HUVEC cells. The TransWell inserts were gently removed from their well and placed into the wells containing previously grown HUVEC cells with Matrigel™ (lower chamber), after fresh M199 media was added to both wells and inserts. To the TransWell inserts (upper chamber), 10 µL of previously diluted B. bacilliformis was added and the plate was incubated at 37°C, 5% CO₂ in a humidified incubator. At each time point, photomicrographs were taken of the lower uninfected HUVEC cells for angiogenic potential analysis.

Analysis of cross-talk between infected epithelial (HEp-2) and uninfected (HUVEC) cells was accomplished using similar methods. Again, after HUVEC cells had incubated for 24 hours on Matrigel™, unused wells were filled with 1 ml of M199 media. A single TransWell Insert was added to the well followed by 300 µL of M199 media (upper chamber) and HEp-2 cells (4x10⁵ cells/ml) were added into the TransWell Insert directly (upper chamber). The cell culture plates were allowed to incubate for 24 hours at 37°C, 5% CO₂ in a humidified incubator. Infection and photomicrograph monitoring were carried out as described above, except that HEp-2 cells were infected with B. bacilliformis after 24 hours of growth in the upper chamber.

Separation of B. bacilliformis Membranes. B. bacilliformis inner and outer membranes were separated via sucrose gradient (Minnick, 1994) as follows. Previously harvested B. bacilliformis was prepared in 5 ml of ice-cold 0.2M Tris-1mM MgSO₄ (pH 8.0), and centrifuged at 6000xg for 5 minutes at 4°C. The B. bacilliformis pellet was then re-suspended in 5 ml of 0.2M Tris pH 8.0. The suspension was mixed sequentially with 5 ml of 1M
sucrose in 0.2M Tris (pH8.0), 10 μL of 0.5M EDTA and 75 μL of freshly prepared lysozyme (25mg/ml stock), then incubated on ice for three hours. After the three-hour incubation, 10 ml of ice-cold deionized H₂O was forcefully added to the mixture and the incubation was continued for 30 minutes on ice; then 20 ml of 0.2M dithiothreitol (DTT) was added. To break the cells completely, the mixture was passed through a French press at least twice. Cell debris was removed by centrifuging at 10,000xg for 15 minutes at 4°C. The supernatant was collected into ultracentrifuge tubes and diluted with one volume of deionized H₂O. The supernatant was then centrifuged at 240,000xg for 2 hours at 4°C to isolate the total membrane fraction. The total membrane pellet was re-suspended in 0.5 ml of 20% sucrose-1mM EDTA-2mM DTT. The sample was then layered onto a two-step sucrose gradient of 53%-70% sucrose-1mM EDTA and centrifuged at 160,000xg, for 16-18 hours at 4°C. The inner membrane was isolated between the 20% and 53% interphase and the outer membrane between the 53% and 70% interphase. The two membranes were carefully aspirated and placed in separate ultracentrifuge tubes. The remaining proteins were precipitated from the membrane fractions with four volumes of 5% (wt/vol) trichloroacetic acid for 16 hours at 4°C, and then centrifuged at 16,000xg for 15 minutes. The isolated membranes were re-suspended in 0.2 volume of Laemmli sample buffer (100mM Tris-HCl, pH6.8, 200 mM dithiothreitol, 4% SDS, 0.2% bromophenol blue and 20% glycerol) and stored at -20°C until needed.

**Proliferation and Cytokine Production Analysis of HMEC-1 in the presence of B. bacilliformis Membranes.** HMEC-1 were detached as described previously, and diluted in sterile PBS, pH 7.4, to a concentration of 5x10⁵ cells/ml. 100 μL of the HMEC-1 cell dilution was added to a low-fluorescence 96-well plate(s) (Fisher) containing 100 μL of pre-
warmed M199 (Cambrex) containing 15% FBS and 2% penicillin-streptomycin. The dilution was calculated to provide each well with 50,000 cells total. The 96-well plate was gently shaken to distribute the cells and then incubated at 37°C in 5% CO₂ for 24 hours. After 24 hours’ incubation, the medium was aspirated and replaced with pre-warmed M199 containing 5% FBS. The incubation was continued for 24 hours in the same conditions. For the testing of inner and outer membranes, extracted as described above, 50µL (50mg/ml) of purified inner and outer membranes were added to each well containing growing HMEC-1. Controls were included for each test condition by adding equivalent volumes of sterile PBS, pH 7.4. After incubation for the prescribed time period, the medium was removed and replaced with 50 µL of 1x CyQuant Proliferation mix (Invitrogen), and the cells were allowed to incubate at 37°C, 5% CO₂ for 45 minutes. The 96-well plate was then read using the Typhoon Variable Imaging System (GE/Amersham) set at 600V using the 520-nm blue laser filter. The data were subsequently transferred to the ImageQuant Analysis software (Amersham) and the pixel values were calculated for each well following the 96-well template. Raw pixel data were then transferred to Excel and cell numbers were calculated from a previously prepared HMEC-1 specific standard curve. ELISA analysis was conducted on collected testing media for each time point noted and ELISA analysis was conducted for each cytokine noted. Each ELISA was done with the manufacturer’s standards and completed with a single control media and two experimental media. The plates were read on a SPECTRAmax plate reader (Molecular Devices) at OD₄₀₅. Raw data were collected and correlated to a best-fit of the given cytokine standard per manufacturer’s instructions. Control and experimental data were averaged to give a final result noted in cytokine concentration (pg/ml).
Proliferation Analysis by Infection of HMEC-1 with Live and Dead *B. bacilliformis*.

HMEC-1 were detached as described previously, and diluted in sterile PBS, pH 7.4, to a concentration of 5x10⁵ cells/ml. 100 μL of the HMEC-1 cell dilution was added to a low-fluorescence 96-well plate(s) (Fisher) containing 100 μL of pre-warmed M199 (Cambrex) containing 15% FBS and 2% penicillin-streptomycin. The dilution was calculated to provide each well with 50,000 cells total. The 96-well plate was gently shaken to distribute the cells and then incubated at 37°C in 5% CO₂ for 24 hours. After 24 hours’ incubation, the medium was aspirated and replaced with pre-warmed M199 containing 5% FBS. The incubation was continued for 24 hours in the same conditions. For the testing of live bacteria, *B. bacilliformis* (passage 2-4) was added at a MOI of 100:1, and the cells were washed three times in sterile PBS, pH 7.4. For the testing of dead bacteria, formalin-killed *B. bacilliformis* (passage 2-4) was added at a MOI of 100:1, and the cells were washed three times in sterile PBS, pH 7.4. Negative growth controls were prepared by adding 25-50 μL of sterile PBS, pH 7.4, which had been incubated on BHI plates containing 10% sheep’s blood for eight days at 25°C under conditions of saturated humidity. Controls were included for each test condition by adding equivalent volumes of sterile PBS, pH 7.4. After incubation for the prescribed time period, the medium was removed and replaced with 50 μL of 1x CyQuant Proliferation mix (Invitrogen), and the cells were allowed to incubate at 37°C, 5% CO₂ for 45 minutes. The 96-well plate was then read using the Typhoon Variable Imaging System (GE/Amersham) set at 600V using the 520-nm blue laser filter. The data were subsequently transferred to the ImageQuant Analysis software (Amersham) and the pixel values were calculated for each well following the 96-well template. Raw pixel data were then
transferred to Excel and cell numbers were calculated from a previously prepared HMEC-1 specific standard curve.

**HMEC-1 growth on Matrigel.** Angiogenesis analysis was conducted with HMEC-1 cells grown on Matrigel™ (BD BioSciences). Briefly, HMEC-1 cells were grown in T75 flasks (Starsted) as noted above. Following cell pellet re-suspension in sterile PBS, the cells were counted via hemocytometer and diluted to 1x10^6 cells/ml in sterile PBS. 100 µl of the HMEC-1 dilution was added to each well containing a 1ml mixture of 50% M199 (Cambrex) (15% FBS and 2% penicillin-streptomycin) and 50% EGM-2 (Cambrex), along with 100 µl of pre-warmed, solidified Matrigel™. The cells were then incubated for 24 hours in 5% CO₂ at 37°C. After 24 hours, the medium was aspirated and replaced with pre-warmed M199 with 5% FBS (Cambrex), and the cells were allowed to incubate in 5% CO₂ at 37°C for either 24 hours for “Newly-formed Vessels” or 48 hours for “Pre-formed Vessels,” depending on the testing to be completed.

**Angiogenesis Analysis of HMEC-1 Infection by Live and Dead* B. bacilliformis.**

HMEC-1 were grown as previous stated on Matrigel until “Newly-Formed and Pre-formed Vessels” were present for testing. Live *B. bacilliformis* or formalin-killed *B. bacilliformis*, prepared as described above and diluted in 100 µL of sterile PBS, pH 7.4, to give an MOI of 100:1, were added to each well. At the time of infection (time zero), two randomly chosen areas in each well were marked and microphotographs were taken. At each prescribed time point, the same field of view was photographed again. Once all time points had been captured, the microphotographs were compiled and printed using a color laser printer. Each microphotograph was analyzed for the number of angiogenic nodes, defined as the convergence point of three vessels. These raw data were averaged for each well per time
point in Excel (Microsoft) and graphed as needed. Each of these experiments was completed in triplicate.

**Growth of *B. bacilliformis* for Enhanced GroEL Production.** *B. bacilliformis* KC584 (passage 2) were grown by the inoculation of 100 µL of bacteria stock onto 10 BHI plates supplemented with 10% sheep’s blood and a subsequent incubation at 25°C with saturated humidity for 96 hours. After 96 hours, 15 ml of sterile PBS, pH 7.4, was added to each of the *B. bacilliformis*-containing plates and the plates were incubated at 25°C with saturated humidity for another 96 hours. The *B. bacilliformis* was gently harvested as described above, and the PBS/*B. bacilliformis* mixture was placed in 50-ml (Falcon) tubes. The bacteria were centrifuged at 2000xg for 15 minutes at room temperature and stored at 4°C until needed.

**Crude Purification of *B. bacilliformis* GroEL from Culture Supernatants.** *B. bacilliformis* GroEL was harvested immediately from *B. bacilliformis* culture supernatants. To precipitate the proteins, ammonium sulfate was added to the culture supernatants to give a 50% saturated solution, and the samples were equilibrated for 1 hour at 4°C. The mixture was then centrifuged at 12000xg for 30 minutes. The precipitated proteins were re-suspended in 5 ml of Equilibration Buffer (50mM Tris-HCl, 0.5mM KCl, 0.5mM NaCl, 0.2mM PMSF and 5mM MgCl$_2$, pH 7.5), which was then measured for protein concentration using the Bradford method (Bradford, 1976). The presence of GroEL was determined by SDS-PAGE on a 4-12% Bis-Tris gel (Invitrogen) and Western blot analysis.

**Purification of *B. bacilliformis* GroEL via FPLC.** Crude *B. bacilliformis* GroEL fractions were further purified by FPLC. Briefly, an ATP-agarose column (Kamireddi et al., 1997; Kandekar et al., 1993) was equilibrated with Equilibration Buffer (50mM Tris-HCl, 0.5mM KCl, 0.5mM NaCl, 0.2mM PMSF and 5mM MgCl$_2$, pH 8.2) at a flow rate of 0.2 ml/min for
five column volumes. To the equilibrated column, 1 ml of the crude purification of *B.*

*bacilliformis* culture supernatants was added to the equilibrated ATP-agarose column; and

allowed to re-circulate for 12-16 hours at 4°C at 0.2mL/min. One column volume of

Equilibration Buffer was then allowed to move through the column before the Elution Buffer

(Equilibration Buffer containing 10mM ATP, pH 8.2) was added. Fractions of 2 ml were

collected and these were then subjected to SDS-PAGE to determine whether they contained a

band corresponding in size to that predicted for GroEL (65kDa). All fractions containing *B.*

*bacilliformis* GroEL were then concentrated further using an Amicon 30,000 dalton cutoff

membrane centrifuged for 10 minutes at 5000xg at 4°C. SDS-PAGE and Western blot

analysis were subsequently used to verify the presence and estimate the purity of *B.*

*bacilliformis* GroEL.

**Proliferation Analysis of HMEC-1 Exposed to Purified *B. bacilliformis* GroEL with**

**HMEC-1.** HMEC-1 were grown as previous stated and diluted to 5x10^5 cells/ml in sterile

PBS, pH 7.4. 100 µL of diluted cells were inoculated into each well of the low-flocculence

96 well plate(s) containing 100 µL of pre-warmed M199 (Cambrex) (15% FBS and 2%

penicillin-streptomycin) to a final concentration of 50,000 cells per well. The cells were then

incubated at 37°C and 5% CO₂. After 24 hours, the medium was aspirated and replaced with

100 µL of M199 containing 5% FBS, and the cells were subsequently incubated at 37°C and

5% CO₂. After 6 hours, 10 ng of GroEL was added to each well in a volume of 10 µL, while

10 µL of sterile PBS was added to each control well. Following an incubation for the

prescribed time period, the medium was removed and replaced with 50 µL of 1x CyQuant

Proliferation mix (Invitrogen) and allowed to incubate at 37°C and 5% CO₂ for 45 minutes.

The 96-well plate was then read using the Typhoon Variable Imaging System
(GE/Amersham) set at 600V and using the 520 nm blue laser filter. The data were then transferred to the ImageQuant Analysis software (Amersham) and the pixel values were calculated for each well following a 96-well template. Raw pixel data were then transferred to Excel (Microsoft) and cell numbers were calculated from a previously prepared HMEC-1 specific standard curve.

**Angiogenesis Analysis of HMEC-1 in the Presence of Purified *B. bacilliformis* GroEL.**

HMEC-1 were grown on Matrigel as previously described until “Newly-Formed and Pre-formed Vessels” were present for testing. Ten ng of purified *B. bacilliformis* GroEL was added to each experimental well in 10 µL of sterile PBS, pH 7.4. At the time of infection (time zero) two randomly chosen areas in each well were marked and microphotographs were taken. At each prescribed time point, the same field of view was photographed again. Once all time points had been captured, the microphotographs were compiled and printed using a color laser printer. Each microphotograph was analyzed for the number of angiogenic nodes, defined as the point of convergence of three vessels. The raw data were averaged for each well per time point and graphed as needed.

**Angiogenesis Analysis of HMEC-1 in the Presence of Purified *E. coli* GroEL.**

HMEC-1 were grown and inoculated as previous stated, except that 10 ng of purified *E. coli* GroEL in 10 µL of sterile PBS, pH 7.4, was added to each experimental well. Analysis of angiogenic potential was completed as described above.

**Angiogenesis Analysis of HMEC-1 in the Presence of Purified *B. bacilliformis* GroEL and Rabbit *E. coli* Anti-GroEL antibodies.**

HMEC-1 were grown as previous described on Matrigel until “Newly Formed Vessels” were present for testing. 10 ng of purified *B. bacilliformis* GroEL (in 10 ml of sterile PBS, pH7.4) was added to each experimental well
along with a 1:5000 dilution of Rabbit Anti-\textit{E. coli} GroEL antibodies that had been previously shown to react to purified \textit{B. bacilliformis} GroEL. Analysis of angiogenic potential was completed as described above.

**Analysis of Cytokine Production by ELISA.** Testing for the production of various cytokines was done per the manufacturers’ recommendations. HMEC-1 cells were seeded in 96 well plates at 50,000 cells per well, and grown for 24 hours in pre-warmed EGM-2 media (Cambrex). After 24 hours, the medium was decanted and replaced with pre-warmed M199 containing 5% FBS. After the addition of live \textit{B. bacilliformis}, dead \textit{B. bacilliformis}, or purified \textit{B. bacilliformis} GroEL, testing media were collected and ELISA analysis was conducted for each cytokine noted. Each ELISA was done with the manufacturer’s standards and completed with a single control media and two experimental media. The plates were read on a SPECTRAmax plate reader (Molecular Devices) at OD\textsubscript{405}. Raw data were collected and correlated to a best-fit of the given cytokine standard per manufacturer’s instructions. Control and experimental data were averaged to give a final result noted in cytokine concentration (pg/ml).
Results

Effect of B. bacilliformis during infection of HMEC-1

**HMEC-1 proliferation in the presence of B. bacilliformis.**

HMEC-1 cells were analyzed for the induction of proliferation in the presence of live and formalin-killed *B. bacilliformis* over a period of 48 hours. As shown in Figure 3.1, the initial response by HMEC-1 cells to *B. bacilliformis* is indistinguishable from that of mock-infected control HMEC-1 cells. However, there is a dramatic 5.5-fold increase in HMEC-1 cell number at six hours post infection with live *B. bacilliformis*, with a continued proliferative effect at 12 hours of almost 2.5-fold. This effect is also evident at 24 hours post infection, with a 1.5-fold increase in HMEC-1 infected cells, but drops to less than background levels at 36 hours post infection. Cell proliferation is not seen when HMEC-1 cells are infected with formalin-killed *B. bacilliformis*, as most time points are not significantly different from those seen with mock-infected control cells.
Figure 3.1 – HMEC-1 Proliferation during Infection with B. bacilliformis.
HMEC-1 cells were grown in EGM-2 media for 24 hours, then in M199 with 5% FBS for another 12 hours. Live or formalin-killed *B. bacilliformis*, at an MOI of 100:1, were added to the HMEC-1 cells and proliferation was assessed after various time points using CyQuant (Invitrogen) dye, measured at 520 nm.
HMEC-1 Tubule Formation in the Presence of *B. bacilliformis*.

Infection studies were conducted using HMEC-1 cells grown on Matrigel, an environment that is optimized for tubule formation. HMEC-1 tubules allowed to grow for 48 hours before infection clearly showed a decrease in angiogenic vessels beginning at 24 hours post infection with live *B. bacilliformis*. The maximum effect was observed at 72 and 96 hours, at which time there was nearly a 30-fold difference in nodule formation between the infected and uninfected cultures (Figure 3.2). However, this effect was only observed following infection with live bacteria: the presence of formalin-killed *B. bacilliformis* produced no significant decrease in tubules relative to the uninfected control cells. HMEC-1 cells that were allowed to produce tubules for 24 hours prior to infection showed a slightly decreased response as related to those that were allowed to grow for 48 hours before infection; a decrease in vessel number of approximately 2.5 relative to the control is observed after 72-96 hours (Figure 3.3). Again, the presence of dead *Bartonella bacilliformis* had no overall effect on the angiogenic profile of these HMEC-1 cells.
Figure 3.2 – Pre-formed HMEC-1 Tubule-formation in the presence of B. bacilliformis. HMEC-1 cells were grown on Matrigel in EGM-2 media for 48 hours. The medium was then changed to a low serum medium, M199 with 5% FBS, and the incubation was continued for 12 additional hours before Bartonella was added at a MOI of 100:1. Photomicrographs were taken at the time points noted above and each frame was analyzed for the presence of blood vessel nodules. These were then used as a comparison from Time Point 0 (normalized to 100%).
Figure 3.3 – Newly-formed HMEC-1 Tubule formation in the presence of B. bacilliformis. HMEC-1 cells were grown on Matrigel in EGM-2 medium for 24 hours. The medium was then changed to a low serum media, M199 with 5% FBS, and the incubation was continued for an additional 12 hours before Bartonella was added at a MOI of 100:1. Photomicrographs were taken at the time points noted above and each frame was analyzed for the presence of blood vessel nodules. These were then used as a comparison from Time Point 0 (normalized to 100%).
Analysis of Crosstalk between Infected and Uninfected Endothelial cells.

Cell to cell crosstalk studies were conducted using the Corning TransWell™ system, which allows for the movement of proteins across a membrane but does not allow the crossing of live bacteria from one chamber to the next. Uninfected HUVEC cells were allowed to grow in the lower chamber in a tubule-forming environment for 48 hours before the upper layer of HUVEC cells was infected with *B. bacilliformis* at an MOI of 100:1. Photomicrographs were taken at various time points over the subsequent 48-hour period. While mock infected cells (data not shown) showed no appreciable degradation in tubules formed over the 48 hour monitoring period, a dramatic decrease in tubules was noted after 24 hours of incubation in the lower chamber of uninfected HUVEC cells, which continues through the monitored 48 hours (Figure 3.4). Further cell crosstalk studies were conducted using infected HEp-2 cells, an epithelial cell line, in the top chamber of the Corning transwell system while uninfected HUVEC cells were grown in a tubule-forming environment in the bottom. The photomicrographs reveal that within 8 hours there is a decrease in the number of angiogenic vessels as compared to the previous time points measured (Figure 3.5), while studies with mock infected cells showed no tubule degradation (data not shown). These results indicate that the presence of live *B. bacilliformis* is not required for the degradation of pre-formed tubules during the infection of endothelial and epithelial cells, and suggests instead that a protein or some other soluble factor able to cross the TransWell barrier promotes tubule degradation.
Figure 3.4 – Cross-talk analysis of uninfected HUVEC cells in the presence of infected HUVEC cells.

Cross-talk studies were conducted using the Corning TransWell™ system allowing for the diffusion of small molecules from the upper chamber, which contains *B. bacilliformis*-infected HUVEC cells, to the lower chamber, which contains uninfected HUVEC cells growing in a tubule-forming environment. Photomicrographs were taken at the times noted after addition of *B. bacilliformis* to the upper chamber (MOI 100:1).
Figure 3.5 – Cross-talk analysis of uninfected HUVEC cells in the presence of infected HEp-2 cells.

Cross-talk studies were conducted using the Corning TransWell™ system allowing for the diffusion of small molecules from the upper chamber, which contains *B. bacilliformis*-infected HEp-2 cells to the lower chamber, which contains HUVEC cells growing in a tubule-forming environment. Photomicrographs were taken at the times noted after addition of *B. bacilliformis* to the upper chamber (MOI 100:1).
ELISA Analysis of HMEC-1 Cells in the Presence of *B. bacilliformis*.

ELISA analysis was conducted to determine the production of various cytokines over the course of infection by *B. bacilliformis* of HMEC-1 cells growing in a non-tubule forming environment. Initial studies were conducted with IL-2, IL-6 and TNF-alpha. IL-2 and TNF-alpha showed no overall change from control conditions (Figures 3.6-3.8); however, at 24 hours post infection there was a slight decrease in IL-6 production in infected cells (Figure 3.7). Changes in the production of these cytokines was also monitored after infection with formalin-killed bacteria. Again, there was no statistically significant change in production (figure 3.9-3.11), with the single exception of a three-fold decrease in IL-6 after 36 hours of infection (Figure 3.10).

Further studies were carried out with a larger battery of cytokines. IL-17 production by HMEC-1 infected with live *B. bacilliformis* increased approximately 2.5-fold 48 hours post infection (Figure 3.12). All other cytokines such as IGF-I (data not shown), IL-8 (Figure 3.13) and IL-18 (Figure 3.14) showed no overall change in production during infection with live *B. bacilliformis* as compared with the uninfected control. However, there were significant increases in the production of several cytokines in the presence of formalin-killed bacteria. Infection with formalin-killed *B. bacilliformis* showed an increase of IL-17 production at both six and 48 hours post infection, with a maximum increase of three-fold after 48 hours (Figure 3.12). ELISA analysis of IL-8 production also showed increases at six, 24 and 48 hours, with the largest increase (approximately seven-fold) occurring at 48 hours (Figure 3.13). Finally, the production of IL-18 in the presence of formalin-killed *B. bacilliformis* with HMEC-1 cells showed an increase (relative to the control) of approximately six fold at the 48 hour time point (Figure 3.14). It should be noted that in
nearly all cases formalin-killed *B. bacilliformis* induced cytokine production at a higher rate than live *B. bacilliformis*. 
Figure 3.6 – ELISA analysis of IL-2 production during infection with live *B. bacilliformis*. IL-2 production by HMEC-1 cells was determined by ELISA analysis after the addition of *B. bacilliformis*. HMEC-1 cells were grown for 24 hours in EGM-2. The medium was replaced with M199 with 5% FBS and live *B. bacilliformis* was added at a MOI of 100:1. ELISA was carried out per manufacturer’s instructions using a single control and two experimental media. After the ELISA reaction was complete the 96-well plate was read using a SPECTRAmax plate reader set at 450 nm.
Figure 3.7 – ELISA analysis of IL-6 production during infection with live B. bacilliformis. IL-6 production by HMEC-1 cells was determined by ELISA analysis after the addition of B. bacilliformis. HMEC-1 cells were grown for 24 hours in EGM-2. The medium was replaced with M199 with 5% FBS and live B. bacilliformis was added at a MOI of 100:1. ELISA was carried out per the manufacturer’s instructions using a single control and two experimental media. After the ELISA reaction was complete, the 96-well plate was read using a SPECTRAmax plate reader set at 450 nm.
Figure 3.8 – ELISA analysis of TNFa production during infection with live B. bacilliformis. TNF-α production by HMEC-1 cells was determined by ELISA analysis after the addition of B. bacilliformis. HMEC-1 cells were grown for 24 hours in EGM-2. The medium was replaced with M199 with 5% FBS and live B. bacilliformis was added at a MOI of 100:1. ELISA was carried out per the manufacturer’s instructions using a single control and two experimental media. After the ELISA reaction was complete, the 96-well plate was read using a SPECTRAmax plate reader set at 450 nm.
IL-2 HMEC-1 production was determined by ELISA analysis after the addition of formalin-killed *B. bacilliformis*. HMEC-1 cells were grown for 24 hours in EGM-2. The medium was replaced with M199 with 5% FBS and formalin-killed *B. bacilliformis* was added at a MOI of 100:1. ELISA was carried out per the manufacturer’s instructions using a single control and two experimental media. After the ELISA reaction was complete, the 96-well plate was read using a SPECTRAmax plate reader set at 450 nm.

Figure 3.9 – ELISA analysis of IL-2 production during infection with formalin-killed *B. bacilliformis*.
IL-6 production of HMEC-1 was determined by ELISA analysis after the addition of formalin-killed *B. bacilliformis*. HMEC-1 cells were grown for 24 hours in EGM-2. The medium was replaced with M199 with 5% FBS and formalin-killed *B. bacilliformis* was added at a MOI of 100:1. ELISA was carried out per the manufacturer’s instructions using a single control and two experimental media. After the ELISA reaction was complete, the 96-well plate was read using a SPECTRAmax plate reader at set 450 nm.
Figure 3.11 – ELISA analysis of TNFa production during infection with formalin-killed B. bacilliformis.

TNF-α production was determined by ELISA analysis after the addition of formalin-killed B. bacilliformis. HMEC-1 cells were grown for 24 hours in EGM-2. The medium was replaced with M199 with 5% FBS and formalin-killed B. bacilliformis was added at a MOI of 100:1. ELISA was carried out per the manufacturer’s instructions using a single control and two experimental media. After the ELISA reaction was complete, the 96-well plate was read using a SPECTRAmax plate reader set at 450 nm.
Figure 3.12 – ELISA Analysis of IL-17 Production in the presence of B. bacilliformis.
IL-17 production of HMEC-1 was determined by ELISA analysis after the addition of B. bacilliformis. HMEC-1 cells were grown for 24 hours in EGM-2. The medium was replaced with M199 with 5% FBS and live or formalin-killed B. bacilliformis was added at a MOI of 100:1. ELISA was carried out per the manufacturer’s instructions using a single control and two experimental media. After the ELISA reaction was complete the 96-well plate was read using a SPECTRAmax plate reader set at 450 nm. Analysis was completed based on per cell number data obtained from proliferation assays in the presence of live and formalin-killed B. bacilliformis.
Figure 3.1 – ELISA Analysis of IL-8 Production in the presence of B. bacilliformis.
IL-8 production by HMEC-1 cells was determined by ELISA analysis after the addition of B. bacilliformis. HMEC-1 cells were grown for 24 hours in EGM-2. The medium was replaced with M199 with 5% FBS and live or formalin-killed B. bacilliformis was added at a MOI of 100:1. ELISA was carried out per the manufacturer’s instructions using a single control and two experimental media. After the ELISA reaction was complete the 96-well plate was read using a SPECTRAmax plate reader set at 450 nm. Analysis was completed based on per cell number data obtained from proliferation assays in the presence of live and formalin-killed B. bacilliformis.
Figure 3.14 – ELISA Analysis of IL-18 Production in the presence of *B. bacilliformis*. IL-18 production of HMEC-1 was determined by ELISA analysis after the addition of *B. bacilliformis*. HMEC-1 cells were grown for 24 hours in EGM-2. The medium was replaced with M199 with 5% FBS and live or formalin-killed *B. bacilliformis* was added at a MOI of 100:1. ELISA was carried out per the manufacturer’s instructions using a single control and two experimental media. After the ELISA reaction was complete the 96-well plate was read using a SPECTRAmax plate reader set at 450 nm. Analysis was completed based on per cell number data obtained from proliferation assays in the presence of live and formalin-killed *B. bacilliformis*. 
HMEC-1 proliferation in the presence of *B. bacilliformis* membranes.

HMEC-1 cells were studied for their proliferative response to the presence of inner and outer *B. bacilliformis* membranes. As the data indicate (Figure 3.15), the presence of inner membranes from *B. bacilliformis* induced an increase of approximately 1.5 fold in HMEC-1 cell concentration at both 6 and 36 hours relative to the untreated control cells. In contrast, the presence of *B. bacilliformis* outer membranes caused a four-fold decrease in cell number at 36 hours post infection, with a similar but less dramatic decrease at six hours post infection.
Figure 3.15 – HMEC-1 Proliferation in the presence of *B. bacilliformis* membranes.
HMEC-1 cell proliferation was determined after the addition of *B. bacilliformis* inner (IM) and outer (OM) membranes. HMEC-1 cells were grown in EGM-2 media for 24 hours, then in M199 with 5% FBS for another 12 hours. Purified *B. bacilliformis* membranes, as noted, were added to the HMEC-1 cells and proliferation was assessed after six and 36 hours using CyQuant (Invitrogen) dye, as measured at 520 nm.
ELISA analysis of HMEC-1 cells in the presence of *B. bacilliformis* cellular components

Production of IL-2, IL-6 and TNF-alpha by HMEC-1 cells was measured in the presence of *B. bacilliformis* inner and outer membranes in order to determine the cytokine response of HMEC-1 cells to these bacterial components. As shown in Figure 3.16, IL-2 production in the presence of either inner or outer membrane fractions decreased by approximately 1.5 fold relative to the control at 36 hours post incubation. Analysis of IL-6 production shows an increase at both six and 36 hours in the presence of *B. bacilliformis* outer membranes and at 36 hours in the presence of *B. bacilliformis* inner membranes (Figure 3.17). Finally, TNF-alpha production exhibits an overall decrease at 36 hours in the presence of *B. bacilliformis* outer membranes (Figure 3.18).
IL-2 production by HMEC-1 cells was determined by ELISA analysis after the addition of *B. bacilliformis* inner (IM) and outer (OM) membranes. HMEC-1 cells were grown for 24 hours in EGM-2. The medium was replaced with M199 with 5% FBS and *B. bacilliformis* membranes were added. ELISA was carried out per the manufacturer’s instructions using a single control and two experimental media. After the ELISA reaction was complete the 96-well plate was read using a SPECTRAmax plate reader set at 450 nm.
IL-6 production by HMEC-1 cells was determined by ELISA analysis after the addition of *B. bacilliformis* inner (IM) and outer (OM) membranes. HMEC-1 cells were grown for 24 hours in EGM-2. The medium was replaced with M199 with 5% FBS and *B. bacilliformis* membranes were added. ELISA was carried out per the manufacturer’s instructions using a single control and two experimental media. After the ELISA reaction was complete the 96-well plate was read using a SPECTRAmax plate reader set at 450 nm.
Figure 3.17 – ELISA analysis of TNFα production in the presence of B. bacilliformis membranes.

TNFα production by HMEC-1 cells was determined by ELISA analysis after the addition of B. bacilliformis inner (IM) and outer (OM) membranes. HMEC-1 cells were grown for 24 hours in EGM-2. The medium was replaced with M199 with 5% FBS and B. bacilliformis membranes were added. ELISA was carried out per the manufacturer’s instructions using a single control and two experimental media. After the ELISA reaction was complete the 96-well plate was read using a SPECTRAmax plate reader set at 450 nm.
Analysis of Production of *B. bacilliformis* GroEL.

Recent studies have shown that extracts containing the molecular chaperone GroEL have a proliferative effect on *B. bacilliformis*-infected cells. To determine whether the protein plays a direct role in cell proliferation, we purified GroEL and measured its mitogenic abilities in culture. As a first step, we sought to optimize conditions for the isolation and purification of *B. bacilliformis* GroEL. Initial studies evaluated GroEL production by both *Bartonella bacilliformis* KC584 and *Bartonella bacilliformis* JB584 on BHI (Figure 3.19a) and TSA (Figure 3.19b) agar with a supplement of 10% sheep's blood. After 10 days of growth on BHI agar (Figure 3.19a), the bacteria were physically removed from the plate and concentrated via centrifugation. The re-suspension was then examined using SDS-PAGE and Western blot analysis for bacterial GroEL. After 10 days of growth on solid media, no detectable amount of *Bartonella* GroEL was visualized via SDS-PAGE or Western blot. Further studies were conducted with *B. bacilliformis* KC584 grown on TSA with 10% sheep's blood (Figure 3.19b), and again the bacteria were physically harvested and clarified using centrifugation. GroEL production was monitored at growth days 1, 3, 5, 7 and 10 using SDS-PAGE and Western blot (data not shown). As shown in Figure 3.19, bacterial GroEL was not obtained under these conditions either. Further studies were conducted in liquid media consisting of Schaedler broth supplemented with 10% sheep's blood. *Bartonella bacilliformis* KC584 was evaluated for the secretion of GroEL in this liquid environment over a 10-day time course. At days 1, 3, 5, 7, and 10 the liquid was clarified by centrifugation and the supernatant was subjected to both SDS-PAGE and Western blot analysis (Figure 3.20). These conditions resulted in the identification of a protein migrating at approximately 65 kilodaltons, the size predicted for *B. bacilliformis*
GroEL. The 65-kilodalton protein was observed at high concentrations on both the SDS-PAGE and Western blot starting at growth day four. The SDS-PAGE is further distinguished by a characteristic double banding pattern produced in response to rabbit-produced *E. coli* anti-GroEL antibodies. This additional band has been reported previously with purified GroEL fractions from other *Bartonella* species (Haake *et al.*, 1997), and has been attributed to dimerization of GroEL or the presence of additional proteins bound to GroEL. Further studies were conducted to verify the secretion of GroEL in the presence of both HUVEC cells and HMEC-1 cells, and production of GroEL was evident in both tissue culture environments (data not shown).
Figure 3.19 – SDS & Western blot Analysis of B. bacilliformis Growth on Solid Media.  
**Figure A** - B. bacilliformis KC584 (I) and JB584 (II) were grown on solid BHI and samples taken after 10 days growth, Western blot analysis was done against GroEL using anti-*E. coli* GroEL antibodies.  
**Figure B** - TSA agar (B) supplemented with 10% sheep’s blood over the course of 10 days, with samples of *B. bacilliformis* taken every other day starting at Day 1 post inoculation (growth day indicated above lanes).  SDS-PAGE was conducted on each sample, after clarification, as noted above, and Western blot analysis was completed (data not shown).
B. bacilliformis grown in Schaedler broth with 10% SB

Figure 3.20 – SDS-PAGE and Western Blot Analysis of B. bacilliformis growth in liquid media.

B. bacilliformis was grown in 100 ml bottles of Schaedler broth supplemented with 10% sheep’s blood. Samples were taken, and after sample clarification and RBC lysis with double distilled H₂O each sample was run on SDS-PAGE (lanes indicate growth day 1, 3, 5, 7, 9 & 10). Western blot analysis was completed using rabbit-based E. coli Anti-GroEL antibodies. The arrows indicate the position expected for GroEL (65 kDa) and the position of a possible dimer (145 kDa).
GroEL purification.

Purification of GroEL was carried out on extracts of *Bartonella bacilliformis* KC584 using both ammonium sulfate and ATP-agarose column purification (Figure 3.21 and 3.22). At each step, the presence of an immunoreactive protein with the predicted molecular weight of GroEL (65 KDa) was monitored by SDS-PAGE and Western blot analysis. Western blot analysis (Figure 3.23) was conducted using rabbit-produced *E. coli* anti-GroEL antibodies. Each positive Western blot shows a unique double banding, with immunoreactive proteins migrating at approximately 145kDa and 65kDa. This additional band has been reported previously with purified GroEL fractions from other *Bartonella* species (Haake *et al*., 1997), and has been attributed to GroEL dimerization or the presence of additional proteins bound to GroEL.
Figure 3.21 – SDS-PAGE analysis of *B. bacilliformis* GroEL purification after Ammonium Sulfate Fractionation.

*B. bacilliformis* was grown on BHI with 10% sheep’s blood for 4 days followed by 4 days of growth under PBS, then harvested by scraping. After clarification, the sample was mixed with 50% ammonium sulfate and the proteins were allowed to precipitate. This mixture was then centrifuged and re-suspended in buffer and a sample, shown in lane 2, was run on SDS-PAGE. A Western blot was carried out (not shown) in order to verify the presence of the 65 kDa GroEL protein (indicated by the arrow). The position of a possible dimer migrating at approximately 145 kDa is also shown.
Figure 3.22 – SDS-PAGE Analysis of *B. bacilliformis* GroEL purification after ATP-Agarose elution.

An ATP-agarose column was used to further purify *B. bacilliformis* GroEL, after ammonium sulfate fractionation. The crude fraction believed to contain GroEL was added to the ATP-column and allowed to circulate for 16 hours, then eluted in 10mM ATP containing buffer. The SDS-PAGE gel shows the fractions collected in lanes 2-7. The positions of proteins reacting against anti-*E. coli* GroEL antibodies are indicated by the arrows (65 kDa and 145 kDa).
After ATP-column purification the *B. bacilliformis* GroEL was polished using an Amicon filter, MW Cutoff 30,000 kDa, as per the manufacturer’s instructions. The SDS-PAGE (A) indicates purified GroEL (145kDa and 65kDa), lane 1 shows the protein marker (Bio-Rad, All Blue), and lane 2 shows purified GroEL after Amicon polishing. Western blot analysis (B) indicating the presence of purified GroEL using anti-*E. coli* GroEL antibodies.
Induction of HMEC-1 Proliferation by Purified *Bartonella bacilliformis* GroEL.

Purified *B. bacilliformis* GroEL was evaluated for its ability to induce proliferation of HMEC-1 cells in 96-well plates. After a series of purified *B. bacilliformis* GroEL infection studies were completed to determine the best possible proliferative dilutions (data not shown), a range of 10 ng to 1 ng of purified GroEL was chosen as the optimal conditions for the proliferation studies. Further experiments showed that GroEL at most of these concentrations had no detectable effect on proliferation of HMEC-1 cells that were not in a tubule-forming environment; only 10 ng of GroEL gave any consistent yet weak proliferative effect (data not shown).

**HMEC-1 Tubule Formation in the Presence of purified GroEL.**

Purified *B. bacilliformis* GroEL was incubated with HMEC-1 cells that were allowed to grow in a tubule-forming environment for either 24 or 48 hours prior to GroEL addition. Incubation of cells with 5 ng of purified GroEL produced an overall increase in angiogenesis as compared to controls, with a maximum increase of two fold at 48 hours with 24-hour, “newly-formed” HMEC-1 tubules (data not shown). Studies using 10 ng of purified *Bartonella bacilliformis* GroEL showed a dramatic increase in tubule formation across time points from six to 96 hours (Figure 3.24). This angiogenic effect reached a maximum at 72 hours, where a five-fold increase in angiogenesis as compared to the control was observed. Further studies were conducted to determine the effect of incubating HMEC-1 with both live *B. bacilliformis* (MOI of 100:1) and 10 ng/ml of purified *B. bacilliformis* GroEL. The results of these studies indicate that the presence of *B. bacilliformis* GroEL continues to induce angiogenesis in HMEC-1 cells despite ongoing infection by *B. bacilliformis*. As shown in Figure 3.25, there is a stable increase in angiogenesis seen after 24 hours of infection which
continues throughout the 96 hour monitoring period. This increase in angiogenesis is seen maximally at 48 hours as a two-fold increase relative to mock infected HMEC-1 cells, and continues through the remaining time points. In order to ensure that the angiogenesis seen was induced by *B. bacilliformis* GroEL and not by a minor contaminant of the GroEL protein preparation, a series of control experiments was carried out in which HMEC-1 cells were incubated with *E. coli* anti-GroEL antibodies in the presence of live *B. bacilliformis*, *B. bacilliformis* GroEL, or *E. coli* GroEL (Figures 3.26-3.29). The results indicate that anti-GroEL antibodies significantly reduce the angiogenic effect seen with purified *B. bacilliformis* GroEL; furthermore, they show that neither *E. coli* GroEL nor anti-GroEL antibodies themselves affect angiogenesis in HMEC-1 cells.
Figure 3.24 – HMEC-1 Tubule-formation in the presence of purified *B. bacilliformis* GroEL. Ten ng of purified *B. bacilliformis* GroEL was added to HMEC-1 cells that had been grown for 36 hours in EGM-2 on Matrigel followed by 12 hours’ growth in M199 media containing 5% FBS. Photomicrographs were taken at the time points noted above and each frame was analyzed for the presence of blood vessel nodules. The 0 time points for experimental and control samples were each normalized to 100; subsequent time point values are expressed as a percent of the initial time point.
Figure 3.25 – HMEC-1 Tubule-formation in the presence of Live B. bacilliformis and GroEL. Purified B. bacilliformis GroEL was added to HMEC-1 cells that had B. bacilliformis at an MOI of 100:1 and 10 ng of purified GroEL were added to HMEC-1 cells that had been grown for 36 hours in EGM-2 on Matrigel followed by 12 hours’ growth in a low serum M199 medium containing 5% FBS. Photomicrographs were taken at the time points noted above and each frame was analyzed for the presence of blood vessel nodules. The 0 time points for experimental and control samples were each normalized to 100; subsequent time point values are expressed as a percentage of the initial time point.
Figure 3.26 – HMEC-1 Tubule-formation in the presence of E. coli GroEL Antibodies.
Rabbit-based E. coli Anti-GroEL antibodies (diluted 1:5000) were added to HMEC-1 cells that had been grown for 36 hours in EGM-2 on Matrigel followed by 12 hours in a low serum M199 medium containing 5% FBS. Photomicrographs were taken at the time points noted above and each frame was analyzed for the presence of blood vessel nodules. The 0 time points for experimental and control samples were each normalized to 100; subsequent time point values are expressed as a percent of the initial time point.
Figure 3.27 – HMEC-1 Tubule-formation in the presence of Live *B. bacilliformis* and *E. coli* Anti-GroEL Antibodies. Live *B. bacilliformis* and anti-GroEL antibodies (diluted 1:5000) were added to HMEC-1 cells that had been grown for 36 hours in EGM-2 on Matrigel followed by growth for 12 hours in a low serum M199 medium containing 5% FBS. Photomicrographs were taken at the time points noted above and each frame was analyzed for the presence of blood vessel nodules. The 0 time points for experimental and control samples were each normalized to 100; subsequent time point values are expressed as a percent of the initial time point.
Figure 3.28 – HMEC-1 Tubule-formation in the presence of B. bacilliformis GroEL and E. coli GroEL antibodies.

Purified B. bacilliformis GroEL (10 ng) in the presence of E. coli anti-GroEL antibodies (diluted 1:5000) were added to HMEC-1 cells that had been grown for 36 hours in EGM-2 on Matrigel followed by 12 hours’ growth in a low serum, M199 with 5% FBS, media. Photomicrographs were taken at the time points noted above and each frame was analyzed for the presence of blood vessel nodules. These were then used as a comparison from Time Point 0 to determine the up- or down-regulation of HMEC-1 tubule formation.
Figure 3.29 – HMEC-1 Tubule-formation in the presence of purified E. coli GroEL and E. coli Anti-GroEL antibodies. 
Purified E. coli GroEL (10 ng) and Anti-GroEL antibodies (diluted 1:5000) were added to HMEC-1 cells that had been grown for 36 hours in EGM-2 on Matrigel followed by 12 hours’ growth in a low serum M199 medium containing 5% FBS. Photomicrographs were taken at the time points noted above and each frame was analyzed for the presence of blood vessel nodules. The 0 time points for experimental and control samples were each normalized to 100; subsequent time point values are expressed as a percent of the initial time point.
ELISA Analysis of HMEC-1 cells in the Presence of Purified *B. bacilliformis* GroEL.

ELISA analysis was carried out to determine the production of various cytokines by HMEC-1 after incubation with 10 ng GroEL in a tubule-forming environment. Overall, cytokine production of IL-2 and IL-6 showed a general increase relative to the control, while IL-8, IL-17 and IL-18 showed little to no change. Specifically, IL-2 induction was seen after 24 hours, with a seven-fold increase in IL-2 production over that of the mock incubated HMEC-1 (Figure 3.30). Unlike IL-2, IL-6 production showed an overall increase at all measured time points, with the greatest increase (10-fold) noted at six hours (Figure 3.31). Production of IL-8 showed a slight decrease relative to the control at all measured time points, but none of statistical significance (Figure 3.32). IL-17 cytokine production (Figure 3.33) exhibited almost no change from control values. Production of IL-18 showed a slight increase at 12 hours post incubation while other time points showed little change (Figure 3.34).
Figure 3.30 – ELISA Analysis of IL-2 production in the presence of B. bacilliformis GroEL. HMEC-1 cells were grown on Matrigel for 24 hours in EGM-2; then the media was replaced with M199 containing 5% FBS and 10 ng of purified B. bacilliformis GroEL was added. ELISA was carried out per the manufacturer’s instructions using a single control and two experimental media. After the ELISA reaction was complete, the 96-well plate was read using a SPECTRAmax plate reader set at 450 nm.
Figure 3.31 – ELISA Analysis of IL-6 production in the presence of B. bacilliformis GroEL. HMEC-1 cells were grown on Matrigel for 24 hours in EGM-2; the media was then replaced with M199 containing 5% FBS and 10 ng of purified *B. bacilliformis* GroEL was added. ELISA was carried out per the manufacturer’s instructions using a single control and two experimental media. After the ELISA reaction was complete, the 96-well plate was read using a SPECTRAmax plate reader set at 450 nm.
Figure 3.32 – ELISA Analysis of IL-8 production in the presence of *B. bacilliformis* GroEL. HMEC-1 cells were grown on Matrigel for 24 hours in EGM-2; the medium was then replaced with M199 containing 5% FBS and 10 ng of purified *B. bacilliformis* GroEL was added. ELISA was carried out per the manufacturer’s instructions using a single control and two experimental media. After the ELISA reaction was complete, the 96-well plate was read using a SPECTRAmax plate reader set at 450 nm.
Figure 3.33 – ELISA Analysis of IL-17 production in the presence of B. bacilliformis GroEL. HMEC-1 cells were grown on Matrigel for 24 hours in EGM-2; the medium was then was replaced with M199 containing 5% FBS and 10 ng of purified B. bacilliformis GroEL was added. ELISA was carried out per the manufacturer’s instructions using a single control and two experimental media. After the ELISA reaction was complete, the 96-well plate was read using a SPECTRAmax plate reader set at 450 nm.
Figure 3.34 – ELISA Analysis of IL-18 production in the presence of *B. bacilliformis* GroEL. HMEC-1 cells were grown on Matrigel for 24 hours in EGM-2; the medium was then replaced with M199 containing 5% FBS and 10 ng of purified *B. bacilliformis* GroEL was added. ELISA was carried out per the manufacturer’s instructions using a single control and two experimental media. After the ELISA reaction was complete, the 96-well plate was read using a SPECTRAmax plate reader set at 450 nm.
Motif analysis of *Bartonella bacilliformis* KC584 GroEL.

DNA and protein sequence analyses were conducted on *B. bacilliformis* KC583 GroEL (Accession YP989430) in order to search for any unique motifs that may be present in this protein. DNA sequence analysis using Vector NTI AlignX (Invitrogen) was conducted to compare the GroEL open reading frame deduced from the published *B. bacilliformis* KC583 with those of other bacterial species, as well as those coding for GroEL proteins and homologues implicated in disease and immunosuppression (Table 3.1). *B. bacilliformis* GroEL DNA shares high sequence identity to the GroEL open reading frames of *B. henselae* (85.0%), *B. quintana str Toulouse* (84.7%) and a lower 45.5% identity to that of *B. tribocorum* GroEL, with a similar degree of identity to homologues of other *Bartonella* species and other members of the α-2 Proteobacteria family (data not shown). Comparison of the gene encoding *B. bacilliformis* GroEL to bacterial DNA sequence(s) from other genera shows high individual identity, with the highest being *B. abortus* (72.5%), followed by *E. coli* K12 and *M. loti*, with 65.8% and 65.7% identity, respectively. The degree of identity between DNA sequences coding for *B. bacilliformis* GroEL and GroEL proteins implicated in disease states from 34% to 63.1%, with Human HSP70 and *C. trachomatis* GroEL exhibiting the lowest and highest level of identity, respectively. Finally, a comparison of *B. bacilliformis* GroEL DNA sequences of eukaryotic GroEL homologues exhibited little or no sequence identity above random background, with the possible exception of Mouse HSP60.

Comparison of the predicted amino acid sequences of the GroEL open reading frames reveals a high degree of identity, as well as functional similarity. Within the genus *Bartonella*, the identity exceeded 90% for all species tested. When protein homology was determined between *B. bacilliformis* and other common bacterial GroELs there was an 88.4%
similarity between all sequences noted with the highest similarity to *B. abortus* (92.5%). As with the DNA sequence comparisons, amino acid identity and functional similarity between *B. bacilliformis* and disease implicated GroEL species are lower (ranging from 20.2% to 79.6%) and the comparison with two of the three immunosuppressive GroEL proteins reveals no significant identity or similarity. The very low identity within this grouping is not unexpected as these proteins are derived from eukaryotic sources.

Motif analysis (MotifScan) indicates that the *B. bacilliformis* GroEL amino acid sequence contains an unusual sequence of amino acids at position 466-492. This sequence, termed the staphylocoagulase binding motif, is found in several strains of *Staphylococcus aureus* (Figure 3.35) and is known to be able to form complexes with prothrombin (Kawabata *et al.*, 1985). Interestingly, the GroEL proteins from *B. henselae* and *B. quintana* also contain a similar staphylocoagulase motif site, with each differing from the *B. bacilliformis* protein at five positions (Figure 3.35). Motif-based searches of other human, α-2-proteobacterial and infective bacterial GroEL proteins do not reveal other organisms that share this unique staphylocoagulase-binding site.

In order to determine the hydrophobicity and antigenicity of the *B. bacilliformis* GroEL protein, a series of Kyte/Doolittle and Hopp/Woods plots were prepared based on the published *B. bacilliformis* KC583 GroEL DNA sequence. Examination of the Kyte/Doolittle hydrophobicity plot indicates that *B. bacilliformis* GroEL is hydrophilic overall, which is expected of a cytosolic/extracellular protein (Figure 3.36). The Hopp/Woods antigenicity plot of *B. bacilliformis* GroEL indicates that there are several acceptable epitope sites for antibody production; the highest scores are observed for sites between amino acids 350-435, a region located at a distance from the Staphylocoagulase-binding site motif. Further
Kyte/Doolittle hydrophobicity analysis reveals that amino acids between 468 and 485 are weakly scored as being buried inside the GroEL globular protein structure, while amino acids 486-500 are predicted to be on the outer surface of the protein (Figure 3.37). A detailed Hopp/Woods antigenicity analysis of amino acids 460-500 indicates a mix of weak epitope sites. This analysis shows amino acids 467-475 to be predicted epitope sites, whereas 475-495 are unlikely to be epitopes.
Table 3.1 - *B. bacilliformis* GroEL DNA and Protein Sequence Homology to Bacterial GroELs/Eukaryotic HSP Homologues.

DNA and protein sequence homology analysis was completed via AlignX (Vector NTI) between common bacterial GroEL proteins, GroEL-implicated disease factors and GroEL homologues with known immunosuppressant roles in disease.

<table>
<thead>
<tr>
<th></th>
<th>DNA Sequence</th>
<th>Protein Sequence</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>Identity</td>
<td>Identity</td>
</tr>
<tr>
<td><strong>Bartonella GroEL Homologues</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td><em>B. henselae</em></td>
<td>85.0%</td>
<td>91.6%</td>
</tr>
<tr>
<td><em>B. quintana str Toulouse</em></td>
<td>84.7%</td>
<td>91.4%</td>
</tr>
<tr>
<td><em>B. tribocorum</em></td>
<td>45.5%</td>
<td>90.9%</td>
</tr>
<tr>
<td><strong>GroEL Homologues of Other Bacteria</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td><em>M. loti</em></td>
<td>65.7%</td>
<td>78.3%</td>
</tr>
<tr>
<td><em>R. Prowazekii</em></td>
<td>64.5%</td>
<td>64.9%</td>
</tr>
<tr>
<td><em>E. coli K12</em></td>
<td>65.8%</td>
<td>65.8%</td>
</tr>
<tr>
<td><em>R. typhi</em></td>
<td>64.9%</td>
<td>64.9%</td>
</tr>
<tr>
<td><em>H. pylori</em></td>
<td>60.7%</td>
<td>61.6%</td>
</tr>
<tr>
<td><em>M. pneumonia</em></td>
<td>54.1%</td>
<td>44.3%</td>
</tr>
<tr>
<td><em>B. abortis</em></td>
<td>72.5%</td>
<td>85.5%</td>
</tr>
<tr>
<td><strong>GroEL-Implicated Disease Factor</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td><em>C. trachomatis</em></td>
<td>63.1%</td>
<td>61.9%</td>
</tr>
<tr>
<td><em>P. gingivalis</em></td>
<td>61.7%</td>
<td>65.1%</td>
</tr>
<tr>
<td>Human HSP60</td>
<td>57.9%</td>
<td>51.7%</td>
</tr>
<tr>
<td>Human HSP70</td>
<td>34.0%</td>
<td>11.4%</td>
</tr>
<tr>
<td><strong>GroEL-Homologues with Known Immunosuppressant Roles</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Rat HSP60</td>
<td>19.0%</td>
<td>7.3%</td>
</tr>
<tr>
<td>Human HSP10</td>
<td>10.0%</td>
<td>3.1%</td>
</tr>
<tr>
<td>Mouse HSP60</td>
<td>57.4%</td>
<td>51.7%</td>
</tr>
</tbody>
</table>
Figure 3.35 – Analysis of a possible staphylocoagulase motif site in *B. bacilliformis* GroEL. AlignX (Invitrogen) was used to conduct a protein sequence-based alignment of the known GroEL sequences for various *Bartonella* species, including *B. henselae* (BH), *B. quintana* Toulouse (BQT) and *B. bacilliformis* (BB). This view of amino acids 451-500, shows the predicted staphylocoagulase binding site of *B. bacilliformis* in red, with the unique amino acid residues as compared to the other *Bartonella* species noted in blue. The remainder of the protein sequence alignment can be found in Appendix I.
Figure 3.36 – Hydrophilicity and antigenicity plots for *B. bacilliformis* GroEL. Panel A & B above represent the hydrophilicity (A) and antigenicity (B) of the *B. bacilliformis* GroEL protein as conducted via MacVector 9.5. The *B. bacilliformis* GroEL protein sequence was used to complete both the Kyte/Doolittle (hydrophilicity) and Hopp/Woods (antigenicity) plots using an analysis window of 7.
Figure 3.37 – Hydrophilicity & antigenicity plots for aa 460-500 of *B. bacilliformis* GroEL. Panels A and B above represent the hydrophilicity (A) and antigenicity (B) of the approximate location of the established Staphylocoagulase binding-site motif of *B. bacilliformis* GroEL protein as conducted via MacVector 9.5. The *B. bacilliformis* GroEL protein sequence from amino acid 460-500 was used to complete both the Kyte/Doolittle (Hydrophilicity) and Hopp/Woods (Antigenicity) plots using an analysis window of 7.
Discussion

Carrion’s disease, the infection caused by *B. bacilliformis*, is marked in the latter phase by the formation of verruga, which are known to be proliferative lesions brought about by cutaneous uncontrolled angiogenesis. These lesions form after the migration of *B. bacilliformis* from host RBCs to the endothelial cells lining blood vessels and the subsequent invasion of these cells. Several studies have reported results implicating *B. bacilliformis* supernatants and possible secreted factors in verruga formation, although none have yet presented a cohesive model for how this could occur (Garcia *et al.*, 1992; Minnick *et al.*, 2003; Smitherman *et al.*, 2005). In this study we attempt to identify the role played by *B. bacilliformis* and the highly antigenic BB65 protein, which has been previously determined to be a potential virulence factor and has been tentatively identified as a GroEL homologue (Garcia *et al.*, 1990; Knobloch, 1988; Knobloch *et al.*, 1990).

Inoculation of HMEC-1 cells with live *B. bacilliformis* resulted in a significant, though transient, increase in cell number (relative to the mock infected control) at 6 and 12 hours post infection. These results are very similar to what has been noted previously by Liberto *et al.* (2004) in their studies of *B. quintana*. These investigators reported that between 8 and 24 hours post infection of HMEC-1 cells with *B. quintana*, p38 map kinase and JNK/SAPK signaling is inhibited, resulting in the induction of anti-apoptotic factors and an increase in cell proliferation due to the decrease in host cell apoptosis (Liberto *et al.*, 2004). Our data suggest that this effect may also be in play during *B. bacilliformis* infection. The transient nature of the cell proliferation observed in our studies may be due to the production of cells that are unable to attach properly and therefore become free-floating; since HMEC-1 require polarity to live, these free-floating cells would subsequently die.
Also, it should be noted that we only observed proliferation in the presence of live \textit{B. bacilliformis}, but not with formalin-killed bacteria. This could indicate that not only are live bacteria required but also that they are producing a factor(s) that is inducing proliferation in HMEC-1 cells. Research with \textit{B. henselae} suggests that the presence of the bacteria in co-culture with HUVEC cells is all that is required for the cells to proliferate as long as the bacteria are alive; direct cell-to-bacteria contact is not required. \textit{B. quintana} have been shown to increase the production of the anti-apoptotic factor Bcl-2 at approximately 10 hours post infection. The resulting cell survival would have a positive effect on \textit{B. quintana} infection as well, since it would provide a larger number of host cells able to support bacterial growth (Liberto \textit{et al.}, 2004).

\textbf{Cytokine Production in the Presence of \textit{Bartonella bacilliformis}}

In order to assess the effect of \textit{B. bacilliformis} infection on the cytokine profile of HMEC-1 cells these host cells were infected with both live and formalin-killed \textit{B. bacilliformis} and monitored for alterations in the cytokine production. Infection with live \textit{B. bacilliformis} resulted in little or no change in IL-2, IL-6, or TNF alpha cytokine production. IL-17 production, on the other hand, was increased by three fold during the time course. This increase in IL-17 production could indicate the initiation of an angiogenesis cascade that, due to the lack of proper environmental signals, was not completed. Interestingly, we did not observe an increase in IL-8 or IL-18 production from the HMEC-1 cells during incubation with \textit{B. bacilliformis}. This observation contrasts with that of Resto-Ruiz, \textit{et al.} (2002), who reported an increase in IL-8 production by HMEC-1 cells following 6 hours of incubation with \textit{B. henselae}.

Our data suggest that formalin-killed \textit{B. bacilliformis} is generally able to induce a
higher cytokine response than live *B. bacilliformis*, exhibiting an increase in IL-6, IL-8, IL-17 and IL-18 evident between 36 and 48 hours of incubation. This may be due to increased persistence of the killed bacteria in the extracellular environment.

Incubation of HMEC-1 cells with isolated membranes of *B. bacilliformis* generated results that correlate more closely with those reported for other *Bartonella* species than the results we observed with live bacteria. Incubation with fractionated inner or outer membranes produced an increase of IL-6 production at the 6- and 36-hour time points. This increase has also been seen with *B. henselae* during macrophage infection, and with *B. quintana* infection of HUVECs (Capo et al., 2003; Musso et al., 2001). Also, we note a decrease in the overall production of TNF alpha in the presence of *B. bacilliformis* outer membranes, seen maximally at 36 hours. This could indicate that, much like *B. quintana*, the LPS of *B. bacilliformis* is a poor inducer of inflammatory responses normally observed with other Gram-negative bacteria (Liberto et al., 2003).

The addition of membrane components also had a demonstrable effect on the number of HMEC-1 cells in culture. Inner membranes caused a slight (approximately 1.5 fold) increase in cell number relative to the mock infected control after both 6 and 36 hours of incubation. Conversely, outer membranes produced a four-fold decrease in cell number after 36 hours. These results raise the possibility that *B. bacilliformis* outer membranes contain a factor(s) that negatively affects cell proliferation or viability.

**B. bacilliformis Infection and Angiogenesis**

Our results indicate that *B. bacilliformis* not only affects cell number, but also promotes changes in the blood vessels that are the hallmark of angiogenesis. Live *B. bacilliformis* was found to have a significant effect on the stability of tubules formed by
endothelial cells, causing a 30-fold decrease in pre-formed tubules (relative to mock infected controls) over a 96 hour time period. These data would appear to suggest that live B. bacilliformis causes a decrease in angiogenesis, a finding that would conflict with the clinical observations of increased angiogenesis during B. bacilliformis induced verruga peruana formation. The degradation of tubules could be advantageous at early stages of infection as it would increase the localized environment of red blood cells, thus allowing for a higher concentration of hemin in the localized environment and providing an additional nutritional source for the infecting bacteria. Previous work by Verma et al. (2000) has shown that B. bacilliformis is able to induce cytoskeletal rearrangement and therefore disrupts cell-to-cell contacts. Their research also suggests that endothelial cell motility is decreased by B. bacilliformis infection. This decrease in motility could therefore interfere with the endothelial cells’ ability to form tubules, causing them to be unable to take part in further angiogenesis (Verma et al., 2001; Verma et al., 2000; Verma et al., 2002). The degradative effect on preexisting tubules, or the effect of infection itself, may also establish conditions that promote a response by the cells that ultimately leads to new blood vessel formation. It is interesting to note that the expression of genes coding for two subunits of hypoxia induced growth factor (HIF), a protein that has been shown to promote angiogenesis, are significantly upregulated following B. bacilliformis infection (Chapter II). Taken together, these processes could result in the poorly formed blood vessels characteristic of verruga peruana.

**Crosstalk analysis and angiogenesis**

Our work with cell-signaling involved studies with both endothelial and epithelial cell lines (HUVEC and HEp-2, respectively) using the Corning TransWell™ System. This system allows for the movement of proteins, but not bacteria, from the infected to uninfected
chamber, thus facilitating the analysis of cell signaling molecules. Our data suggests that components produced by infected endothelial or epithelial cells are able to decrease the numbers of established tubules formed by uninfected HUVEC within approximately 24 hours of exposure. These data suggest that the infection by *B. bacilliformis* can result in an alteration of the angiogenic profile of cells which are uninfected, and raise the possibility that cell-signaling events are occurring between infected and uninfected cells. This would not be surprising as work with endothelial cells has suggested that the induction of cytokines and the inflammatory response of cells can result in vascular injury of uninfected endothelial cells over time (Waltenberger et al., 1999). Several other studies with *B. henselae* have suggested that macrophages are called into sites of infection and act as effector cells on both infected and uninfected endothelial cells to induce angiogenesis (Dehio, 1999; Dehio, 2003; McCord et al., 2005; Resto-Ruiz et al., 2002). The results of our cell-signaling and cytokine studies raise the possibility that the cytokines which are produced are allowing for the infiltration of macrophages into the *B. bacilliformis*-infected area and that these effector cells might also be altering the angiogenic profile of endothelial cells in the localized environment.

**The Role of GroEL in Angiogenesis**

The search for angiogenic and other virulence factors produced by *B. bacilliformis* has been ongoing for several years. Research in this area was initiated by Garcia *et al.* (1990), who reported that *B. bacilliformis* produces a factor between 12 and 14 kilodaltons that is able to stimulate tissue plasminogen activator (t-PA), a thrombolytic protein implicated in angiogenesis. Using immunoprecipitation, Knobloch *et al.* (1990) identified 24 antigens produced by *B. bacilliformis*, including Bb65, a highly immunogenic protein that is now believed to be a homologue of GroEL.
Classically GroEL, a molecular chaperone, is not considered a virulence factor in most bacteria. Subsequent work, however, led to the proposal that GroEL may enhance the virulence of numerous bacteria, including *H. pylori* (Phadnis *et al.*, 1996), *M. tuberculosis* (Ranford *et al.*, 2002), and *L. pneumophila* (Garduno *et al.*, 1998). Recently, *B. bacilliformis* has been added to the list of bacteria that may use GroEL as a virulence factor. In 2003, Minnick and coworkers reported the identification of a mitogenic and/or angiogenic factor produced by *B. bacilliformis* (Minnick *et al.*, 2003). The factor was found to be unaffected by polymyxin B, indicating that it is not related to LPS, and was also shown to be heat and trypsin sensitive, suggesting a proteinaceous nature. Further investigation by Minnick *et al.* (2003) led to the proposal that this angiogenic factor is GroEL, based primarily on their findings that a) a GroEL over-producing strain of *B. bacilliformis* enhances endothelial cell growth by 6-20 fold and b) cell proliferation is inhibited by anti-GroEL antibodies. Our results with purified *B. bacilliformis* GroEL are in agreement with Minnick’s observations. Although we did not observe a direct proliferative effect on cell proliferation, we found that addition of GroEL to endothelial cells stimulates the formation of the tubules that are characteristic of angiogenesis. Moreover, this effect is abolished by the presence of anti-GroEL antibodies, again implicating GroEL directly in the angiogenesis process. Unlike our previous observations, where the addition of live *B. bacilliformis* led to tubule degradation, exposure of cells to the bacteria in the presence of purified GroEL, actually increases angiogenesis. This suggests that not only does GroEL play a role in angiogenesis but it is actually protective against the effects of live *B. bacilliformis* infection on the angiogenic process. The angiogenic effect was not observed with *E. coli* GroEL, suggesting that it is due to amino acids unique to the *B. bacilliformis* homologue.
DNA and protein analysis of *B. bacilliformis* GroEL suggests a high homology to other *Bartonella* species GroEL, as would be expected since bacterial GroEL proteins are highly conserved. Interestingly, motif analysis reveals suggests a staphylocoagulase binding site between amino acids at positions 466-496. Hydrophobicity and antigenicity plots suggest that this unique motif site is present on the outer surface of the *B. bacilliformis* GroEL and is therefore expose the localized environment. The staphylocoagulase binding site may play a role in the binding of prothrombin to the surface of the *B. bacilliformis* GroEL. Given the repetitive nature of the GroEL subunits which make up the GroEL structure, a maximum of 14 staphylocoagulase sites could be exposed for prothrombin binding. This may produce *in vivo a B. bacilliformis* GroEL that is covered with prothrombin in the interstitial environment. Studies have shown the role of prothrombin to be vast. Prothrombin has been reported to interact directly with α5β3 integrin, one of a set of cell surface receptors that have been implicated in adherence and invasion by pathogenic bacteria. Prothrombin was shown to bind to the α5β3 integrin through the tripeptide RGD, a motif that is recognized by integrins. The binding of prothrombin to the integrin is reported to support increased adhesion of stimulated endothelial cells and smooth muscle, both in suspension and cell monolayers. This activity is mediated by the protein kinase C and calpain signaling pathways, as inhibition of those molecules prevented increased adhesion. The authors of this study suggest that the maintenance of vascular homeostasis may be related to the presence of prothrombin in limited quantities (Byzova *et al.*, 1998). Further studies indicate that the binding and activate of α5β3 integrin to higher concentrations of localized prothrombin may result in a proliferation and focal adhesion formation effect on smooth muscle cells due to the activation of JUN kinase-1 (Byzova *et al.*, 1998; Stouffer *et
Thrombin has also been shown to interact with the PAF-1 receptor to induce endothelial cell tube formation \textit{in vitro} and to increase bFGF-induced angiogenesis \textit{in vivo} (Rhim \textit{et al.}, 1998). Taken together, the extracellular localized increase of prothrombin due to its binding of \textit{B. bacilliformis} GroEL could lead to the activation of integrin signaling pathways which in turn could activate the angiogenesis cascade. In the case of \textit{B. bacilliformis} infected endothelial cells, however, the activation and angiogenic cycle of these cells may be compromised by the volatile nature of extracellular protein degradation and a general limitation on prothrombin availability. These limits could then manifest themselves as the poorly formed and highly porous vessels seen in patients exhibiting verruga peruana.

To date there is no evidence for a staphylocoagulase binding site in GroEL homologues from organisms other than \textit{Bartonella}. The binding site seen in other \textit{Bartonella} GroEL proteins differs by five amino acids from that of \textit{B. bacilliformis}. Further studies will need to be conducted to determine whether the staphylocoagulase motif plays a role in stimulating either the cell proliferation or angiogenesis.

Tests of \textit{B. bacilliformis} purified GroEL for its ability to induce a change in the cytokine profile in HMEC-1 cells revealed an IL-2 and IL-6 increase between six and 24 hours of incubation with a maximal increase for IL-2 and IL-6 of five fold at 24 hours. The secretion of these cytokines may be the host cells’ initial response to invasion and would bring about the infiltration of macrophages and other immune cells in order to begin fighting off the \textit{Bartonella} infection. These cytokines are also known to prime endothelial cells to begin the angiogenesis cascade as other environmental signals become present. Interestingly, there was an overall decrease in IL-8 production, the hallmark of angiogenesis, which may indicate that IL-8 production is not necessary for the induction of angiogenesis in the
formation of verruga peruana. This could be an interesting differentiation between the infective profile of *B. bacilliformis* versus that of *B. henselae*, which has been shown to increase IL-8 production in HUVEC cells (McCord *et al.*, 2007). It is not uncommon for various bacterial GroEL proteins to induce cytokine changes; incubation of *E. coli* GroEL with monocytes shows increased IL-1β and IL-6 production even under circumstances when the *E. coli* GroEL has been partially degraded (Tabona *et al.*, 1998). Work by Galdiero *et al.* (1997) shows the increased production by monocytes of GM-CSF, IL-6, E-selectin, ICAM-1 and VCAM-1 in the presence of *E. coli* HSP60. This increase in ICAM-1 and VCAM-1 on the outer surface of monocytes allows for migration by the cells into various regions and increases the likelihood of cell-to-cell contact (Galdiero *et al.*, 1997). If this characteristic is also shared by *B. bacilliformis* GroEL, then it could also prime endothelial cells for migration resulting in the production of tubules.

In conclusion, the localized environment of *B. bacilliformis* infected endothelial or epithelial cells is likely to contain a mix of signals. We have shown cytokine induction under conditions of exposure to bacteria or to GroEL that would be expected not only to aid in the activation and priming of endothelial cells toward angiogenesis, but also to induce the infiltration of effector macrophages. This in turn should produce a barrage of cytokines including IL-8, the primary angiogenesis signal with probable VEGF involvement. This along with the tubule-destructive nature of live *B. bacilliformis* should result in endothelial cell proliferation and reduced endothelial cell migration, leading to poorly-formed and degrading tubules. However, the addition of localized high concentrations of secreted *B. bacilliformis* GroEL with its unique staphylocoagulase binding site, may activate α5β3 integrins, resulting in a boost to the angiogenic signaling in the localized environment. This
may be the true hallmark of *B. bacilliformis* induced verruga peruana formation. The infective cycle, which would result in host cell proliferation, infiltration of hemin and other nutrients, would support the continued growth, invasion and immune evasion of *B. bacilliformis* and give rise to the formation of verruga peruana in those with Carrion’s disease.
Concluding Remarks: A model for the formation of Verruga Peruana

The interaction of any bacteria with its host results in a variety of changes for both organisms. The purpose of this project was to determine what role *B. bacilliformis* plays in the formation of verruga peruana during Carrion’s disease. The data presented in Chapter II and Chapter III provide the basis for our model of verruga peruana formation. According to this model, once *B. bacilliformis* exits the RBCs it will migrate to and infect the endothelial cells lining the subcutaneous capillary beds. The invasion of *B. bacilliformis* into the endothelial cells and surrounding areas occurs within 30 minutes to 2 hours post-infection followed by a rapid proliferation of endothelial cells at 6 hours post-infection. These new endothelial cells provide an excellent location for the surrounding *B. bacilliformis* to hide from the migrating effector macrophages. As infection progresses, active macrophages in the area are able to kill some interstitial *B. bacilliformis*, resulting the presence of *B. bacilliformis* membranes and whole dead *B. bacilliformis* in the localized environment. We have found that the presence of these bacterial components and whole dead bacteria induces the production of IL-6, IL-8, IL-17 and IL-18 cytokines from neighboring endothelial cells. While the release of IL-6 can result in the increased migration of effector macrophages, the other cytokines present are proangiogenic and able to prime endothelial cells into the angiogenesis cascade. Also, during this time, infected cells increase transcription of proangiogenic factors such as VEGF and hypoxia factors HIF1α and HIF2α. These factors further prime endothelial cells to begin angiogenesis and increase localized tubule formation. We have noted the degradation of pre-formed tubules by the presence of live *B. bacilliformis* as infection continues, which could allow for greater numbers of host RBCs, hemin and serum components to enter the infected interstitial spaces. Each of these components could
contribute to bacterial growth and survival. Finally, our data show that infected endothelial cells begin to transcribe greater quantities of HIF3α, which may aid in localized tubule degradation. The persistent infection of B. bacilliformis may result in an increased localized concentration of its unique, secreted GroEL. This GroEL has been shown to stabilize and maintain tubule formation, and in some instances increase angiogenesis. As infection moves from hours to days, the localized environment would be flooded with proangiogenic cytokines and proteins, which along with the presence of a prothrombin-coated GroEL may continue to push angiogenesis forward, resulting in the formation of incomplete, damaged tubules. These would be unable to support proper blood flow, allowing the migration of host RBCs into the area of infection and the formation of verruga.
Bibliography


of the MutT Motif Family and Has Homologs in Other Invasive Bacteria." Biochemical and Biophysical Research Communications 256: 474-479.


Lipoprotein of *Bartonella bacilliformis* that has Homology to NlpD/LppB." *Infection and Immunity* 68(9): 4972-4979.


secretion substrates of *Bartonella henselae* into human cells." PNAS 102(3): 856-861.


Appendix
AP.1 - Bartonella quintana - virB Operon Sequence

1  TTTAAACCCA AAAATGACAG AGACTATATC CAGAAATATT
41  ATTTTTATCG TTATCGTGCT GCTGTAAACA GCACCTTGTTG
81  TATCAAATCC CTCTTATGCT GCAGAATAGT GTAGTAGTCT
121  GGGAAACGTT GATAGTGTTT TACAGATAAT TGTTACGATG
161  ATGACGGGGGA CAACAGCAAA GCTGATTGCA ATTATATGTTG
201  TTGCAGCTGT GGGCATTGGT TGGATGTCCG GCTTTATTGA
241  TTTAGCAAAA GCGCTTTATT GATCTCGGG CATTGGGATT
281  GTTTTTGTGG CCCCACTCT TGTTAGTACA TTATGGGCT
321  CATCATAATG GAATCAGAGAT ACTCTTTTTCC TGCCCTGAC
361  GCGACCAGCT ACCTTGGCACG TGTCACAAT GGAAGGAATG
401  GCCCTTAATG TCATGGCGAC ATCAATATGC
441  CCAGCGAATG TCAGATATG TCATGCGTGCA ATTATATGTTG
481  CTCTTATTTTGGTGCA AAACATACGA CCACACTCCG
521  TTTCCGGTAG TATTGGCTTG GCTCAACATA TCATTATATTCC
561  AAAAACACT CACAGATGG GGAAGGAATG CTACATCTCC
601  CCTACGCTTAT ATGCTACTGG TGGGGGATTA GACACATGTTG
641  CAATATAGAA ACCTTGGCTTC TTACCTGGAAG ATATATATTCC
681  TTACATACGC CACGTCACCC AACAGTCAT TGGCAAAATG
721  TCACGCTAGT ATAGTACTGG TATGGCTGTT GAGGGGATTA
761  ATTTTGATAC TGCAAAGATG TCACATCTC CAATGCTTAC
801  CAACACTTTG CCACTCAGT GCAGGATATG CATGCTGGAT
841  CGTGTGGTCT TATATCTCA CATCATCCTG GTGCCGCAAG
881  CGATCCTATCC AGAGAGTCGT TTTTTTTTTC GCTCTGAGC
921  AACACTAGAT GAAAATACAA AAAGAAATG GTTTCGCAAG
961  AGCTGTATAG AAATGATCTG TTTCGTTTCA CTGCTGGAAG
1001  ATCCAAATAC ATGCTACTGG TGGGGGATTA GACACATGTTG
1041  TCGCTCAATTT ACAAAAGCGA AGAAGAACCA ATCTGAACCA
1081  GACATGGAAG CATTCTGCAA AATTAAGAG TGAAGGAAG
1121  ATCTTATAACA AGGTGGTGGG AGCTATGGAAG CGCAGCTTCTT
1161  GTCAGTCTAT GCACATGAGG GCTTTTTTGGT TTTGCAACAA
1201  AGTGAATTTTC TACACAGATT ATGGGAGGAA GCGCTGAC
1241  GATTTCTCTC ACCTTTGGTA CCCATCTCCT CAAGATTTA
1281  CTCAGACCGT GAATTTTTGGG CAAGAAGAAAT GATCGAAATT
1321  CGTCATGAAA GCAATGACAG CTTTGTTGGC ATGTTGGCT
1361  GGGAAAGAAA TCTCCTTAT ACCAAAGCCG ATGATGACAG
1401  TGGTTTACTC ACACTCCAGT TTGAATTAT TAAACACAA
1441  TCTTTTGGCTT TTAAGAGTAA AGCAGCTGCC AGGGTATTA
1481  TGGGCGCGAA ACAAATCAG ATGATATGAG CAGCGGATCG
1521  TGCTAGCTCG CAAATTGACG CACTTGTAGA AGCGCTTGTG
1561  GATTTGAAGA AAAAACTGGT GTTTTGGGGT GCTAAACAGA
1601  TCTCTCTAGC GTTGGGATAG GCTATTGCGT GATCAACCAAA
1641  TGAATACCTC TCAAAGCCG CGCCTACTTT AAcACATTGT
1681  GGAGCGGGTTA TCGCAGAGA AGATCAGAGA TTAGAAGCTG
AP.2 - Bartonella claridgeiae - virB Operon Sequence

1  ATGACAGACA CTATATCCAG GAACATCATTT TTTATCATCA
41  TCTATCTGCT GTTAAACAGCG CTCGTTGTAT CAGACCCCTC
81  TTATGCTGCT GCTGCTACGG GTAGTGCCAG TAGTCTGGGA
121  AACGTTGATA ATGTTTTACA AAATATTGTT ACGATGATGA
161  CAGGAACAAC AGCAAAGCTG ATTTGCAACAA TATGTCTGGC
201  AGCTGTGGGGA ATTTGTTGGA TGTCCGCTTT TATTGATTTA
241  CGCGAAACCG CTTATTTGAT TCTCCGGCATG GGGATTGTCT
281  TTGGTGCCCC CACTCTTTGT AGTACATTAA TGGGCTCACC
321  ATAAATGAAT GAGATTTACG TGTTGCTCTC AACAAGAGG AGAAAAAAGA
361  AAACCTACCC AGATGAGGGGAG GAGGATCTAC ATCTCCCTTA
401  CGCCTATCC GTGAATTTCAA TGCTGCTTAA CAGGGAAACC
441  AGATGTGTAAGT CTTTTGTTGCT CTTTTAGATTG ATGACCTTTT
481  GTATGTCGATA GATGACAAAA ATACGACCAT CGACTTTTCC
521  TCTATTTTGT GCTTGTGCTTT GTTATCGGACG GAAAGGAAA
561  TAATACCGCTTAG GTCCAACAAAC AGTACCTGAT TCTCCCTCTA
601  ACCTGGATGACG TTCTTGTCTTT ATATTCTCTAC ATCACTCTCC
641  AGATATGACG TCTTATTTCTC AGGAGGCTTG GATGATATCT
681  ATATCTCTTAA CACAGTTATG TGACTCTCCT CTACGTTTTT
721  ATTGACCGAA ATGACCGACC AACCAGTTAA AAACATCTAT
761  AGGGGGGTGAC GATGATATTT TGTGGCTCTC AACATCGACAG
801  TTCCCTACAC AACAGCTTAA ACACGCTCTT GAGAATTATC
841  GCAGCGGTAAAC GATCTATCCA GAGAGTCTAT TTTGTTTTTT
881  GGCACGAAAG GATCTATCCA GAGAGTCTAT TTTGTTTTTT
921  TTTGCAAGCA ACACTAGATG AAAATAACA AAAGAATACT
961  GTTTGGCAAG AGCTGTATAG AAAATGCTAC TCTGGCTTAC
1001  TGCTGTGGAAA TCAACATCAG GGTAAAGACTG AGCAACTTGC
1041  TCTATTATT CAGGATTTAA AAAAAAGCTT AAAAAGAACA
1081  TCTGAAACGAG ACATGGAAGC CATTCTGTAA TATGAGAGAT
1121  TAAGCCCAAGA CTCTTATCAA GGGGGAGGA CAGATGATGAG
1161  GCGACCTTCTT TAGCTGCTTG AATAATGAGA CTTGCTTTAC
1201  TCCGAACAAAA GTGAAATTTT TCAACGTTA GTGGGAGGAA
1241  GCGTGAGCG CATTCTACTT TAGCTGCTTG CATTGCTACG
1281  AACGATTCTT TCGACCTGCG TCACTTATGG CAAAGAAATG
1321  ATCGAAATTTC ATGTCAGAAA CAATGAAAGC TCTGGGCGCA
1361  TGTTATGGCC AAAAAATGAT CATACTCAA CAGGCCCCAG
1401  TAGATCACAGAT GGTAAAACTCA CAGACGTTA TGAATTATC
1441  TAAACACAAAA CTGTGTTGCTG ACGGCGCCGG GCTGCTGTCC
1481  AGGGTACATT TGGGCGGCCA AAAAATACAG ATGATTAATG
1521  CAGCGGTAGT TGCTAGCTCG AAAATGGATG CACTGGATGA
1561  AGCGCTCTGAT GATTTAGAT AAAACCGTTT TGTGTTGGGC
<table>
<thead>
<tr>
<th></th>
<th>GAACATCATC TCTCTCTAGC CGTTTTTGGCT GATCAGAACTG</th>
</tr>
</thead>
<tbody>
<tr>
<td>1601</td>
<td>AAACATTTGCT GAGATACCTC TACAAAAAGCGC GCGCTCAGTT</td>
</tr>
<tr>
<td>1641</td>
<td>AAACATTTGCT TGGCTGGATA TGCAGAGAGA GATCTAGAGG</td>
</tr>
<tr>
<td>1681</td>
<td>TTAGAGTGGT GAGATAGGCT TGGCTGGAGA GCAATTACCA GCCAGAAATTT</td>
</tr>
<tr>
<td>1721</td>
<td>TGGTGGACTAC TGGCTGGAGA GCAATTACCA GCCAGAAATTT</td>
</tr>
<tr>
<td>1761</td>
<td>CTTGGATGGAT TTTCTGAGGA GAGATCTTGA TATGTCTGTA</td>
</tr>
<tr>
<td>1801</td>
<td>AAAACATTTGCT GAGATACCTC TACAAAAAGCGC GCGCTCAGTT</td>
</tr>
<tr>
<td>1841</td>
<td>TACAAAAACCA AAGTATAGGGA AACATTTGCT GATCAGAACTG</td>
</tr>
<tr>
<td>1881</td>
<td>TGGTGGACTAC TGGCTGGAGA GCAATTACCA GCCAGAAATTT</td>
</tr>
<tr>
<td>1921</td>
<td>CTTGGATGGAT TTTCTGAGGA GAGATCTTGA TATGTCTGTA</td>
</tr>
<tr>
<td>1961</td>
<td>AAAACATTTGCT GAGATACCTC TACAAAAAGCGC GCGCTCAGTT</td>
</tr>
<tr>
<td>2001</td>
<td>TACAAAAACCA AAGTATAGGGA AACATTTGCT GATCAGAACTG</td>
</tr>
<tr>
<td>2041</td>
<td>TGGTGGACTAC TGGCTGGAGA GCAATTACCA GCCAGAAATTT</td>
</tr>
<tr>
<td>2081</td>
<td>CTTGGATGGAT TTTCTGAGGA GAGATCTTGA TATGTCTGTA</td>
</tr>
<tr>
<td>2121</td>
<td>AAAACATTTGCT GAGATACCTC TACAAAAAGCGC GCGCTCAGTT</td>
</tr>
<tr>
<td>2161</td>
<td>TACAAAAACCA AAGTATAGGGA AACATTTGCT GATCAGAACTG</td>
</tr>
<tr>
<td>2201</td>
<td>TGGTGGACTAC TGGCTGGAGA GCAATTACCA GCCAGAAATTT</td>
</tr>
<tr>
<td>2241</td>
<td>CTTGGATGGAT TTTCTGAGGA GAGATCTTGA TATGTCTGTA</td>
</tr>
<tr>
<td>2281</td>
<td>AAAACATTTGCT GAGATACCTC TACAAAAAGCGC GCGCTCAGTT</td>
</tr>
<tr>
<td>2321</td>
<td>TACAAAAACCA AAGTATAGGGA AACATTTGCT GATCAGAACTG</td>
</tr>
<tr>
<td>2361</td>
<td>TGGTGGACTAC TGGCTGGAGA GCAATTACCA GCCAGAAATTT</td>
</tr>
<tr>
<td>2401</td>
<td>CTTGGATGGAT TTTCTGAGGA GAGATCTTGA TATGTCTGTA</td>
</tr>
<tr>
<td>2441</td>
<td>AAAACATTTGCT GAGATACCTC TACAAAAAGCGC GCGCTCAGTT</td>
</tr>
<tr>
<td>2481</td>
<td>TACAAAAACCA AAGTATAGGGA AACATTTGCT GATCAGAACTG</td>
</tr>
<tr>
<td>2521</td>
<td>TGGTGGACTAC TGGCTGGAGA GCAATTACCA GCCAGAAATTT</td>
</tr>
<tr>
<td>2561</td>
<td>CTTGGATGGAT TTTCTGAGGA GAGATCTTGA TATGTCTGTA</td>
</tr>
<tr>
<td>2601</td>
<td>AAAACATTTGCT GAGATACCTC TACAAAAAGCGC GCGCTCAGTT</td>
</tr>
<tr>
<td>2641</td>
<td>TACAAAAACCA AAGTATAGGGA AACATTTGCT GATCAGAACTG</td>
</tr>
<tr>
<td>2681</td>
<td>TGGTGGACTAC TGGCTGGAGA GCAATTACCA GCCAGAAATTT</td>
</tr>
<tr>
<td>2721</td>
<td>CTTGGATGGAT TTTCTGAGGA GAGATCTTGA TATGTCTGTA</td>
</tr>
<tr>
<td>2761</td>
<td>AAAACATTTGCT GAGATACCTC TACAAAAAGCGC GCGCTCAGTT</td>
</tr>
<tr>
<td>2801</td>
<td>TACAAAAACCA AAGTATAGGGA AACATTTGCT GATCAGAACTG</td>
</tr>
<tr>
<td>2841</td>
<td>TGGTGGACTAC TGGCTGGAGA GCAATTACCA GCCAGAAATTT</td>
</tr>
<tr>
<td>2881</td>
<td>CTTGGATGGAT TTTCTGAGGA GAGATCTTGA TATGTCTGTA</td>
</tr>
<tr>
<td>2921</td>
<td>AAAACATTTGCT GAGATACCTC TACAAAAAGCGC GCGCTCAGTT</td>
</tr>
<tr>
<td>2961</td>
<td>TACAAAAACCA AAGTATAGGGA AACATTTGCT GATCAGAACTG</td>
</tr>
<tr>
<td>3001</td>
<td>TGGTGGACTAC TGGCTGGAGA GCAATTACCA GCCAGAAATTT</td>
</tr>
<tr>
<td>3041</td>
<td>CTTGGATGGAT TTTCTGAGGA GAGATCTTGA TATGTCTGTA</td>
</tr>
<tr>
<td>3081</td>
<td>AAAACATTTGCT GAGATACCTC TACAAAAAGCGC GCGCTCAGTT</td>
</tr>
<tr>
<td>3121</td>
<td>TACAAAAACCA AAGTATAGGGA AACATTTGCT GATCAGAACTG</td>
</tr>
<tr>
<td>3161</td>
<td>TGGTGGACTAC TGGCTGGAGA GCAATTACCA GCCAGAAATTT</td>
</tr>
<tr>
<td>3201</td>
<td>CTTGGATGGAT TTTCTGAGGA GAGATCTTGA TATGTCTGTA</td>
</tr>
<tr>
<td>3241</td>
<td>AAAACATTTGCT GAGATACCTC TACAAAAAGCGC GCGCTCAGTT</td>
</tr>
<tr>
<td>3281</td>
<td>TACAAAAACCA AAGTATAGGGA AACATTTGCT GATCAGAACTG</td>
</tr>
</tbody>
</table>
AAAAAGCCA AGCAATGCA GAAAAATA ACGACACTTC
ACCGAACCA ATCGAAAGAA AACCTGATGA AACAGCACA
CGCTTTAATC ATCTCTCAA ACCGACAAAC CTTGAAGGTA
TTCATGCTTC AACACTTACT AATCGAAACT ACATCATCGC
AATGGGTCGTC TCCATTCCAT GTATTTTGA AACGGCAATC
AGCAGTGACCC CGAGGGGATT TACCAGTTGT ATCGTTTCTA
GAGATACCGC ACCGGGACGT CGACCACCGG TATGAAACAA
AACCTGCAATA AATTGAGCAA TGGAACTGTC GCGATTGTT
TAACAAAAACT TGAACCTATC AGTACCTTTC TGGAGAGAT
GAGTCTTTTT GAAATTGTCGA TCAATCGTCC CTATCAAGTG
ATGACAGAAG GAATGGAGGG ATGGAAAAAC ATAGAAGCAC
CAGCTCTCTC ATTTAATGAG TCGTCAATGAG ATTGCTAAAGT
TGCTCGGTCC TATTCTAAGC AAAATATATC AGGAAAATAAT
CCAATATTAT CAGCCACCTT ACCAGGCAAT GAGCGTATTC
AAATTGTCAT TCCACCTGCA GTAGAAAAAG ACACAATCAG
TATGACAATT CGCAAAACCAC CATCGCGGAAG TTTTCACTC
GAAGAGCTGG CAAATAAAGG TCTCTTTTCA GTGTGTGAAC
AAGTCTCATT CAGCCCAATTG AATGATTATC AATCGCGTTT
TAGTGAACTC AAACACATATG ACATAACTT AACGGTATGC
TATTCAATAA AGGTATTTGT CTCCTTTTAA AATCAGGCTG
TAAAATGCCA AAAAAATATT TTGATTGCAG GAAAAACCGG
TTCCGGGTAAA ACAAACGCTAT CAAAGGCATT AATCGCAAAA
ATTC
CAGAATTTGT CCTACCACAG CCAAATATG TCTCTATGAT
CTATTCAAAAA GATGTTCAAG GCTTACCCCT CTTGGGTCCA
AAAGAATTGCT TGAATCTGCT TTTACGCATG CGTCTGATC
GCAAATTTTAC AAGAGCGTCT CGAGATGGTA CAGCGCTTTA
TTATAATCCGC AATGTAACCC ATGGACATCAG AGGTTCATT
ACCACGTTTC ATGCATCAAC AGCACTTGCT GCCTTTGAGC
AAATGACCCCT TTTGGTCAAA GAAAGTGAAG GAGGAGGAGA
TTAGAGCGGT GATATCGAG GCCTGGTGAT TT
The program AlignX (Invitrogen) was used to prepare a protein sequence alignment for *B. henselae* (BH), *B. quintana* str. *Tolouse* (BQT) and *B. bacilliformis* (BB). The predicted *B. bacilliformis* Staphylocoagulase binding-motif has been underlined and the amino acids which differ between *B. bacilliformis*, *B. henselae* and *B. quintana* are red.

<table>
<thead>
<tr>
<th></th>
<th>BH_GroEL</th>
<th>BQT_GroEL</th>
<th>BB_GroEL</th>
</tr>
</thead>
<tbody>
<tr>
<td>1</td>
<td>MAAKEVKFGR</td>
<td>MAAKEVKFGR</td>
<td>MAAKEVKFGR</td>
</tr>
<tr>
<td>2</td>
<td>EARERLLRGV</td>
<td>EARERLLRGV</td>
<td>EARERLLRGV</td>
</tr>
<tr>
<td>3</td>
<td>DILANAVKVT</td>
<td>DILANAVKVT</td>
<td>DILANAVKVT</td>
</tr>
<tr>
<td>4</td>
<td>LGPKGRNVVI</td>
<td>LGPKGRNVVI</td>
<td>LGPKGRNVVI</td>
</tr>
<tr>
<td>5</td>
<td>DKSFGAPRIT</td>
<td>DKSFGAPRIT</td>
<td>DKSFGAPRIT</td>
</tr>
<tr>
<td>6</td>
<td>KDGVSVAKEI</td>
<td>KDGVSVAKEI</td>
<td>KDGVSVAKEI</td>
</tr>
<tr>
<td>7</td>
<td>ELEDKFENMG</td>
<td>ELEDKFENMG</td>
<td>ELEDKFENMG</td>
</tr>
<tr>
<td>8</td>
<td>AQMLREVASK</td>
<td>AQMLREVASK</td>
<td>AQMLREVASK</td>
</tr>
<tr>
<td>9</td>
<td>TNDIAGDGTT</td>
<td>TNDIAGDGTT</td>
<td>TNDIAGDGTT</td>
</tr>
<tr>
<td>10</td>
<td>TATVLGQAIV</td>
<td>TATVLGQAIV</td>
<td>TATVLGQAIV</td>
</tr>
<tr>
<td>11</td>
<td>QEGVKAVAAG</td>
<td>QEGVKAVAAG</td>
<td>QEGVKAVAAG</td>
</tr>
<tr>
<td>12</td>
<td>MNPMDLKRGI</td>
<td>MNPMDLKRGI</td>
<td>MNPMDLKRGI</td>
</tr>
<tr>
<td>13</td>
<td>DAAVEEVGN</td>
<td>DAAVEEVGN</td>
<td>DAAVEEVGN</td>
</tr>
<tr>
<td>14</td>
<td>LFKKAKKIQT</td>
<td>LFKKAKKIQT</td>
<td>LFKKAKKIQT</td>
</tr>
<tr>
<td>15</td>
<td>SAEIAQVGTI</td>
<td>SAEIAQVGTI</td>
<td>SAEIAQVGTI</td>
</tr>
<tr>
<td>16</td>
<td>SANGAAEIGK</td>
<td>SANGAAEIGK</td>
<td>SANGAAEIGK</td>
</tr>
<tr>
<td>17</td>
<td>MIADAMEKVG</td>
<td>MIADAMEKVG</td>
<td>MIADAMEKVG</td>
</tr>
<tr>
<td>18</td>
<td>NEGVITVEEA</td>
<td>NEGVITVEEA</td>
<td>NEGVITVEEA</td>
</tr>
<tr>
<td>19</td>
<td>KTAETELEV</td>
<td>KTAETELEV</td>
<td>KTAETELEV</td>
</tr>
<tr>
<td>20</td>
<td>EGMQFDRGYL</td>
<td>EGMQFDRGYL</td>
<td>EGMQFDRGYL</td>
</tr>
<tr>
<td>21</td>
<td>SPYFVTNAEK</td>
<td>SPYFVTNAEK</td>
<td>SPYFVTNAEK</td>
</tr>
<tr>
<td>22</td>
<td>MVADLDDPYI</td>
<td>MVADLDDPYI</td>
<td>MVADLDDPYI</td>
</tr>
<tr>
<td>23</td>
<td>LIHEKKLSNL</td>
<td>LIHEKKLSNL</td>
<td>LIHEKKLSNL</td>
</tr>
<tr>
<td>24</td>
<td>QSLLPVLEAV</td>
<td>QSLLPVLEAV</td>
<td>QSLLPVLEAV</td>
</tr>
<tr>
<td>25</td>
<td>VQSGKPLLII</td>
<td>VQSGKPLLII</td>
<td>VQSGKPLLII</td>
</tr>
<tr>
<td>26</td>
<td>AEDVEGELA</td>
<td>AEDVEGELA</td>
<td>AEDVEGELA</td>
</tr>
<tr>
<td>27</td>
<td>TLVKNKLRRG</td>
<td>TLVKNKLRRG</td>
<td>TLVKNKLRRG</td>
</tr>
<tr>
<td>28</td>
<td>LKIAAVKAPG</td>
<td>LKIAAVKAPG</td>
<td>LKIAAVKAPG</td>
</tr>
<tr>
<td>29</td>
<td>FGDRRKAMLLE</td>
<td>FGDRRKAMLLE</td>
<td>FGDRRKAMLLE</td>
</tr>
<tr>
<td>30</td>
<td>DIAILTSQGV</td>
<td>DIAILTSQGV</td>
<td>DIAILTSQGV</td>
</tr>
<tr>
<td>31</td>
<td>ISEDVGIKLE</td>
<td>ISEDVGIKLE</td>
<td>ISEDVGIKLE</td>
</tr>
<tr>
<td>32</td>
<td>NVTLDMGRA</td>
<td>NVTLDMGRA</td>
<td>NVTLDMGRA</td>
</tr>
<tr>
<td>33</td>
<td>KKVNISKENT</td>
<td>KKVNISKENT</td>
<td>KKVNISKENT</td>
</tr>
<tr>
<td>34</td>
<td>TIIIDAGQKKS</td>
<td>TIIIDAGQKKS</td>
<td>TIIIDAGQKKS</td>
</tr>
<tr>
<td>35</td>
<td>EINARVNIK</td>
<td>EINARVNIK</td>
<td>EINARVNIK</td>
</tr>
<tr>
<td>36</td>
<td>VQIEETTSDY</td>
<td>VQIEETTSDY</td>
<td>VQIEETTSDY</td>
</tr>
<tr>
<td>37</td>
<td>DREKLQERLA</td>
<td>DREKLQERLA</td>
<td>DREKLQERLA</td>
</tr>
<tr>
<td>38</td>
<td>KLAGGAVIR</td>
<td>KLAGGAVIR</td>
<td>KLAGGAVIR</td>
</tr>
<tr>
<td>39</td>
<td>VGGATEVEK</td>
<td>VGGATEVEK</td>
<td>VGGATEVEK</td>
</tr>
<tr>
<td>40</td>
<td>EKKDRVDDAL</td>
<td>EKKDRVDDAL</td>
<td>EKKDRVDDAL</td>
</tr>
<tr>
<td>41</td>
<td>AQIEETTSDY</td>
<td>AQIEETTSDY</td>
<td>AQIEETTSDY</td>
</tr>
<tr>
<td>42</td>
<td>DREKLQERLA</td>
<td>DREKLQERLA</td>
<td>DREKLQERLA</td>
</tr>
<tr>
<td>43</td>
<td>KLAGGAVIR</td>
<td>KLAGGAVIR</td>
<td>KLAGGAVIR</td>
</tr>
<tr>
<td>44</td>
<td>VGGATEVEK</td>
<td>VGGATEVEK</td>
<td>VGGATEVEK</td>
</tr>
<tr>
<td>45</td>
<td>EKKDRVDDAL</td>
<td>EKKDRVDDAL</td>
<td>EKKDRVDDAL</td>
</tr>
<tr>
<td>46</td>
<td>NATRAAVEEG</td>
<td>NATRAAVEEG</td>
<td>NATRAAVEEG</td>
</tr>
<tr>
<td>47</td>
<td>IVAGGTLA</td>
<td>IVAGGTLA</td>
<td>IVAGGTLA</td>
</tr>
<tr>
<td>48</td>
<td>RAANALTVKG</td>
<td>RAANALTVKG</td>
<td>RAANALTVKG</td>
</tr>
<tr>
<td>49</td>
<td>SNPDQEAGIN</td>
<td>SNPDQEAGIN</td>
<td>SNPDQEAGIN</td>
</tr>
<tr>
<td>50</td>
<td>IVRRALQAPA</td>
<td>IVRRALQAPA</td>
<td>IVRRALQAPA</td>
</tr>
<tr>
<td>51</td>
<td>NATRAAVEEG</td>
<td>NATRAAVEEG</td>
<td>NATRAAVEEG</td>
</tr>
<tr>
<td>52</td>
<td>IVPGGTTALL</td>
<td>IVPGGTTALL</td>
<td>IVPGGTTALL</td>
</tr>
<tr>
<td>53</td>
<td>RAAKALSIGK</td>
<td>RAAKALSIGK</td>
<td>RAAKALSIGK</td>
</tr>
<tr>
<td>54</td>
<td>KNPDQEAGIG</td>
<td>KNPDQEAGIG</td>
<td>KNPDQEAGIG</td>
</tr>
<tr>
<td>55</td>
<td>IIRRALQAPA</td>
<td>IIRRALQAPA</td>
<td>IIRRALQAPA</td>
</tr>
</tbody>
</table>
451
BH\_GroEL  RQIATNAGEE AAIIVGKVLE NNADTFGYNT ATGEFGLIA LGIVDPVKVV
BQT\_GroEL  RQIATNAGEE AAIIVGKVLE NNADTFGYNT ATGQFGLIA LGIVDPVKVV
BB\_GroEL  RQIAHNAGEE AAIVVGKVLE NCSDTFGYN  ATAQFGDLIS FGIVDPVKVV

501
BH\_GroEL  RSALQNAASI ASLLITTEAM VAEVPKKDP T VPPMFGGGMG GMGGMD
BQT\_GroEL  RSALQNAASI ASLLITTEAM VAEVPKKDP MPPMFGGGMG GMGGMD

547